<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Helicobacter pylori eradication for the prevention of gastric neoplasia - Ford, AC - 2020 | Cochrane Library</title> <meta content="Helicobacter pylori eradication for the prevention of gastric neoplasia - Ford, AC - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005583.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Helicobacter pylori eradication for the prevention of gastric neoplasia - Ford, AC - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005583.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD005583.pub3" name="dc.identifier" scheme="DOI"/> <meta content="&lt;i&gt;Helicobacter pylori&lt;/i&gt; eradication for the prevention of gastric neoplasia" name="citation_title"/> <meta content="Alexander C Ford" name="citation_author"/> <meta content="St. James's University Hospital" name="citation_author_institution"/> <meta content="Yuhong Yuan" name="citation_author"/> <meta content="McMaster University" name="citation_author_institution"/> <meta content="David Forman" name="citation_author"/> <meta content="International Agency for Research on Cancer" name="citation_author_institution"/> <meta content="Richard Hunt" name="citation_author"/> <meta content="McMaster University" name="citation_author_institution"/> <meta content="Paul Moayyedi" name="citation_author"/> <meta content="McMaster University" name="citation_author_institution"/> <meta content="moayyep@mcmaster.ca" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD005583.pub3" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/07/06" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005583.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005583.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005583.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anti-Bacterial Agents [*therapeutic use]; Anti-Ulcer Agents [therapeutic use]; Asymptomatic Infections [*therapy]; Carcinoma, Squamous Cell [epidemiology]; Drug Therapy, Combination [adverse effects, methods]; Esophageal Neoplasms [epidemiology]; Helicobacter Infections [*drug therapy]; *Helicobacter pylori; Incidence; Precancerous Conditions [drug therapy]; Randomized Controlled Trials as Topic; Stomach Neoplasms [microbiology, mortality, *prevention &amp; control]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005583.pub3&amp;doi=10.1002/14651858.CD005583.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005583.pub3&amp;doi=10.1002/14651858.CD005583.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005583.pub3&amp;doi=10.1002/14651858.CD005583.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005583.pub3&amp;doi=10.1002/14651858.CD005583.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005583.pub3&amp;doi=10.1002/14651858.CD005583.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005583.pub3&amp;doi=10.1002/14651858.CD005583.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005583.pub3&amp;doi=10.1002/14651858.CD005583.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005583.pub3&amp;doi=10.1002/14651858.CD005583.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005583.pub3&amp;doi=10.1002/14651858.CD005583.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005583.pub3&amp;doi=10.1002/14651858.CD005583.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005583.pub3&amp;doi=10.1002/14651858.CD005583.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005583.pub3&amp;doi=10.1002/14651858.CD005583.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005583.pub3&amp;doi=10.1002/14651858.CD005583.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005583.pub3&amp;doi=10.1002/14651858.CD005583.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005583.pub3&amp;doi=10.1002/14651858.CD005583.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005583.pub3&amp;doi=10.1002/14651858.CD005583.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005583.pub3&amp;doi=10.1002/14651858.CD005583.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005583.pub3&amp;doi=10.1002/14651858.CD005583.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005583.pub3&amp;doi=10.1002/14651858.CD005583.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005583.pub3&amp;doi=10.1002/14651858.CD005583.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005583.pub3&amp;doi=10.1002/14651858.CD005583.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005583.pub3&amp;doi=10.1002/14651858.CD005583.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005583.pub3&amp;doi=10.1002/14651858.CD005583.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="QzbxnhyM";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD005583\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD005583\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005583\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005583\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","th","ko","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD005583.pub3",title:"\u003ci\u003eHelicobacter pylori\u003c/i\u003e eradication for the prevention of gastric neoplasia",firstPublishedDate:"Jul 6, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gut Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=QzbxnhyM&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005583.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005583.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD005583.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD005583.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005583.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD005583.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD005583.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD005583.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD005583.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD005583.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>13211 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD005583.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005583.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005583.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005583.pub3/full#CD005583-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005583.pub3/full#CD005583-sec-0075"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005583.pub3/full#CD005583-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005583.pub3/full#CD005583-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005583.pub3/full#CD005583-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005583.pub3/full#CD005583-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005583.pub3/full#CD005583-sec-0048"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005583.pub3/full#CD005583-sec-0069"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005583.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005583.pub3/appendices#CD005583-sec-0080"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005583.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005583.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/table_n/CD005583StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/table_n/CD005583StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005583.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005583.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005583.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005583.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005583.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD005583.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en"><i>Helicobacter pylori</i> eradication for the prevention of gastric neoplasia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005583.pub3/information#CD005583-cr-0004">Alexander C Ford</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005583.pub3/information#CD005583-cr-0005">Yuhong Yuan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005583.pub3/information#CD005583-cr-0006">David Forman</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005583.pub3/information#CD005583-cr-0007">Richard Hunt</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005583.pub3/information#CD005583-cr-0008"><i class="icon corresponding-author fa fa-envelope"></i>Paul Moayyedi</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/information/en#CD005583-sec-0088">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 06 July 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD005583.pub3">https://doi.org/10.1002/14651858.CD005583.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD005583-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005583-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005583-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005583-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005583-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD005583-abs-0008">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD005583-abs-0006">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD005583-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD005583-abs-0001" lang="en"> <section id="CD005583-sec-0001"> <h3 class="title" id="CD005583-sec-0001">Background</h3> <p>Gastric cancer is the third most common cause of cancer death worldwide. Individuals infected with <i>Helicobacter pylori</i> have a higher likelihood of developing gastric cancer than individuals who are not infected. Eradication of <i>H. pylori</i> in healthy asymptomatic individuals in the general population may reduce the incidence of gastric cancer, but the magnitude of this effect is unclear. </p> </section> <section id="CD005583-sec-0002"> <h3 class="title" id="CD005583-sec-0002">Objectives</h3> <p>To assess the effectiveness of eradication of <i>H. pylori</i> in healthy asymptomatic individuals in the general population in reducing the incidence of gastric cancer. </p> </section> <section id="CD005583-sec-0003"> <h3 class="title" id="CD005583-sec-0003">Search methods</h3> <p>We identified trials by searching the Cochrane Central Register of Controlled Trials (CENTRAL; 2020, Issue 1), MEDLINE (1946 to February 2020), and EMBASE (1974 to February 2020). We handsearched reference lists from trials selected by electronic searching to identify further relevant trials. We handsearched published abstracts from conference proceedings from the United European Gastroenterology Week (published in <i>Gut</i> ) and Digestive Disease Week (published in <i>Gastroenterology</i>) between 2001 and 2019. We contacted members of the Cochrane Upper Gastrointestinal and Pancreatic Diseases Review Group and experts in the field and asked them to provide details of outstanding clinical trials and any relevant unpublished materials. </p> </section> <section id="CD005583-sec-0004"> <h3 class="title" id="CD005583-sec-0004">Selection criteria</h3> <p>We analysed randomised controlled trials comparing at least one week of <i>H. pylori</i> therapy with placebo or no treatment in preventing subsequent development of gastric cancer in otherwise healthy and asymptomatic <i>H. pylori</i>‐positive adults. Trials had to follow up participants for at least two years and needed to have at least two participants with gastric cancer as an outcome. We defined gastric cancer as any gastric adenocarcinoma, including intestinal (differentiated) or diffuse (undifferentiated) type, with or without specified histology. </p> </section> <section id="CD005583-sec-0005"> <h3 class="title" id="CD005583-sec-0005">Data collection and analysis</h3> <p>We collected data on incidence of gastric cancer, incidence of oesophageal cancer, deaths from gastric cancer, deaths from any cause, and adverse effects arising due to therapy. </p> </section> <section id="CD005583-sec-0006"> <h3 class="title" id="CD005583-sec-0006">Main results</h3> <p>Six trials met all our eligibility criteria and provided extractable data in the previous version. Following our updated search, one new RCT was identified, meaning that seven trials were included in this updated review. In addition, one previously included trial provided fully published data out to 10 years, and another previously included trial provided fully published data out to 22 years of follow‐up. Four trials were at low risk of bias, one trial was at unclear risk, and two trials were at high risk of bias. Six trials were conducted in Asian populations. </p> <p>In preventing development of subsequent gastric cancer, <i>H. pylori</i> eradication therapy was superior to placebo or no treatment (RR 0.54, 95% confidence interval (CI) 0.40 to 0.72, 7 trials, 8323 participants, moderate certainty evidence). Only two trials reported the effect of eradication of <i>H. pylori</i> on the development of subsequent oesophageal cancer. Sixteen (0.8%) of 1947 participants assigned to eradication therapy subsequently developed oesophageal cancer compared with 13 (0.7%) of 1941 participants allocated to placebo (RR 1.22, 95% CI 0.59 to 2.54, moderate certainty evidence). <i>H. pylori</i> eradication reduced mortality from gastric cancer compared with placebo or no treatment (RR 0.61, 95% CI 0.40 to 0.92, 4 trials, 6301 participants, moderate certainty evidence). There was little or no evidence in all‐cause mortality (RR 0.97, 95% CI 0.85 to 1.12, 5 trials, 7079 participants, moderate certainty evidence). Adverse events data were poorly reported. </p> </section> <section id="CD005583-sec-0007"> <h3 class="title" id="CD005583-sec-0007">Authors' conclusions</h3> <p>We found moderate certainty evidence that searching for and eradicating <i>H. pylori</i> reduces the incidence of gastric cancer and death from gastric cancer in healthy asymptomatic infected Asian individuals, but we cannot necessarily extrapolate this data to other populations. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD005583-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005583-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005583-abs-0018">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005583-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005583-abs-0016">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD005583-abs-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD005583-abs-0011">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD005583-abs-0009">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD005583-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/th#CD005583-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD005583-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD005583-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD005583-abs-0002" lang="en"> <h3>Helicobacter pylori treatment for the prevention of stomach cancer</h3> <p><b>Review question</b> </p> <p>Whether testing healthy people for <i>Helicobacter pylori</i> and treating those infected with a course of antibiotics decreases the number of new cases of gastric cancer. </p> <p><b>Background</b> </p> <p><i>Helicobacter pylori</i> (<i>H. pylori</i> ) is a bacteria that lives in the lining of the stomach with people usually not aware they are carrying the infection. People with <i>H. pylori</i> infection are more likely to develop gastric cancer than people who are not infected with the bacterium. For this reason, <i>H. pylori</i> is classed as carcinogenic (causing cancer) to humans. Many people worldwide die of gastric cancer every year, because by the time those affected seek the opinion of a doctor, the condition is often advanced. However, <i>H. pylori</i> infection is easily treatable with a one‐week course of antibiotics. </p> <p><b>Study characteristics</b> </p> <p>A literature search up to 02 Feburary 2020 found seven trials (containing 8323 participants, four trials at low risk of bias). Six of the studies were based in Asia. </p> <p><b>Key results</b> </p> <p>We found that antibiotics for <i>H. pylori</i> have a small benefit in preventing gastric cancer (68 (1.6%) of 4206 participants given treatment developed gastric cancer subsequently, compared with 125 (3.0%) of 4117 given no treatment or a placebo), and in decreasing the number of deaths from gastric cancer (36 (1.1%) of 3154, compared with 59 (1.9%) of 3147); but it is unclear whether or not they increase or decrease the number of deaths due to any cause, or increase or decrease the number of cases of oesophageal cancer. Data about side effects of treatment were poorly reported. </p> <p><b>Quality of the evidence</b> </p> <p>Four trials were at low risk of bias, one trial was at unclear risk, and two trials were at high risk of bias. One study was at high risk of bias because no placebo was used for the active eradication therapy regimen, and so this part of the trial was unblinded, and the other study was at high risk of bias due to inconsistencies in data reporting at the two points of follow‐up. We were unable to resolve this discrepancy despite contacting the original authors. As a result, we downgraded the quality of evidence from high to moderate due to serious risk of bias. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD005583-sec-0075" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD005583-sec-0075"></div> <h3 class="title" id="CD005583-sec-0076">Implications for practice</h3> <section id="CD005583-sec-0076"> <p>These data provide moderate certainty evidence that searching for and eradicating <i>H. pylori</i> can reduce the future incidence of gastric cancer in healthy asymptomatic people who are infected with the bacterium. However, as the only trial conducted in a non‐Asian population failed to demonstrate any benefit of such an approach, these findings may not necessarily apply to the rest of the world. </p> <p>The findings of this systematic review and meta‐analysis add to the increasing evidence that eradicating <i>H. pylori</i> in the general population has the potential to prevent gastric cancer. International guidelines for the management of <i>H. pylori</i> infection may change as a result. </p> </section> <h3 class="title" id="CD005583-sec-0077">Implications for research</h3> <section id="CD005583-sec-0077"> <p>Given that any population‐based approach to mass screening for <i>H. pylori</i> , with eradication of the infection in positive individuals, will involve healthy subjects, there needs to be more information on any potential harms of <i>H. pylori</i> eradication before such a strategy can be advocated as a means of preventing gastric cancer. Further trials are therefore needed in different populations to extend the evidence base, and these should report on both the benefits and harms of such an approach. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD005583-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD005583-sec-0008"></div> <div class="table" id="CD005583-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">H. pylori eradication therapy compared to control for the prevention of gastric neoplasia in healthy asymptomatic infected individuals</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><i><b>H. pylori</b> </i><b>eradication therapy compared to control for the prevention of gastric neoplasia in healthy asymptomatic infected individuals</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> healthy asymptomatic <i>H. pylori‐</i>infected individuals<br/><b>Settings:</b> general population<sup>1</sup><br/><b>Intervention:</b><i>H. pylori</i> eradication therapy to prevent subsequent gastric cancer <sup>2</sup><br/><b>Comparison:</b> control </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><i><b>H. pylori</b> </i><b>eradication therapy to prevent subsequent gastric cancer</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of gastric cancer ‐ modified ITT analysis</b><br/>Histological examination<br/>Follow‐up: 4 to 22 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>30 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 1000</b><br/>(12 to 22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.54</b> <br/>(0.40 to 0.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8323<br/>(7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>3,4,5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number need to treat to benefit was 72 (95% CI 55 to 118)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death from gastric cancer ‐ modified ITT analysis</b> </p> <p>Follow up: 7‐22 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b><br/>(7 to 17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.61</b> <br/>(0.40 to 0.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6301<br/>(4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>4,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number need to treat to benefit was 137 (95% CI 89 to 667)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death from all causes ‐ modified ITT analysis</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>92 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>89 per 1000</b><br/>(78 to 103) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.97</b> <br/>(0.85 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7079<br/>(5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>4,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of oesophageal squamous cell carcinoma ‐ modified ITT analysis</b> </p> <p>Follow up: 7‐22 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b><br/>(4 to 17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.22</b> <br/>(0.59 to 2.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3888<br/>(2 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events were poorly reported across the studies and could not be summarised.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; ITT: intention‐to‐treat; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> As all but one study was conducted in East Asia, it is not possible to assess the effect of searching for and eradicating <i>H. pylori</i> in Western populations.<br/><sup>2</sup> Modified ITT analysis.<br/><sup>3</sup> The quality of evidence was downgraded from high to moderate due to serious risk of bias: Fourtrials were at low risk of bias, one trial was at unclear risk, and two trials were at high risk of bias. In addition, because of the factorial design of some of the trials, it is difficult to determine whether the reduction in relative risk of subsequent gastric cancer was due to <i>H. pylori</i> eradication therapy alone. The eradication regimens used varied considerably between the individual trials, although this reflects the fact that several of these studies were designed before the widespread adoption of proton pump inhibitor triple therapy, which was first described in 1994, as the gold standard for H. pylori eradication.<br/><sup>4</sup> No significant heterogeneity was seen between studies.<br/><sup>5</sup> The beneficial effect seemed to be more pronounced in the two studies that co‐administered antioxidants and vitamins to participants, but it should be noted that one of these contained the majority of gastric cancers and had the longest duration of follow‐up. There was no significant benefit of <i>H. pylori</i> eradication therapy in preventing subsequent occurrence of gastric cancer when only those participants either with or without preneoplastic lesions at baseline were considered in the analysis. There were no significant subgroup differences.<br/><sup>6</sup> Funnel plots were not produced, as there were less than 10 studies included in the analyses.<br/><sup>7</sup> The quality of evidence was downgraded from high to moderate due to serious risk of bias: one trial was at high risk of bias.<br/><sup>8</sup> Only two studies were available for this outcome, with wide 95% CI. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD005583-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD005583-sec-0009"></div> <section id="CD005583-sec-0010"> <h3 class="title" id="CD005583-sec-0010">Description of the condition</h3> <p>Gastric cancer is the third most common cause of death from malignant disease worldwide, resulting in 750,000 deaths each year (<a href="./references#CD005583-bbs2-0052" title="FerlayJ , ShinHR , BrayF , FormanD , MathersC , ParkinDM . Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer. Journal International du Cancer2010;127:2839-917.">Ferlay 2010</a>). In most high‐income countries, the incidence of gastric cancer is falling, (<a href="./references#CD005583-bbs2-0065" title="LauM , LeA , El-SeragHB . Noncardia gastric adenocarcinoma remains an important and deadly cancer in the United States: secular trends in incidence and survival. American Journal of Gastroenterology2006;101(11):2485-92.">Lau 2006</a>), but the increase in age of the world population means that the total number of deaths from gastric cancer is set to rise for the foreseeable future (<a href="./references#CD005583-bbs2-0057" title="FormanD . Helicobacter pylori: the gastric cancer problem. Gut1998;43 Suppl 1:S33-4.">Forman 1998</a>). The treatment of gastric cancer is unsatisfactory. Almost half of gastric cancers are inoperable at the time of diagnosis (<a href="./references#CD005583-bbs2-0067" title="LelloE , FurnesB , EdnaTH . Short and long-term survival from gastric cancer. A population-based study from a county hospital during 25 years. Acta Oncologica2007;46(3):308-15.">Lello 2007</a>), and the five‐year survival of these individuals is close to zero. Those undergoing operative treatment often require extensive surgery, with a 5‐year survival rate of only 20% to 30% (<a href="./references#CD005583-bbs2-0048" title="CunninghamSC , KamangarF , KimMP , HammoudS , HaqueR , MaitraA , et al. Survival after gastric adenocarcinoma resection: eighteen-year experience at a single institution. Journal of Gastrointestinal Surgery2005;9(5):718-25.">Cunningham 2005</a>). Survival may be improved if the disease is diagnosed at an earlier stage (<a href="./references#CD005583-bbs2-0049" title="DegiuliM , CalvoF . Survival of early gastric cancer in a specialized European center. Which lymphadenectomy is necessary?World Journal of Surgery2006;30(12):2193-203.">Degiuli 2006</a>), but the cost of population screening for gastric cancer with upper gastrointestinal (GI) endoscopy would be prohibitive. Even if only those with upper GI symptoms that may be indicative of an occult gastric cancer, such as dyspepsia, were screened by endoscopy, the cost of detecting one malignant lesion has been estimated to be as high as USD 83,000. (<a href="./references#CD005583-bbs2-0087" title="VakilN , TalleyN , vanZantenSV , FlookN , PerssonT , BjörckE , et al. Cost of detecting malignant lesions by endoscopy in 2741 primary care dyspeptic patients without alarm symptoms. Clinical Gastroenterology and Hepatology2009;7(7):756-61.">Vakil 2009</a>) One possible way to make a significant impact on mortality from gastric cancer could therefore be via primary prevention of the disease. </p> <p>The discovery of <i>Helicobacter pylori</i> and the observation that it was responsible for the development of chronic gastritis, with subsequent gastric atrophy and intestinal metaplasia, raised the possibility that this organism was a necessary contributor to the carcinogenic process in most cases of gastric cancer (<a href="./references#CD005583-bbs2-0045" title="CorreaP , HaenszelW , CuelloC , TannenbaumS , ArcherM . A model for gastric cancer epidemiology. The Lancet1975;2(7924):58-60.">Correa 1975</a>; <a href="./references#CD005583-bbs2-0046" title="CorreaP . The gastric precancerous process. Cancer Surveys1983;2:437-50.">Correa 1983</a>; <a href="./references#CD005583-bbs2-0074" title="MarshallBJ , ArmstrongJA , McGechieDB , GlancyRJ . Attempt to fulfil Koch's postulates for pyloric Campylobacter . Medical Journal of Australia1985;142(8):436-9.">Marshall 1985</a>; <a href="./references#CD005583-bbs2-0089" title="WarrenJR , MarshallBJ . Unidentified curved bacilli on gastric epithelium in active chronic gastritis. The Lancet1983;1(8336):1273-5.">Warren 1983</a>). Early nested case‐control studies confirmed that individuals infected with <i>H. pylori</i> were between three and six times more likely to develop gastric cancer, compared with uninfected controls (<a href="./references#CD005583-bbs2-0056" title="FormanD , NewellDG , FullertonF , YarnellJW , StaceyAR , WaldN , et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ1991;302:1302-5.">Forman 1991</a>; <a href="./references#CD005583-bbs2-0077" title="NomuraA , StemmermannGN , ChyouPH , KatoI , Perez-PerezGI , BlaserMJ . Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. The New England Journal of Medicine1991;325(16):1132-6.">Nomura 1991</a>; <a href="./references#CD005583-bbs2-0078" title="ParsonnetJ , FriedmanGD , VandersteenDP , ChangY , VogelmanJH , OrentreichN , et al. Helicobacter pylori infection and the risk of gastric carcinoma. The New England Journal of Medicine1991;325(16):1127-31.">Parsonnet 1991</a>). This observation led the World Health Organization and the International Agency Research on Cancer to conclude that <i>H. pylori</i> was a class I carcinogen (<a href="./references#CD005583-bbs2-0063" title="International Agency for Research on Cancer. Schistosomes, liver flukes and Helicobacter pylori . IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans1994;61:177-241.">IARC 1994</a>). </p> <p>A systematic review and meta‐analysis that identified 12 nested prospective case‐control studies suggested that <i>H. pylori</i> was associated with an almost three‐fold increase in odds of developing non‐cardia gastric cancer (<a href="./references#CD005583-bbs2-0061" title="Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut2001;49(3):347-53.">HCCG 2001</a>). A policy of screening populations at high risk of gastric cancer for <i>H. pylori</i> with a non‐invasive test, such as the carbon‐urea breath test, and treating those who are infected could lead, theoretically, to a reduction in the incidence of gastric cancer (<a href="./references#CD005583-bbs2-0079" title="ParsonnetJ , HarrisRA , HackHM , OwensDK . Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. The Lancet1996;348(9021):150-4.">Parsonnet 1996</a>). However, healthcare providers have not seriously considered this policy, and are unlikely to do so until randomised controlled trials (RCTs) have shown such a screening programme to be effective. There are also concerns from nested case‐control studies that the risk of oesophageal adenocarcinoma is increased in people who are not infected with <i>H. pylori</i>, although these data are less consistent (<a href="./references#CD005583-bbs2-0093" title="WuAH , CrabtreeJE , BernsteinL , HawtinP , CockburnM , TsengCC , et al. Role of Helicobacter pylori CagA+ strains and risk of adenocarcinoma of the stomach and esophagus. International Journal of Cancer2003;103:815-21.">Wu 2003</a>; <a href="./references#CD005583-bbs2-0094" title="YeW , HeldM , LagergrenJ , EngstrandL , BlotWJ , McLaughlinJK , et al. Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. Journal of the National Cancer Institute2004;96(5):388-96.">Ye 2004</a>). These concerns stem from the theory that <i>H. pylori</i> eradication may induce gastro‐oesophageal reflux symptoms in some individuals, and therefore an increased risk of Barrett's oesophagus and oesophageal adenocarcinoma. </p> <p>At the inception of this Cochrane review, the only fully published systematic review of RCTs reported a significant reduction in the relative risk of developing gastric cancer with <i>H. pylori</i> eradication therapy, compared with placebo (<a href="./references#CD005583-bbs2-0058" title="FuccioL , ZagariRM , EusebiLH , LaterzaL , CennamoV , CeroniL , et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer?Annals of Internal Medicine2009;151(2):121-8.">Fuccio 2009</a>). However, the authors included data from the same trial twice, at two different follow‐up points (<a href="./references#CD005583-bbs2-0054" title="FordAC , MoayyediP . Redundant data in the meta-analysis on Helicobacter pylori eradication. Annals of Internal Medicine2009;151(7):513-4.">Ford 2009</a>). When only data from one or other of these follow‐up points were included, the effect was no longer statistically significant. We therefore performed another systematic review and meta‐analysis in 2015 (<a href="./references#CD005583-bbs2-0108" title="FordAC , FormanD , HuntR , YuanY , MoayyediP . Helicobacter pylori eradication for the prevention of gastric neoplasia. The Cochrane database of systematic reviews2015;(7):CD005583. [PMID: 26198377]">Ford 2015</a>), which demonstrated a 34% reduction in the relative risk (RR) of an incident gastric cancer, and a number needed to treat to benefit (NNTB) of 124. Given that it has been five years since the publication of this meta‐analysis, the possibility that there may now be more published trials, as well as longer duration of follow‐up in the existing trials, led us to update the review. </p> </section> <section id="CD005583-sec-0011"> <h3 class="title" id="CD005583-sec-0011">Description of the intervention</h3> <p><i>H. pylori</i> eradication therapy consists of antibiotics, either alone or in combination with acid suppressant therapy, bismuth, or both. Proton pump inhibitor‐based triple therapy remains the 'gold standard' for the treatment of infection with <i>H. pylori</i> . With the development of accurate methods of diagnosing <i>H. pylori</i> infection, it has become relatively straightforward to confirm successful treatment, or eradication, of the infection. </p> </section> <section id="CD005583-sec-0012"> <h3 class="title" id="CD005583-sec-0012">How the intervention might work</h3> <p>There are biologically plausible mechanisms that may explain the association between <i>H. pylori</i> and gastric cancer. The infection leads to a hyperproliferative state, intragastric concentration of ascorbic acid is reduced, and the levels of mucosal reactive oxygen metabolites capable of inducing DNA damage are increased. The eradication of <i>H. pylori</i> normalises gastric cell turnover, luminal ascorbic acid concentrations, and the level of reactive oxygen species in the mucosa (<a href="./references#CD005583-bbs2-0076" title="MoayyediP , DixonMF . Significance of Helicobacter pylori infection and gastric cancer: implications for screening. Gastrointestinal Endoscopy Clinics of North America1997;7(1):47-64.">Moayyedi 1997</a>). </p> </section> <section id="CD005583-sec-0013"> <h3 class="title" id="CD005583-sec-0013">Why it is important to do this review</h3> <p>Population screening for and treatment of <i>H. pylori</i> infection may reduce the incidence of gastric cancer, particularly in populations with a high prevalence of infection with the bacterium who also have a high risk of gastric cancer. The aim of this systematic review and meta‐analysis of RCTs was to evaluate the effect of <i>H. pylori</i> eradication therapy in preventing gastric cancer in otherwise healthy and asymptomatic <i>H. pylori</i>‐positive individuals. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD005583-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD005583-sec-0014"></div> <p>To assess the effectiveness of eradication of <i>H. pylori</i> in healthy asymptomatic individuals in the general population in reducing the incidence of gastric cancer. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD005583-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD005583-sec-0015"></div> <section id="CD005583-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD005583-sec-0017"> <h4 class="title">Types of studies</h4> <p>We considered only parallel‐group RCTs comparing <i>H. pylori</i> eradication with placebo or no treatment for this review. </p> </section> <section id="CD005583-sec-0018"> <h4 class="title">Types of participants</h4> <p>Otherwise healthy and asymptomatic adults over 16 years of age who were <i>H. pylori</i> ‐positive, as assessed invasively by any of histology, rapid urease testing, culture (all from antrum or body biopsies obtained at endoscopy), or non‐invasively via <i>H. pylori</i> serology or carbon‐urea breath testing. </p> </section> <section id="CD005583-sec-0019"> <h4 class="title">Types of interventions</h4> <p>The <i>H. pylori</i> eradication therapy regimen had to have an eradication rate as reported in the literature of at least 50% and was defined as any of the following, with duration of therapy of at least one week: </p> <p> <ol id="CD005583-list-0001"> <li> <p>Proton pump inhibitor (PPI) dual therapy (PPI plus either amoxicillin or clarithromycin);</p> </li> <li> <p>PPI triple therapy (PPI plus any two of the following: amoxicillin, macrolide, 5‐nitroimidazole);</p> </li> <li> <p>Histamine<sub>2</sub>‐receptor antagonist (H<sub>2</sub>RA) triple therapy (H<sub>2</sub>RA plus any two of the following: amoxicillin, macrolide, 5‐nitroimidazole); </p> </li> <li> <p>Bismuth triple therapy (bismuth salt and 5‐nitroimidazole with either amoxicillin or tetracycline); </p> </li> <li> <p>Bismuth quadruple therapy (as bismuth triple therapy, but with the addition of a PPI);</p> </li> <li> <p>Ranitidine bismuth citrate (RBC) dual therapy (RBC plus either amoxicillin or clarithromycin);</p> </li> <li> <p>RBC triple therapy (RBC plus any two of the following: amoxicillin, macrolide, 5‐nitroimidazole);</p> </li> <li> <p>Clarithromycin monotherapy.</p> </li> </ol> </p> <p>These were compared with either placebo or no treatment.</p> <p>In trials that were of factorial design that included the evaluation of dietary supplements (for example vitamin C or selenium) as well as <i>H. pylori</i> eradication, the main analysis included arms that randomised all participants to eradication therapy or placebo or no treatment, regardless of their allocation to these supplements. </p> </section> <section id="CD005583-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>Participants had to have been followed up for at least two years, and trials needed to report data on subsequent incidence of gastric cancer as an outcome. We defined gastric cancer as any gastric adenocarcinoma, including intestinal (differentiated) or diffuse (undifferentiated) type, or without specified histology. </p> <section id="CD005583-sec-0021"> <h5 class="title">Primary outcomes</h5> <p>To assess the proportion of <i>H. pylori</i>‐positive individuals randomised to receive eradication therapy that developed gastric cancer, compared with those who received placebo or no treatment. </p> </section> <section id="CD005583-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p>We assessed the following secondary outcomes in <i>H. pylori</i> ‐positive participants randomised to <i>H. pylori</i> eradication compared with placebo or no treatment: </p> <p> <ol id="CD005583-list-0002"> <li> <p>The proportion of individuals who developed oesophageal adenocarcinoma;</p> </li> <li> <p>The proportion of individuals who developed oesophageal squamous cell carcinoma;</p> </li> <li> <p>The proportion of individuals who died from gastric cancer;</p> </li> <li> <p>The proportion of individuals who died from any cause;</p> </li> <li> <p>The proportion of adverse events (such as diarrhoea, skin rash, nausea or vomiting, headache, altered taste) dichotomised into present or absent. </p> </li> </ol> </p> </section> </section> </section> <section id="CD005583-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <p>We conducted searches to identify all published and unpublished RCTs. We included articles published in any language. </p> <section id="CD005583-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases in 2013, and performed an updated search on 02 February 2020: </p> <p> <ol id="CD005583-list-0003"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane Library 2020, Issue 1) (<a href="./appendices#CD005583-sec-0081">Appendix 1</a>); </p> </li> <li> <p>MEDLINE (1946 to 02 February 2020) by Ovid (<a href="./appendices#CD005583-sec-0082">Appendix 2</a>); </p> </li> <li> <p>EMBASE (1974 to 02 February 2020) by Ovid (<a href="./appendices#CD005583-sec-0083">Appendix 3</a>). </p> </li> </ol> </p> </section> <section id="CD005583-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We handsearched reference lists from trials selected by electronic searching to identify further relevant trials. </p> <section id="CD005583-sec-0026"> <h5 class="title">Abstracts</h5> <p>We handsearched Digestive Disease Week (published in <i>Gastroenterology</i> ) and United European Gastroenterology Week (published in <i>Gut</i>) abstract books between 2001 and 2013. Conference abstracts after 2013 were indexed by Embase so no hand‐searching was needed. We contacted authors of trial reports published only as abstracts and asked them to contribute full data sets or completed papers. </p> </section> <section id="CD005583-sec-0027"> <h5 class="title">Correspondence</h5> <p>We contacted experts in the field registered with the Cochrane Upper Gastrointestinal and Pancreatic Diseases Review Group for leads on unpublished studies. </p> </section> </section> </section> <section id="CD005583-sec-0028"> <h3 class="title" id="CD005583-sec-0028">Data collection and analysis</h3> <section id="CD005583-sec-0029"> <h4 class="title">Selection of studies</h4> <p>The lead review author screened titles and abstracts of studies that had been identified by the search strategy for articles possibly eligible for the review. The lead review author then screened the selected trials to confirm eligibility, using predesigned eligibility forms. A second review author, masked to the initial assessment, also evaluated all identified trials for eligibility. A third review author adjudicated any discrepancies, and a consensus view was taken. </p> </section> <section id="CD005583-sec-0030"> <h4 class="title">Data extraction and management</h4> <p>The lead review author extracted data and recorded it on to specially developed forms. The second review author did a blinded check on this, and any discrepancies were resolved by consensus. Data entry into <a href="./references#CD005583-bbs2-0080" title="The Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a> was also double‐checked. Due to the outcome of interest under study, several groups of trial investigators followed‐up trial participants at more than one time point. Where we found multiple articles for a single study, we extracted only data from the latest publication from each eligible study. </p> <p>We recorded the following characteristics for each trial:</p> <p> <ul id="CD005583-list-0004"> <li> <p>geographical location</p> </li> <li> <p>country of origin</p> </li> <li> <p>number of centres</p> </li> <li> <p>method used to confirm <i>H. pylori</i> infection </p> </li> <li> <p>type of eradication regimen used (including dose and schedule of individual drugs within it) </p> </li> <li> <p>duration of treatment</p> </li> <li> <p>eradication rate</p> </li> <li> <p>length of follow‐up</p> </li> <li> <p>dropouts reported and their reasons</p> </li> <li> <p>subsequent occurrence of gastric cancer</p> </li> <li> <p>subsequent occurrence of oesophageal cancer (adenocarcinoma or squamous carcinoma)</p> </li> <li> <p>mortality from gastric cancer</p> </li> <li> <p>mortality from other causes</p> </li> <li> <p>total number of adverse events reported</p> </li> </ul> </p> <p>In addition, as some of the trials we identified performed upper gastrointestinal endoscopy and obtained gastric biopsy specimens in all recruited individuals, we were able to obtain the number of participants in these RCTs with preneoplastic lesions at baseline (defined as presence of gastric atrophy, intestinal metaplasia, or dysplasia). </p> <p>We extracted data using a modified intention‐to‐treat (ITT) analysis. In this, we excluded from the analysis individuals found to be ineligible after randomisation, and those who did not receive the intervention to which they were assigned. Due to the relatively rare nature of the primary outcome of interest, we assumed that all participants lost to follow‐up had not developed gastric cancer, but kept them in the denominator for the study. We did this because the shortest duration of follow‐up in the studies we identified was greater than or equal to four years, and therefore drop‐out rates were relatively high. We also performed a complete case analysis, as a sensitivity analysis, where we excluded all participants for whom data were missing or unavailable from the analysis altogether (<a href="./references#CD005583-bbs2-0042" title="AklEA , JohnstonBC , Alonso-CoelloP , NeumannI , EbrahimS , BrielM , et al. Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers. PLoS One2013;8(2):e57132.">Akl 2013</a>). </p> </section> <section id="CD005583-sec-0031"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>One review author assessed and a second review author checked study quality. We assessed the components of quality using the criteria described below. We assessed eight risk domains. We considered a study to have a low risk of bias if all risk domains were assessed as a low risk of bias; a high risk of bias if at least one domain was assessed as high risk; or an unclear risk of bias if at least one domain was assessed as unclear risk without any high risk domains. </p> <section id="CD005583-sec-0032"> <h5 class="title">Random sequence generation (selection bias)</h5> <p>We classified a study as an RCT if it was described as randomised (this includes the use of words such as randomly, random, and randomisation, etc.). We judged the study as low risk, high risk, and unclear risk according to the following: </p> <p> <ul id="CD005583-list-0005"> <li> <p>Low risk, if the allocation sequence was generated by computer‐generated random numbers, published random number table, coin tossing, shuffling cards or envelopes, or throwing dice. </p> </li> <li> <p>Unclear risk, if the trial was described as randomised but the method used for generation of the allocation sequence was not described. </p> </li> <li> <p>High risk, if selection was based on patient numbers, birth dates, visit dates, or alternative allocation. </p> </li> <li> <p>We excluded studies that described selection based on patient or clinical preference, or any selection mechanism that cannot be described as random. We also excluded studies that did not state whether the treatment was randomly allocated. </p> </li> </ul> </p> </section> <section id="CD005583-sec-0033"> <h5 class="title">Allocation concealment (selection bias)</h5> <p> <ul id="CD005583-list-0006"> <li> <p>Low risk, if investigators were unaware of the allocation of each participant before they were entered in the trial. Acceptable methods included: central telephone randomisation schemes, pharmacy‐based schemes, sequentially numbered, opaque, sealed envelopes, or sequentially numbered drug containers of identical appearance. </p> </li> <li> <p>Unclear risk, if the authors did not report or provide a description of an allocation concealment approach that allowed for classification as concealed or not concealed. </p> </li> <li> <p>High risk, when investigators may have been aware of the allocation of each participant before they entered the trial, e.g. when allocation was based on patient data such as date of birth, hospital case note number, or visit dates, sealed envelopes that were not opaque, or a random number table that was not concealed from an investigator. </p> </li> </ul> </p> </section> <section id="CD005583-sec-0034"> <h5 class="title">Blinding of participants and personnel (performance bias)</h5> <p> <ul id="CD005583-list-0007"> <li> <p>Low risk, if both participants and physicians were blinded to the treatment allocation, and it was unlikely that the blinding could have been broken. </p> </li> <li> <p>Unclear risk, if no blinding information was available or there was insufficient information to permit a judgement of low risk or high risk. </p> </li> <li> <p>High risk, if the authors defined the study as an open study, or no party was blinded. Either participants or some key study personnel were not blinded, and the non‐blinding of others was likely to introduce bias. </p> </li> </ul> </p> </section> <section id="CD005583-sec-0035"> <h5 class="title">Blinding of outcome assessment (detection bias)</h5> <p> <ul id="CD005583-list-0008"> <li> <p>Low risk, if outcome assessors were blinded to the assigned treatment arm.</p> </li> <li> <p>Unclear risk, if no information was provided for blinding of outcome assessment.</p> </li> <li> <p>High risk, if outcome assessors were not blinded to the assigned treatment arm. Lack of blinding is likely to influence adverse events as an outcome. However, knowledge of the assigned intervention is unlikely to impact on <i>H. pylori</i> eradication assessment. </p> </li> </ul> </p> </section> <section id="CD005583-sec-0036"> <h5 class="title">Incomplete outcome data (attrition bias)</h5> <p>We assessed attrition bias for <i>H. pylori</i> eradication and adverse events. </p> <p> <ul id="CD005583-list-0009"> <li> <p>Low risk, if there were no missing outcome data; reasons for missing outcome data were unlikely to be related to true outcome; missing outcome data were balanced in numbers across intervention groups, with similar reasons for missing data across groups; the proportion of missing outcomes compared with the observed event risk was not enough to have a clinically relevant impact on the intervention effect estimate; missing data were imputed using appropriate methods. </p> </li> <li> <p>Unclear risk, if insufficient reporting of attrition or exclusions to permit judgement of low risk or high risk (e.g. no reasons for missing data provided). </p> </li> <li> <p>High risk, if reasons for missing outcome data were likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups; the proportion of missing outcomes compared with observed event risk were enough to induce clinically relevant bias in intervention effect estimate; per protocol analysis done with substantial departure of the intervention received from that assigned at randomisation; potentially inappropriate application of simple imputation. </p> </li> </ul> </p> </section> <section id="CD005583-sec-0037"> <h5 class="title">Selective reporting (reporting bias)</h5> <p> <ul id="CD005583-list-0010"> <li> <p>Low risk, if the published reports included all expected outcomes, including those that were prespecified. </p> </li> <li> <p>Unclear risk, if insufficient information to permit judgement of low risk or high risk. </p> </li> <li> <p>High risk, if not all of the study’s prespecified primary outcomes were reported; the primary outcome (gastric cancer) was reported using measurements, analysis methods, or subsets of the data that were not prespecified; the primary outcome was not prespecified or was reported incompletely; or the study report failed to include results for a key outcome that would be expected to have been reported for such a study. </p> </li> </ul> </p> </section> <section id="CD005583-sec-0038"> <h5 class="title">Other bias</h5> <p> <ul id="CD005583-list-0011"> <li> <p>Low risk, if the study appears to be free of other sources of bias.</p> </li> <li> <p>Unclear risk, if there may be a risk of bias but there is either: insufficient information to assess whether an important risk of bias exists (e.g. limited information from a conference proceeding); or insufficient rationale or evidence that an identified problem introduces bias. </p> </li> <li> <p>High risk, if there is at least one important risk of bias; a potential source of bias related to the specific study design used; stopped early due to a data‐dependent process (including a formal stopping rule); extreme baseline imbalance; has been claimed to have been fraudulent; or any other problem. </p> </li> </ul> </p> </section> </section> <section id="CD005583-sec-0039"> <h4 class="title">Measures of treatment effect</h4> <p>We assessed the proportion of otherwise healthy and asymptomatic <i>H. pylori</i>‐positive individuals randomised to receive eradication therapy who developed subsequent gastric cancer, compared with those who received placebo or no treatment. </p> </section> <section id="CD005583-sec-0040"> <h4 class="title">Unit of analysis issues</h4> <p>We included only standard design parallel‐group RCTs with binary outcomes (incidence of gastric cancer). Cluster randomised trials, cross‐over trials, and repeated measurement were not present for the type of RCT. </p> </section> <section id="CD005583-sec-0041"> <h4 class="title">Dealing with missing data</h4> <p>Where possible, we recorded completeness of follow‐up, with drop‐out rates by group. We attempted to contact authors for missing data. If no outcome data were available, we used the modified ITT approach, which included all eligible and randomised participants in the analysis, but we did not consider participants who were found to be ineligible after randomisation in the ITT analysis in the primary analyses. <a href="./references#CD005583-bbs2-0002" title="CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacterpylori therapy. Journal of the National Cancer Institute2000;92(23):1881-8. CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Re: Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. Journal of the National Cancer Institute2001;93(7):559-60. MeraR , FonthamET , BravoLE , BravoJC , PiazueloMB , CamargoMC , et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut2005;54(11):1536-40. RuizB , GarayJ , CorreaP , FonthamET , BravoJC , BravoLE , et al. Morphometric evaluation of gastric antral atrophy: improvement after cure of Helicobacter pylori infection. American Journal of Gastroenterology2001;96(12):3281-7. ">Correa 2000‐Correa 2001</a> and <a href="./references#CD005583-bbs2-0007" title="GailMH , YouWC , ChangYS , ZhangL , BlotWJ , BrownLM , et al. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. Controlled Clinical Trials1998;19(4):352-69. LiWQ , MaJL , ZhangL , BrownLM , LiJY , ShenL , et al. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. Journal of the National Cancer Institute2014;106(7). [DOI: DOI:10.1093/jnci/dju116] [PMID: 24925350]LiWQ , ZhangJY , MaJL , LiZX , ZhangL , ZhangY , et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. BMJ2019;366:l5016. [PMID: 31511230]LiWQ , ZhangL , MaJL , BrownL , LiJY , ShenL , et al. Fifteen-year effects of Helicobacter pylori treatment on gastric cancer incidence and mortality among participants with different baseline gastric lesions and ages. American Journal of Epidemiology2013;177 (Suppl 11):S61. MaJL , ZhangL , BrownLM , LiJY , ShenL , PanKF , et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. Journal of the National Cancer Institute2012;104(6):488-92. WangY , ZhangL , MoslehiR , MaJ , PanK , ZhouT , et al. Long-term garlic or micronutrient supplementation, but not anti-Helicobacter pylori therapy, increases serum folate or glutathione without affecting serum vitamin B-12 or homocysteine in a rural Chinese population. Journal of Nutrition2009;139(1):106-12. YouWC , BrownLM , ZhangL , LiJY , JinML , ChangYS , et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. Journal of the National Cancer Institute2006;98(14):974-83. YouWC , ChangYS , HeinrichJ , MaJL , LiuWD , ZhangL , et al. An intervention trial to inhibit the progression of precancerous gastric lesions: compliance, serum micronutrients and S-allyl cysteine levels, and toxicity. European Journal of Cancer Prevention2001;10(3):257-63. ZhangL , GailMH , WangYQ , BrownLM , PanKF , MaJL , et al. A randomized factorial study of the effects of long-term garlic and micronutrient supplementation and of 2-wk antibiotic treatment for Helicobacter pylori infection on serum cholesterol and lipoproteins. American Journal of Clinical Nutrition2006;86(4):912-9. ZhangL , MaJL , LiuWD , JiangJ , PanKF , PanYS , et al. A randomized multi-intervention trial to inhibit gastric cancer in Shandong (progress report). Chinese Journal of Clinical Oncology1998;25(5):338-40. ">You 2006 ‐ Li 2019</a> both excluded participants from the analyses after randomisation (as they were subsequently found to be ineligible or did not take the treatment). We included these ineligible participants in the sensitivity analyses. Since the incidence of gastric cancer is low, we did not presume that missing participants had developed subsequent gastric cancer (worst‐case scenario). </p> <p>We also performed a complete case analysis, as a sensitivity analysis, where we excluded all participants for whom data were missing or unavailable from the analysis altogether (<a href="./references#CD005583-bbs2-0042" title="AklEA , JohnstonBC , Alonso-CoelloP , NeumannI , EbrahimS , BrielM , et al. Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers. PLoS One2013;8(2):e57132.">Akl 2013</a>). We also performed sensitivity analyses with missing data imputation based on the assumptions that: 1) incidence of gastric cancer for missing participants in both arms was the same as observed in the trial control arm; 2) incidence of gastric cancer for missing participants in the treatment arm was the same as that observed in the trial control arm, but there were no new gastric cancer cases in the control arm among those with missing data (<a href="./references#CD005583-bbs2-0042" title="AklEA , JohnstonBC , Alonso-CoelloP , NeumannI , EbrahimS , BrielM , et al. Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers. PLoS One2013;8(2):e57132.">Akl 2013</a>). </p> </section> <section id="CD005583-sec-0042"> <h4 class="title">Assessment of heterogeneity</h4> <p>We pooled data using a random‐effects model to give a more conservative estimate of the effect of <i>H. pylori</i> eradication therapy on the subsequent occurrence of gastric cancer, allowing for any heterogeneity between studies (<a href="./references#CD005583-bbs2-0050" title="DerSimonianR , LairdN . Meta-analysis in clinical trials. Controlled Clinical Trials1986;7(3):177-88.">DerSimonian 1986</a>). We assessed heterogeneity using both the I<sup>2</sup> statistic with a cutoff of greater than or equal to 50%, and the Chi<sup>2</sup> test with a P value less than 0.10 used to define a significant degree of heterogeneity (<a href="./references#CD005583-bbs2-0062" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>). </p> </section> <section id="CD005583-sec-0043"> <h4 class="title">Assessment of reporting biases</h4> <p>We did not produce funnel plots in any of our analyses, as less than 10 studies were included in these in all cases. (<a href="./references#CD005583-bbs2-0083" title="SterneJA , SuttonAJ , IoannidisJP , TerrinN , JonesDR , LauJ , et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ2011;343:d4002.">Sterne 2011</a>) </p> </section> <section id="CD005583-sec-0044"> <h4 class="title">Data synthesis</h4> <p>For all primary and secondary outcomes, which were dichotomous, we expressed the impact of the intervention as a risk ratio (RR) together with 95% confidence intervals. We calculated the NNTB using the formula 100/(risk ratio reduction x control event rate); that is NNTB = 1/(assumed control risk (ACR) x (1 ‐ RR)), with the ACR based on the pooled control event rate from the eligible studies. There were sufficient data for the generation of a meta‐analysis for this review. </p> </section> <section id="CD005583-sec-0045"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We performed subgroup analyses examining the incidence of subsequent gastric cancer according to the presence or absence of preneoplastic lesions (defined as presence of gastric atrophy, intestinal metaplasia, or dysplasia) at baseline among trial participants, as judged by histopathological interpretation of gastric biopsy specimens, and according to whether trial participants were co‐administered antioxidants or vitamins during the trial. </p> <p>Where we detected significant heterogeneity, we investigated possible explanations informally. We planned to explore reasons for heterogeneity according to the following predefined criteria: </p> <p> <ol id="CD005583-list-0012"> <li> <p>eradication regimen used in the study;</p> </li> <li> <p>geographical location of the study;</p> </li> <li> <p>risk of bias of the study.</p> </li> </ol> </p> </section> <section id="CD005583-sec-0046"> <h4 class="title">Sensitivity analysis</h4> <p> <ol id="CD005583-list-0013"> <li> <p>We performed a complete case analysis, where we excluded all participants for whom data were missing or unavailable from the analysis altogether (<a href="./references#CD005583-bbs2-0042" title="AklEA , JohnstonBC , Alonso-CoelloP , NeumannI , EbrahimS , BrielM , et al. Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers. PLoS One2013;8(2):e57132.">Akl 2013</a>). </p> </li> <li> <p>We performed missing data imputation based on the assumptions that a) incidence of gastric cancer for missing participants in both arms was the same as that observed in the trial control arm; b) incidence of gastric cancer for missing participants in the treatment arm was the same as that observed in the trial control arm, but there were no new gastric cancer cases in the control arm among those with missing data (<a href="./references#CD005583-bbs2-0042" title="AklEA , JohnstonBC , Alonso-CoelloP , NeumannI , EbrahimS , BrielM , et al. Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers. PLoS One2013;8(2):e57132.">Akl 2013</a>). </p> </li> <li> <p>We conducted a modified ITT analysis as well as a complete case analysis, using data from <a href="./references#CD005583-bbs2-0003" title="LeungWK , LinSR , ChingJY , ToKF , NgEK , ChanFK , et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut2004;53(9):1244-9. SungJJ , LinSR , ChingJY , ZhouLY , ToKF , WangRT , et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology2000;119(1):7-14. SungJJ , LinSR , LeungW , NgEK , ChingJY , ToKF , et al. Does eradication of H. pylori prevent deterioration of gastric atrophy and intestinal metaplasia? A 5-year follow-up. In: Gastroenterology. Vol. 122(Suppl 4). 2002:A170. Abstract S1142. ZhouL , LinS , DingS , HuangX , JinZ , CuiR , et al. Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study. Chinese medical journal2014;127(8):1454-8. [PMID: 24762588]ZhouL , SungJJ , LinS , JinZ , DingS , HuangX , et al. A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chinese Medical Journal2003;116(1):11-4. [PMID: 12667379]ZhouL . Ten-year follow-up study on the incidence of gastric cancer and the pathological changes of gastric mucosa after H. pylori eradication in China. In: Gastroenterology. Vol. 134 (4, suppl 1). 2008:A233. Abstract S1606. ZhouLY , LinSR , DingSG , HuangSB , GuoCJ , ZhangL , et al. Eight-year follow-up study on prevalence of gastric cancer and the histological changes of gastric mucosa after H.pylori eradication [除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究]. Chinese Journal of Digestion2005;25(6):324-7. ZhouLY , LinSR , DingSG , HuangSB , GuoCJ , ZhangL , et al. Eight-year follow-up study on the morbidity of gastric cancer and the pathological changes of gastric mucosa after H.pylori eradication [除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究]. www.paper.edu.cn/scholar/downpaper/zhouliya-3 (accessed 10 June 2015). ZhouLY , LinSR , DingSG , HuangXB , ZhangL , MengLM , et al. The changing trends of the incidence of gastric cancer after Helicobacter pylori eradication in Shandong area. Chinese Journal of Digestive Diseases2005;6(3):114-5. ZhouLY , LinSR , ShenZY , ZhongSZ , DingSG , HuangXB , et al. Five-year follow-up study after Helicobacter pylori eradication: Reinfection and peptic ulcer status. Chinese Journal of Digestive Diseases2003;4(1):45-8. ZhouLY , SungJJ , LinSR , JinZ , DingSG , HuangXB , et al. Changes of gastric mucosa histopathology after Helicobacterpylori eradication [根除幽门螺杆菌对胃黏膜炎症变化的人群随访研究]. Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]2003;42(3):162-4. ">Leung 2004‐Zhou 2014</a> (full publication), instead of the conference abstract data presented in <a href="./references#CD005583-bbs2-0105" title="ZhouL . Ten-year follow-up study on the incidence of gastric cancer and the pathological changes of gastric mucosa after H. pylori eradication in China. In: Gastroenterology. Vol. 134 (4, suppl 1). 2008:A233. Abstract S1606.">Zhou 2008</a>. </p> </li> <li> <p>We conducted a modified ITT analysis including the two celecoxib arms (anti‐<i>H. pylori</i> treatment and celecoxib, placebo and celecoxib) from Wong 2012b. </p> </li> <li> <p>We included all randomised subjects, including those who were found to be ineligible or did not receive treatment after randomisation in <a href="./references#CD005583-bbs2-0002" title="CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacterpylori therapy. Journal of the National Cancer Institute2000;92(23):1881-8. CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Re: Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. Journal of the National Cancer Institute2001;93(7):559-60. MeraR , FonthamET , BravoLE , BravoJC , PiazueloMB , CamargoMC , et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut2005;54(11):1536-40. RuizB , GarayJ , CorreaP , FonthamET , BravoJC , BravoLE , et al. Morphometric evaluation of gastric antral atrophy: improvement after cure of Helicobacter pylori infection. American Journal of Gastroenterology2001;96(12):3281-7. ">Correa 2000‐Correa 2001</a> and <a href="./references#CD005583-bbs2-0007" title="GailMH , YouWC , ChangYS , ZhangL , BlotWJ , BrownLM , et al. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. Controlled Clinical Trials1998;19(4):352-69. LiWQ , MaJL , ZhangL , BrownLM , LiJY , ShenL , et al. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. Journal of the National Cancer Institute2014;106(7). [DOI: DOI:10.1093/jnci/dju116] [PMID: 24925350]LiWQ , ZhangJY , MaJL , LiZX , ZhangL , ZhangY , et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. BMJ2019;366:l5016. [PMID: 31511230]LiWQ , ZhangL , MaJL , BrownL , LiJY , ShenL , et al. Fifteen-year effects of Helicobacter pylori treatment on gastric cancer incidence and mortality among participants with different baseline gastric lesions and ages. American Journal of Epidemiology2013;177 (Suppl 11):S61. MaJL , ZhangL , BrownLM , LiJY , ShenL , PanKF , et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. Journal of the National Cancer Institute2012;104(6):488-92. WangY , ZhangL , MoslehiR , MaJ , PanK , ZhouT , et al. Long-term garlic or micronutrient supplementation, but not anti-Helicobacter pylori therapy, increases serum folate or glutathione without affecting serum vitamin B-12 or homocysteine in a rural Chinese population. Journal of Nutrition2009;139(1):106-12. YouWC , BrownLM , ZhangL , LiJY , JinML , ChangYS , et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. Journal of the National Cancer Institute2006;98(14):974-83. YouWC , ChangYS , HeinrichJ , MaJL , LiuWD , ZhangL , et al. An intervention trial to inhibit the progression of precancerous gastric lesions: compliance, serum micronutrients and S-allyl cysteine levels, and toxicity. European Journal of Cancer Prevention2001;10(3):257-63. ZhangL , GailMH , WangYQ , BrownLM , PanKF , MaJL , et al. A randomized factorial study of the effects of long-term garlic and micronutrient supplementation and of 2-wk antibiotic treatment for Helicobacter pylori infection on serum cholesterol and lipoproteins. American Journal of Clinical Nutrition2006;86(4):912-9. ZhangL , MaJL , LiuWD , JiangJ , PanKF , PanYS , et al. A randomized multi-intervention trial to inhibit gastric cancer in Shandong (progress report). Chinese Journal of Clinical Oncology1998;25(5):338-40. ">You 2006 ‐ Li 2019</a>. </p> </li> </ol> </p> </section> <section id="CD005583-sec-0047"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>The results of the main outcomes from this review are presented in the <a href="./full#CD005583-tbl-0001">summary of findings Table 1</a>. The table presents a summary of the available data as well as a evaluation of the robustness of the results according to GRADE (Grades of Recommendation, Assessment, Development and Evaluation) criteria <a href="./references#CD005583-bbs2-0060" title="GuyattG , OxmanAD , AklEA , KunzR , Vist G et al. GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383-94.">GRADE 2011</a>. The GRADE approach evaluates the overall quality of the evidence for a given outcome in terms of risk of bias, precision, directness of the evidence, publication bias and completeness of outcome reporting <a href="./references#CD005583-bbs2-0043" title="BalshemH , HelfandM , SchunemannH , OxmanAD , Kunz R et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology2011;64(4):401-6.">Balshem 2011</a>. This gives an overall assessment of the confidence that can be placed in the data, which in turn can inform decision making. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD005583-sec-0048" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD005583-sec-0048"></div> <section id="CD005583-sec-0049"> <h3 class="title">Description of studies</h3> <p>See: <a href="./references#CD005583-sec-0097" title="">Characteristics of included studies</a> and <a href="./references#CD005583-sec-0098" title="">Characteristics of excluded studies</a>. </p> <section id="CD005583-sec-0050"> <h4 class="title">Results of the search</h4> <p>In 2013, we identified 1560 citations with six eligible RCTs. In the February 2020 updated search, we identified 716 citations with one new RCT, using the search strategy outlined above (<a href="#CD005583-fig-0001">Figure 1</a>). We reviewed the titles and abstracts and thought 56 articles in 2013 and 12 records in 2020 to be potentially eligible for inclusion. Of these 68 articles, 16 were not RCTs (<a href="./references#CD005583-bbs2-0015" title="HamajimaN , MatuoK , WatanabeY , SuzukiT , NakamuraT , MatsuuraA , et al. A pilot study to evaluate stomach cancer risk reduction by Helicobacter pylori eradication. American Journal of Gastroenterology2002;97(3):764-5. ">Hamajima 2002</a>; <a href="./references#CD005583-bbs2-0017" title="HsuPI , LaiKH , HsuPN , LoGH , YuHC , ChenWC , et al. Helicobacter pylori infection and the risk of gastric malignancy. American Journal of Gastroenterology2007;102(4):725-30. ">Hsu 2007</a>; <a href="./references#CD005583-bbs2-0019" title="JuibariM , MoayyediR , GholampourM , BijarchiR , PeterK , KoucharianC , et al. Risk of precancerous pathologic changes in the stomach after appropriate eradication of Helicobacter pylori: A multi-centric study from a developing country. In: Gut. Vol. 52 (Suppl VI). 2003:A148. ">Juibari 2003</a>; <a href="./references#CD005583-bbs2-0020" title="KamangarF , DawseySM , BlaserMJ , Perez-PerezGI , PietinenP , NewschafferCJ , et al. Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. Journal of the National Cancer Institute2006;98(20):1445-52. ">Kamangar 2006</a>; <a href="./references#CD005583-bbs2-0021" title="KatoM , AsakaM , NakamuraT , AzumaT , EomitaA , KamoshidaT , et al. H.pylori eradication prevents the development of gastric cancer- results of a long-term retrospective study in Japan. Alimentary Pharmacology &amp; Therapeutics2006;24(Suppl 4):203-6. ">Kato 2006</a>; <a href="./references#CD005583-bbs2-0022" title="KimN , ParkRY , ChoSI , LimSH , LeeKH , LeeW , et al. Helicobacter pylori infection and development of gastric cancer in Korea: long-term follow up. Journal of Clinical Gastroenterology2008;42(5):448-54. ">Kim 2008</a>; <a href="./references#CD005583-bbs2-0025" title="LeungWK , WongIOL , CheungKS , YeungKF , ChanEW , WongAYS , et al. Effects of Helicobacter pylori Treatment on Incidence of Gastric Cancer in Older Individuals. Gastroenterology2018;155(1):67-75. [PMID: 29550592]">Leung 2018</a>; <a href="./references#CD005583-bbs2-0026" title="MabeK , TakahashiM , OizumiH , TsukumaH , ShibataA , FukaseK , et al. Does Helicobacter pylori eradication therapy for peptic ulcer prevent gastric cancer?World Journal of Gastroenterology2009;15(34):4290-7. ">Mabe 2009</a>; <a href="./references#CD005583-bbs2-0030" title="OguraK , HirataY , YanaiA , ShibataW , OhmaeT , MitsunoY , et al. The effect of Helicobacter pylori eradication on reducing the incidence of gastric cancer. Journal of Clinical Gastroenterology2008;42(3):279-83. ">Ogura 2008</a>; <a href="./references#CD005583-bbs2-0031" title="OhkusaT , FujikiK , TakashimizuI , KumagaiJ , TanizawaT , EishiY , et al. Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated. Annals of Internal Medicine2001;134(5):380-6. ">Ohkusa 2001</a>; <a href="./references#CD005583-bbs2-0032" title="TakeS , MizunoM , IshikiK , NagaharaY , YoshidaT , YokotaK , et al. The effect of eradicating Helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. American Journal of Gastroenterology2005;100(5):1037-42. ">Take 2005</a>; <a href="./references#CD005583-bbs2-0033" title="TakeS , MizunoM , IshikiK , NagaharaY , YoshidaT , YokotaK , et al. Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases. Journal of Gastroenterology2007;42(Suppl 17):21-7. ">Take 2007</a>; <a href="./references#CD005583-bbs2-0034" title="TakenakaR , OkadaH , KatoJ , MakidonoC , HoriS , KawaharaY , et al. Helicobacter pylori eradication reduced the incidence of gastric cancer, especially of the intestinal type. Alimentary Pharmacology &amp; Therapeutics2007;25(7):805-12. ">Takenaka 2007</a>; <a href="./references#CD005583-bbs2-0036" title="UemuraN , OkamotoS , YamamotoS , MatsumuraN , YamaguchiS , YamakidoM , et al. Helicobacter pylori infection and the development of gastric cancer. The New England Journal of Medicine2001;345(11):784-9. ">Uemura 2001</a>; <a href="./references#CD005583-bbs2-0037" title="UemuraN , OkamotoS , YamamotoS . H. pylori infection and the development of gastric cancer. Keio Journal of Medicine2002;51(Suppl 2):63-8. ">Uemura 2002</a>; <a href="./references#CD005583-bbs2-0039" title="YanaokaK , OkaM , OhataH , YoshimuraN , DeguchiH , MukoubayashiC , et al. Eradication of Helicobacter pylori prevents cancer development in subjects with mild gastric atrophy identified by serum pepsinogen levels. International Journal of Cancer. Journal International du Cancer2009;125(11):2697-703. ">Yanaoka 2009</a>); three were RCTs comparing the interventions of interest, but their primary objective was to study the effect of <i>H. pylori</i> eradication therapy on dyspepsia in the community, and they did not report any gastric cancer data (<a href="./references#CD005583-bbs2-0016" title="HarveyRF , LaneJA , MurrayLJ , HarveyIM , DonovanJL , NairP , et al. Randomised controlled trial of effects of Helicobacter pylori infection and its eradication on heartburn and gastro-oesophageal reflux: Bristol Helicobacter project. BMJ2004;328(7453):1417. ">Harvey 2004</a>; <a href="./references#CD005583-bbs2-0029" title="MoayyediP , FeltbowerR , BrownJ , MasonS , MasonJ , NathanJ , et al. Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. Leeds HELP Study Group. The Lancet2000;355(9213):1665-9. ">Moayyedi 2000</a>; <a href="./references#CD005583-bbs2-0038" title="Wildner-ChristensenM , Møller HansenJ , Schaffalitzky De MuckadellOB . Rates of dyspepsia one year after Helicobacter pylori screening and eradication in a Danish population. Gastroenterology2003;125(2):372-9. ">Wildner‐Christensen 2003</a>); and two were RCTs, but with no incident gastric cancers occurring during follow‐up, and therefore did not meet our eligibility criteria for inclusion (<a href="./references#CD005583-bbs2-0011" title="FischbachLA , CorreaP , RamirezH , RealpeJL , CollazosT , RuizB , et al. Anti-inflammatory and tissue-protectant drug effects: results from a randomized placebo-controlled trial of gastritis patients at high risk for gastric cancer. Alimentary Pharmacology &amp; Therapeutics2001;15(6):831-41. ">Fischbach 2001</a>; <a href="./references#CD005583-bbs2-0028" title="MiehlkeS , KirschC , DragosicsB , GschwantlerM , OberhuberG , AntosD , et al. Helicobacter pylori and gastric cancer: current status of the Austrian Czech German gastric cancer prevention trial (PRISMA Study). World Journal of Gastroenterology2001;7(2):243-7. ">Miehlke 2001</a>). In the latter five studies, we contacted the lead or senior authors to ask for the most up‐to‐date information from the most recent follow‐up point of the study, in order to ensure that we were not excluding these articles injudiciously. In all cases, the authors responded and stated that there had been no incident gastric cancers reported at the last point of follow‐up. One RCT presented data on those who had <i>H.pylori</i> eradicated in intervention group vs those <i>H.pylori</i> negative in control group after 3 years, instead of presenting data in all randomized subjects; subjects were those who admitted to hospital or came to hospital for H.pylori testing, instead of general population (<a href="./references#CD005583-bbs2-0035" title="TangJM , ChenY , LuHL , ZhaoGM , XuH , SuRH . Histologic changes and incidence of gastric cancer after Helicobacter pylori eradication: a 3-year follow-up study [根除幽门螺杆菌对胃黏膜组织学变化及胃癌患病率的 3 年随访研究]. Modern Digestion Intervention (现代消化及介入诊疗)2010;15(1):47-49. ">Tang 2010</a>). One was a protocol of a RCT that will randomize participants to test and treat vs controls, instead of eradication vs control (<a href="./references#CD005583-bbs2-0024" title="LejaM , ParkJY , MurilloR , Liepniece-KareleI , IsajevsS , KikusteI , et al. Multicentric randomised study of Helicobacter pylori eradication and pepsinogen testing for prevention of gastric cancer mortality: the GISTAR study. BMJ open2017;7(8):e016999. [PMID: 28801429]">Leja 2017</a>) Another four articles were duplicate publications of studies already classified as ineligible. (<a href="./references#CD005583-bbs2-0013" title="FordAC , FormanD , BaileyAG , AxonAT , MoayyediP . A community screening program for Helicobacter pylori saves money: 10-year follow-up of a randomized controlled trial. Gastroenterology2005;129(6):1910-7. ">Ford 2005</a>; <a href="./references#CD005583-bbs2-0018" title="ImanzadehF , SayyariAA , AkbariMR . Histopathology of the stomach mucosa after treatment for Helicobacter pylori: A multi-centric study. In: Gut. Vol. 53 (Suppl VI). 2004:A292. ">Imanzadeh 2004</a>; <a href="./references#CD005583-bbs2-0023" title="LaneJA , MurrayLJ , NobleS , EggerM , HarveyIM , DonovanJL , et al. Impact of Helicobacter pylori eradication on dyspepsia, health resource use, and quality of life in the Bristol Helicobacter project: randomised controlled trial. BMJ2006;332(7535):199-204. ">Lane 2006</a>; <a href="./references#CD005583-bbs2-0027" title="MasonJ , AxonAT , FormanD , DuffettS , DrummondM , CrocombeW , et al. The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial. Alimentary Pharmacology &amp; Therapeutics2002;16(3):559-68. ">Mason 2002</a>). Four studies were RCTs conducted among patients undergoing endoscopic mucosal resection of early gastric cancer (<a href="./references#CD005583-bbs2-0008" title="ChoiJ , KimSG , YoonH , ImJP , KimJS , KimWH , et al. Eradication of Helicobacter pylori after endoscopic resection of gastric tumors does not reduce incidence of metachronous gastric carcinoma. Clinical Gastroenterology and Hepatology2014;12(5):793-800. ">Choi 2014</a>; <a href="./references#CD005583-bbs2-0009" title="ChoiJM , KimSG , ChoiJ , ParkJY , OhS , YangHJ , LimJH , ImJP , KimJS , JungHC . Effects of Helicobacter pylori eradication for metachronous gastric cancer prevention: a randomized controlled trial. Gastrointest Endosc2018;88(3):475-485.e2. [DOI: 10.1016/j.gie.2018.05.009] [Clinical trial registration number: NCT01510730]">Choi 2018a</a>; <a href="./references#CD005583-bbs2-0010" title="ChoiIJ , KookMC , KimYI , ChoSJ , LeeJY , KimCG , ParkB , NamBH . Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer. N Engl J Med2018;378(12):1085-1095. [DOI: 10.1056/NEJMoa1708423] [ClinicalTrials.gov number, NCT02407119]">Choi 2018b</a>; <a href="./references#CD005583-bbs2-0014" title="FukaseK , KatoM , KikuchiS , InoueK , UemuraN , OkamotoS , et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. The Lancet2008;372(9636):392-7. ">Fukase 2008</a>), rather than healthy asymptomatic infected participants, and the final article did not compare the interventions of interest (<a href="./references#CD005583-bbs2-0012" title="FischbachLA , BravoLE , ZaramaGR , BravoJC , OjhaRP , PriestEL , et al. A randomized clinical trial to determine the efficacy of regimens containing clarithromycin, metronidazole, and amoxicillin among histologic subgroups for Helicobacter pylori eradication in a developing country. Helicobacter2009;14(2):100-8. ">Fischbach 2009</a>). In the updated search, two articles were protocols from Korea for "HEPTER study" (<a href="./references#CD005583-bbs2-0040" title="KCT0001262. Helicobacter Pylori Eradication for Gastric Cancer Prevention in the General Population. http://apps.who.int/trialsearch/Trial2.aspx?TrialID=KCT0001262 . [http://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=5307]NCT02112214. Helicobacter Pylori Eradication for Gastric Cancer Prevention in the General Population (HELPER). https://clinicaltrials.gov/ct2/show/nct02112214 . ">HELPER study</a>) and one article was protocol from China (<a href="./references#CD005583-bbs2-0041" title="PanKF , ZhangL , GerhardM , MaJL , LiuWD , UlmK , et al. A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradication. Gut2016;65(1):9-18. [PMID: 25986943]">Pan 2016</a>)for an ongoing randomised trial. </p> <div class="figure" id="CD005583-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram: review update" data-id="CD005583-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_n/nCD005583-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram: review update</p> </div> </div> </div> <p>This left 33 separate papers, reporting on seven separate RCTs that compared <i>H. pylori</i> eradication therapy with placebo or no treatment and providing data on subsequent incidence of gastric cancer, which therefore appeared to be eligible for inclusion. In the previous version of this review, 19 of 29 of these articles were preliminary or duplicate publications, or protocols of eligible RCTs, and provided no new information or did not report outcomes of interest, and were therefore excluded from the meta‐analysis (<a href="./references#CD005583-bbs2-0051" title="FengGS , MaJL , WongBC , ZhangL , LiuWD , PanKF , et al. Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention. World Journal of Gastroenterology2008;14(28):4535-9.">Feng 2008</a>; <a href="./references#CD005583-bbs2-0069" title="LiWQ , ZhangL , MaJL , BrownL , LiJY , ShenL , et al. Fifteen-year effects of Helicobacter pylori treatment on gastric cancer incidence and mortality among participants with different baseline gastric lesions and ages. American Journal of Epidemiology2013;177 (Suppl 11):S61.">Li 2013</a>; <a href="./references#CD005583-bbs2-0075" title="MeraR , FonthamET , BravoLE , BravoJC , PiazueloMB , CamargoMC , et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut2005;54(11):1536-40.">Mera 2005</a>; <a href="./references#CD005583-bbs2-0081" title="RuizB , GarayJ , CorreaP , FonthamET , BravoJC , BravoLE , et al. Morphometric evaluation of gastric antral atrophy: improvement after cure of Helicobacter pylori infection. American Journal of Gastroenterology2001;96(12):3281-7.">Ruiz 2001</a>; <a href="./references#CD005583-bbs2-0082" title="SaitoD . Present state of Japanese intervention trial of H. pylori . Nihon Rinsho2003;61(1):50-5.">Saito 2003</a>; <a href="./references#CD005583-bbs2-0084" title="SungJJ , LinSR , ChingJY , ZhouLY , ToKF , WangRT , et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology2000;119(1):7-14.">Sung 2000</a>; <a href="./references#CD005583-bbs2-0085" title="SungJJ , LinSR , LeungW , NgEK , ChingJY , ToKF , et al. Does eradication of H. pylori prevent deterioration of gastric atrophy and intestinal metaplasia? A 5-year follow-up. In: Gastroenterology. Vol. 122(Suppl 4). 2002:A170. Abstract S1142.">Sung 2002</a>; <a href="./references#CD005583-bbs2-0088" title="WangY , ZhangL , MoslehiR , MaJ , PanK , ZhouT , et al. Long-term garlic or micronutrient supplementation, but not anti-Helicobacter pylori therapy, increases serum folate or glutathione without affecting serum vitamin B-12 or homocysteine in a rural Chinese population. Journal of Nutrition2009;139(1):106-12.">Wang 2009</a>; <a href="./references#CD005583-bbs2-0090" title="WongBCY , LamS , WongWM , et al. Eradication of Helicobacter pylori infection significantly slows down the progression of precancerous lesions in high risk populations: a 5 year prospective randomized study. In: Gastroenterology. Vol. 122. 2002:A588. Abstract W1216.">Wong 2002</a>; <a href="./references#CD005583-bbs2-0092" title="WongBC . Eradication of Helicobacter pylori for prevention of gastric cancer. In: Journal of Gastroenterology and Hepatology. Vol. 27 (Suppl 5). 2012:5-6. Abstract UA01-05.">Wong 2012b</a>; <a href="./references#CD005583-bbs2-0095" title="YouWC , ChangYS , HeinrichJ , MaJL , LiuWD , ZhangL , et al. An intervention trial to inhibit the progression of precancerous gastric lesions: compliance, serum micronutrients and S-allyl cysteine levels, and toxicity. European Journal of Cancer Prevention2001;10(3):257-63.">You 2001</a>; <a href="./references#CD005583-bbs2-0097" title="ZhangL , MaJL , LiuWD , JiangJ , PanKF , PanYS , et al. A randomized multi-intervention trial to inhibit gastric cancer in Shandong (progress report). Chinese Journal of Clinical Oncology1998;25(5):338-40.">Zhang 1998</a>; <a href="./references#CD005583-bbs2-0098" title="ZhangL , GailMH , WangYQ , BrownLM , PanKF , MaJL , et al. A randomized factorial study of the effects of long-term garlic and micronutrient supplementation and of 2-wk antibiotic treatment for Helicobacter pylori infection on serum cholesterol and lipoproteins. American Journal of Clinical Nutrition2006;86(4):912-9.">Zhang 2006</a>; <a href="./references#CD005583-bbs2-0099" title="ZhouL , SungJJ , LinS , JinZ , DingS , HuangX , et al. A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chinese Medical Journal2003;116(1):11-4.">Zhou 2003a</a>; <a href="./references#CD005583-bbs2-0100" title="ZhouLY , LinSR , ShenZY , ZhongSZ , DingSG , HuangXB , et al. Five-year follow-up study after Helicobacter pylori eradication: Reinfection and peptic ulcer status. Chinese Journal of Digestive Diseases2003;4(1):45-8.">Zhou 2003b</a>; <a href="./references#CD005583-bbs2-0101" title="ZhouLY , SungJJ , LinSR , JinZ , DingSG , HuangXB , et al. Changes of gastric mucosa histopathology after Helicobacterpylori eradication [根除幽门螺杆菌对胃黏膜炎症变化的人群随访研究]. Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]2003;42(3):162-4.">Zhou 2003c</a>; <a href="./references#CD005583-bbs2-0102" title="ZhouLY , LinSR , DingSG , HuangSB , GuoCJ , ZhangL , et al. Eight-year follow-up study on prevalence of gastric cancer and the histological changes of gastric mucosa after H.pylori eradication [除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究]. Chinese Journal of Digestion2005;25(6):324-7.">Zhou 2005a</a>; <a href="./references#CD005583-bbs2-0103" title="ZhouLY , LinSR , DingSG , HuangSB , GuoCJ , ZhangL , et al. Eight-year follow-up study on the morbidity of gastric cancer and the pathological changes of gastric mucosa after H.pylori eradication [除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究]. www.paper.edu.cn/scholar/downpaper/zhouliya-3 (accessed 10 June 2015).">Zhou 2005b</a>; <a href="./references#CD005583-bbs2-0104" title="ZhouLY , LinSR , DingSG , HuangXB , ZhangL , MengLM , et al. The changing trends of the incidence of gastric cancer after Helicobacter pylori eradication in Shandong area. Chinese Journal of Digestive Diseases2005;6(3):114-5.">Zhou 2005c</a>), leaving 10 papers that reported unique and extractable data (<a href="./references#CD005583-bbs2-0002" title="CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacterpylori therapy. Journal of the National Cancer Institute2000;92(23):1881-8. CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Re: Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. Journal of the National Cancer Institute2001;93(7):559-60. MeraR , FonthamET , BravoLE , BravoJC , PiazueloMB , CamargoMC , et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut2005;54(11):1536-40. RuizB , GarayJ , CorreaP , FonthamET , BravoJC , BravoLE , et al. Morphometric evaluation of gastric antral atrophy: improvement after cure of Helicobacter pylori infection. American Journal of Gastroenterology2001;96(12):3281-7. ">Correa 2000‐Correa 2001</a>; <a href="./references#CD005583-bbs2-0047" title="CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Re: Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. Journal of the National Cancer Institute2001;93(7):559-60.">Correa 2001</a>; <a href="./references#CD005583-bbs2-0059" title="GailMH , YouWC , ChangYS , ZhangL , BlotWJ , BrownLM , et al. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. Controlled Clinical Trials1998;19(4):352-69.">Gail 1998</a>; <a href="./references#CD005583-bbs2-0105" title="ZhouL . Ten-year follow-up study on the incidence of gastric cancer and the pathological changes of gastric mucosa after H. pylori eradication in China. In: Gastroenterology. Vol. 134 (4, suppl 1). 2008:A233. Abstract S1606.">Zhou 2008</a>; <a href="./references#CD005583-bbs2-0072" title="MaJL , ZhangL , BrownLM , LiJY , ShenL , PanKF , et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. Journal of the National Cancer Institute2012;104(6):488-92.">Ma 2012</a>; <a href="./references#CD005583-bbs2-0004" title="SaitoD , BokuN , FujiokaT , FukudaY , MatsushimaY , SakakiN , et al. Impact of H. pylori eradication on gastric cancer prevention: endoscopic results of the Japanese Intervention Trial (JITHP-Study). A randomized multi-center trial. In: Gastroenterology. Vol. 128 4 (Supp2). 2005:A4. Abstract 23. SaitoD . Present state of Japanese intervention trial of H. pylori . Nihon Rinsho2003;61(1):50-5. ">Saito 2005</a>; <a href="./references#CD005583-bbs2-0005" title="WongBC , LamSK , WongWM , ChenJS , ZhengTT , FengRE , et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA2004;291(2):187-94. WongBCY , LamS , WongWM , et al. Eradication of Helicobacter pylori infection significantly slows down the progression of precancerous lesions in high risk populations: a 5 year prospective randomized study. In: Gastroenterology. Vol. 122. 2002:A588. Abstract W1216. ">Wong 2004</a>; <a href="./references#CD005583-bbs2-0091" title="WongBC , ZhangL , MaJL , PanKF , LiJY , ShenL , et al. Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut2012;61(6):812-8. ">Wong 2012</a>b; <a href="./references#CD005583-bbs2-0096" title="YouWC , BrownLM , ZhangL , LiJY , JinML , ChangYS , et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. Journal of the National Cancer Institute2006;98(14):974-83.">You 2006</a> ; <a href="./references#CD005583-bbs2-0105" title="ZhouL . Ten-year follow-up study on the incidence of gastric cancer and the pathological changes of gastric mucosa after H. pylori eradication in China. In: Gastroenterology. Vol. 134 (4, suppl 1). 2008:A233. Abstract S1606.">Zhou 2008</a>). One of these studies only reported adverse events data (<a href="./references#CD005583-bbs2-0059" title="GailMH , YouWC , ChangYS , ZhangL , BlotWJ , BrownLM , et al. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. Controlled Clinical Trials1998;19(4):352-69.">Gail 1998</a>). In the updated search, one article provided 22‐year follow‐up data (<a href="./references#CD005583-bbs2-0071" title="LiWQ , ZhangJY , MaJL , LiZX , ZhangL , ZhangY , et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. BMJ2019;366:l5016. [PMID: 31511230]">Li 2019</a>) for one of the previously included RCTs and one record (<a href="./references#CD005583-bbs2-0070" title="LiWQ , MaJL , ZhangL , BrownLM , LiJY , ShenL , PanKF , LiuWD , HuY , HanZX , Crystal-MansourS , PeeD , BlotWJ , Fraumeni JF Jr, YouWC , GailMH . Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. J Natl Cancer Inst2014;106(7):pii: dju116.">Li 2014</a>) reported 15‐ year follow‐up data in subgroups for the same RCT (<a href="./references#CD005583-bbs2-0096" title="YouWC , BrownLM , ZhangL , LiJY , JinML , ChangYS , et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. Journal of the National Cancer Institute2006;98(14):974-83.">You 2006</a>) that included in published version with follow‐up data up to 14.7 years. Data from this study (<a href="./references#CD005583-bbs2-0007" title="GailMH , YouWC , ChangYS , ZhangL , BlotWJ , BrownLM , et al. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. Controlled Clinical Trials1998;19(4):352-69. LiWQ , MaJL , ZhangL , BrownLM , LiJY , ShenL , et al. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. Journal of the National Cancer Institute2014;106(7). [DOI: DOI:10.1093/jnci/dju116] [PMID: 24925350]LiWQ , ZhangJY , MaJL , LiZX , ZhangL , ZhangY , et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. BMJ2019;366:l5016. [PMID: 31511230]LiWQ , ZhangL , MaJL , BrownL , LiJY , ShenL , et al. Fifteen-year effects of Helicobacter pylori treatment on gastric cancer incidence and mortality among participants with different baseline gastric lesions and ages. American Journal of Epidemiology2013;177 (Suppl 11):S61. MaJL , ZhangL , BrownLM , LiJY , ShenL , PanKF , et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. Journal of the National Cancer Institute2012;104(6):488-92. WangY , ZhangL , MoslehiR , MaJ , PanK , ZhouT , et al. Long-term garlic or micronutrient supplementation, but not anti-Helicobacter pylori therapy, increases serum folate or glutathione without affecting serum vitamin B-12 or homocysteine in a rural Chinese population. Journal of Nutrition2009;139(1):106-12. YouWC , BrownLM , ZhangL , LiJY , JinML , ChangYS , et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. Journal of the National Cancer Institute2006;98(14):974-83. YouWC , ChangYS , HeinrichJ , MaJL , LiuWD , ZhangL , et al. An intervention trial to inhibit the progression of precancerous gastric lesions: compliance, serum micronutrients and S-allyl cysteine levels, and toxicity. European Journal of Cancer Prevention2001;10(3):257-63. ZhangL , GailMH , WangYQ , BrownLM , PanKF , MaJL , et al. A randomized factorial study of the effects of long-term garlic and micronutrient supplementation and of 2-wk antibiotic treatment for Helicobacter pylori infection on serum cholesterol and lipoproteins. American Journal of Clinical Nutrition2006;86(4):912-9. ZhangL , MaJL , LiuWD , JiangJ , PanKF , PanYS , et al. A randomized multi-intervention trial to inhibit gastric cancer in Shandong (progress report). Chinese Journal of Clinical Oncology1998;25(5):338-40. ">You 2006 ‐ Li 2019</a>) is being update to the 22‐year follow up data (<a href="./references#CD005583-bbs2-0071" title="LiWQ , ZhangJY , MaJL , LiZX , ZhangL , ZhangY , et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. BMJ2019;366:l5016. [PMID: 31511230]">Li 2019</a>). For another RCT that included in the previous version (<a href="./references#CD005583-bbs2-0003" title="LeungWK , LinSR , ChingJY , ToKF , NgEK , ChanFK , et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut2004;53(9):1244-9. SungJJ , LinSR , ChingJY , ZhouLY , ToKF , WangRT , et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology2000;119(1):7-14. SungJJ , LinSR , LeungW , NgEK , ChingJY , ToKF , et al. Does eradication of H. pylori prevent deterioration of gastric atrophy and intestinal metaplasia? A 5-year follow-up. In: Gastroenterology. Vol. 122(Suppl 4). 2002:A170. Abstract S1142. ZhouL , LinS , DingS , HuangX , JinZ , CuiR , et al. Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study. Chinese medical journal2014;127(8):1454-8. [PMID: 24762588]ZhouL , SungJJ , LinS , JinZ , DingS , HuangX , et al. A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chinese Medical Journal2003;116(1):11-4. [PMID: 12667379]ZhouL . Ten-year follow-up study on the incidence of gastric cancer and the pathological changes of gastric mucosa after H. pylori eradication in China. In: Gastroenterology. Vol. 134 (4, suppl 1). 2008:A233. Abstract S1606. ZhouLY , LinSR , DingSG , HuangSB , GuoCJ , ZhangL , et al. Eight-year follow-up study on prevalence of gastric cancer and the histological changes of gastric mucosa after H.pylori eradication [除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究]. Chinese Journal of Digestion2005;25(6):324-7. ZhouLY , LinSR , DingSG , HuangSB , GuoCJ , ZhangL , et al. Eight-year follow-up study on the morbidity of gastric cancer and the pathological changes of gastric mucosa after H.pylori eradication [除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究]. www.paper.edu.cn/scholar/downpaper/zhouliya-3 (accessed 10 June 2015). ZhouLY , LinSR , DingSG , HuangXB , ZhangL , MengLM , et al. The changing trends of the incidence of gastric cancer after Helicobacter pylori eradication in Shandong area. Chinese Journal of Digestive Diseases2005;6(3):114-5. ZhouLY , LinSR , ShenZY , ZhongSZ , DingSG , HuangXB , et al. Five-year follow-up study after Helicobacter pylori eradication: Reinfection and peptic ulcer status. Chinese Journal of Digestive Diseases2003;4(1):45-8. ZhouLY , SungJJ , LinSR , JinZ , DingSG , HuangXB , et al. Changes of gastric mucosa histopathology after Helicobacterpylori eradication [根除幽门螺杆菌对胃黏膜炎症变化的人群随访研究]. Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]2003;42(3):162-4. ">Leung 2004‐Zhou 2014</a>), data from a conference abstract (<a href="./references#CD005583-bbs2-0105" title="ZhouL . Ten-year follow-up study on the incidence of gastric cancer and the pathological changes of gastric mucosa after H. pylori eradication in China. In: Gastroenterology. Vol. 134 (4, suppl 1). 2008:A233. Abstract S1606.">Zhou 2008</a>) with 10‐year follow up data were used. In the update search, the conference abstract was fully published in 2014 (<a href="./references#CD005583-bbs2-0106" title="ZhouL , LinS , DingS , HuangX , JinZ , CuiR , et al. Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study. Chinese medical journal2014;127(8):1454-8. [PMID: 24762588]">Zhou 2014</a>) but no new data is added to the meta‐analysis. One new RCT is identified in the update search (<a href="./references#CD005583-bbs2-0001" title="ChoiIJ , KimCG , LeeJY , KimYI , KookMC , ParkB , JooJ . Family History of Gastric Cancer and Helicobacter pylori Treatment. New England Journal of Medicine2020;382(5):427-436. ">Choi 2020</a>). Therefore, seven studies (<a href="./references#CD005583-bbs2-0001" title="ChoiIJ , KimCG , LeeJY , KimYI , KookMC , ParkB , JooJ . Family History of Gastric Cancer and Helicobacter pylori Treatment. New England Journal of Medicine2020;382(5):427-436. ">Choi 2020</a>; <a href="./references#CD005583-bbs2-0002" title="CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacterpylori therapy. Journal of the National Cancer Institute2000;92(23):1881-8. CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Re: Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. Journal of the National Cancer Institute2001;93(7):559-60. MeraR , FonthamET , BravoLE , BravoJC , PiazueloMB , CamargoMC , et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut2005;54(11):1536-40. RuizB , GarayJ , CorreaP , FonthamET , BravoJC , BravoLE , et al. Morphometric evaluation of gastric antral atrophy: improvement after cure of Helicobacter pylori infection. American Journal of Gastroenterology2001;96(12):3281-7. ">Correa 2000‐Correa 2001</a>; <a href="./references#CD005583-bbs2-0003" title="LeungWK , LinSR , ChingJY , ToKF , NgEK , ChanFK , et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut2004;53(9):1244-9. SungJJ , LinSR , ChingJY , ZhouLY , ToKF , WangRT , et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology2000;119(1):7-14. SungJJ , LinSR , LeungW , NgEK , ChingJY , ToKF , et al. Does eradication of H. pylori prevent deterioration of gastric atrophy and intestinal metaplasia? A 5-year follow-up. In: Gastroenterology. Vol. 122(Suppl 4). 2002:A170. Abstract S1142. ZhouL , LinS , DingS , HuangX , JinZ , CuiR , et al. Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study. Chinese medical journal2014;127(8):1454-8. [PMID: 24762588]ZhouL , SungJJ , LinS , JinZ , DingS , HuangX , et al. A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chinese Medical Journal2003;116(1):11-4. [PMID: 12667379]ZhouL . Ten-year follow-up study on the incidence of gastric cancer and the pathological changes of gastric mucosa after H. pylori eradication in China. In: Gastroenterology. Vol. 134 (4, suppl 1). 2008:A233. Abstract S1606. ZhouLY , LinSR , DingSG , HuangSB , GuoCJ , ZhangL , et al. Eight-year follow-up study on prevalence of gastric cancer and the histological changes of gastric mucosa after H.pylori eradication [除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究]. Chinese Journal of Digestion2005;25(6):324-7. ZhouLY , LinSR , DingSG , HuangSB , GuoCJ , ZhangL , et al. Eight-year follow-up study on the morbidity of gastric cancer and the pathological changes of gastric mucosa after H.pylori eradication [除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究]. www.paper.edu.cn/scholar/downpaper/zhouliya-3 (accessed 10 June 2015). ZhouLY , LinSR , DingSG , HuangXB , ZhangL , MengLM , et al. The changing trends of the incidence of gastric cancer after Helicobacter pylori eradication in Shandong area. Chinese Journal of Digestive Diseases2005;6(3):114-5. ZhouLY , LinSR , ShenZY , ZhongSZ , DingSG , HuangXB , et al. Five-year follow-up study after Helicobacter pylori eradication: Reinfection and peptic ulcer status. Chinese Journal of Digestive Diseases2003;4(1):45-8. ZhouLY , SungJJ , LinSR , JinZ , DingSG , HuangXB , et al. Changes of gastric mucosa histopathology after Helicobacterpylori eradication [根除幽门螺杆菌对胃黏膜炎症变化的人群随访研究]. Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]2003;42(3):162-4. ">Leung 2004‐Zhou 2014</a>; <a href="./references#CD005583-bbs2-0004" title="SaitoD , BokuN , FujiokaT , FukudaY , MatsushimaY , SakakiN , et al. Impact of H. pylori eradication on gastric cancer prevention: endoscopic results of the Japanese Intervention Trial (JITHP-Study). A randomized multi-center trial. In: Gastroenterology. Vol. 128 4 (Supp2). 2005:A4. Abstract 23. SaitoD . Present state of Japanese intervention trial of H. pylori . Nihon Rinsho2003;61(1):50-5. ">Saito 2005</a>; <a href="./references#CD005583-bbs2-0005" title="WongBC , LamSK , WongWM , ChenJS , ZhengTT , FengRE , et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA2004;291(2):187-94. WongBCY , LamS , WongWM , et al. Eradication of Helicobacter pylori infection significantly slows down the progression of precancerous lesions in high risk populations: a 5 year prospective randomized study. In: Gastroenterology. Vol. 122. 2002:A588. Abstract W1216. ">Wong 2004</a>; <a href="./references#CD005583-bbs2-0006" title="FengGS , MaJL , WongBC , ZhangL , LiuWD , PanKF , et al. Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention. World Journal of Gastroenterology2008;14(28):4535-9. WongBC , ZhangL , MaJL , PanKF , LiJY , ShenL , et al. Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut2012;61(6):812-8. WongBC . Eradication of Helicobacter pylori for prevention of gastric cancer. In: Journal of Gastroenterology and Hepatology. Vol. 27 (Suppl. 5). 2012:5-6. Abstract UA01-05. ">Wong 2012a</a>;<a href="./references#CD005583-bbs2-0007" title="GailMH , YouWC , ChangYS , ZhangL , BlotWJ , BrownLM , et al. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. Controlled Clinical Trials1998;19(4):352-69. LiWQ , MaJL , ZhangL , BrownLM , LiJY , ShenL , et al. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. Journal of the National Cancer Institute2014;106(7). [DOI: DOI:10.1093/jnci/dju116] [PMID: 24925350]LiWQ , ZhangJY , MaJL , LiZX , ZhangL , ZhangY , et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. BMJ2019;366:l5016. [PMID: 31511230]LiWQ , ZhangL , MaJL , BrownL , LiJY , ShenL , et al. Fifteen-year effects of Helicobacter pylori treatment on gastric cancer incidence and mortality among participants with different baseline gastric lesions and ages. American Journal of Epidemiology2013;177 (Suppl 11):S61. MaJL , ZhangL , BrownLM , LiJY , ShenL , PanKF , et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. Journal of the National Cancer Institute2012;104(6):488-92. WangY , ZhangL , MoslehiR , MaJ , PanK , ZhouT , et al. Long-term garlic or micronutrient supplementation, but not anti-Helicobacter pylori therapy, increases serum folate or glutathione without affecting serum vitamin B-12 or homocysteine in a rural Chinese population. Journal of Nutrition2009;139(1):106-12. YouWC , BrownLM , ZhangL , LiJY , JinML , ChangYS , et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. Journal of the National Cancer Institute2006;98(14):974-83. YouWC , ChangYS , HeinrichJ , MaJL , LiuWD , ZhangL , et al. An intervention trial to inhibit the progression of precancerous gastric lesions: compliance, serum micronutrients and S-allyl cysteine levels, and toxicity. European Journal of Cancer Prevention2001;10(3):257-63. ZhangL , GailMH , WangYQ , BrownLM , PanKF , MaJL , et al. A randomized factorial study of the effects of long-term garlic and micronutrient supplementation and of 2-wk antibiotic treatment for Helicobacter pylori infection on serum cholesterol and lipoproteins. American Journal of Clinical Nutrition2006;86(4):912-9. ZhangL , MaJL , LiuWD , JiangJ , PanKF , PanYS , et al. A randomized multi-intervention trial to inhibit gastric cancer in Shandong (progress report). Chinese Journal of Clinical Oncology1998;25(5):338-40. ">You 2006 ‐ Li 2019</a>) with eleven references contributed data to the analyses concerning incidence of gastric cancer in this systematic review. </p> </section> <section id="CD005583-sec-0051"> <h4 class="title">Included studies</h4> <p>Please see <a href="./references#CD005583-sec-0097" title="">Characteristics of included studies</a> table. Three of the trials, reported in five separate publications, were of factorial design with some participants randomised to receive vitamins, antioxidants, or celecoxib in addition to <i>H. pylori</i> eradication therapy (<a href="./references#CD005583-bbs2-0002" title="CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacterpylori therapy. Journal of the National Cancer Institute2000;92(23):1881-8. CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Re: Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. Journal of the National Cancer Institute2001;93(7):559-60. MeraR , FonthamET , BravoLE , BravoJC , PiazueloMB , CamargoMC , et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut2005;54(11):1536-40. RuizB , GarayJ , CorreaP , FonthamET , BravoJC , BravoLE , et al. Morphometric evaluation of gastric antral atrophy: improvement after cure of Helicobacter pylori infection. American Journal of Gastroenterology2001;96(12):3281-7. ">Correa 2000‐Correa 2001</a>; <a href="./references#CD005583-bbs2-0006" title="FengGS , MaJL , WongBC , ZhangL , LiuWD , PanKF , et al. Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention. World Journal of Gastroenterology2008;14(28):4535-9. WongBC , ZhangL , MaJL , PanKF , LiJY , ShenL , et al. Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut2012;61(6):812-8. WongBC . Eradication of Helicobacter pylori for prevention of gastric cancer. In: Journal of Gastroenterology and Hepatology. Vol. 27 (Suppl. 5). 2012:5-6. Abstract UA01-05. ">Wong 2012a</a>; <a href="./references#CD005583-bbs2-0007" title="GailMH , YouWC , ChangYS , ZhangL , BlotWJ , BrownLM , et al. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. Controlled Clinical Trials1998;19(4):352-69. LiWQ , MaJL , ZhangL , BrownLM , LiJY , ShenL , et al. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. Journal of the National Cancer Institute2014;106(7). [DOI: DOI:10.1093/jnci/dju116] [PMID: 24925350]LiWQ , ZhangJY , MaJL , LiZX , ZhangL , ZhangY , et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. BMJ2019;366:l5016. [PMID: 31511230]LiWQ , ZhangL , MaJL , BrownL , LiJY , ShenL , et al. Fifteen-year effects of Helicobacter pylori treatment on gastric cancer incidence and mortality among participants with different baseline gastric lesions and ages. American Journal of Epidemiology2013;177 (Suppl 11):S61. MaJL , ZhangL , BrownLM , LiJY , ShenL , PanKF , et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. Journal of the National Cancer Institute2012;104(6):488-92. WangY , ZhangL , MoslehiR , MaJ , PanK , ZhouT , et al. Long-term garlic or micronutrient supplementation, but not anti-Helicobacter pylori therapy, increases serum folate or glutathione without affecting serum vitamin B-12 or homocysteine in a rural Chinese population. Journal of Nutrition2009;139(1):106-12. YouWC , BrownLM , ZhangL , LiJY , JinML , ChangYS , et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. Journal of the National Cancer Institute2006;98(14):974-83. YouWC , ChangYS , HeinrichJ , MaJL , LiuWD , ZhangL , et al. An intervention trial to inhibit the progression of precancerous gastric lesions: compliance, serum micronutrients and S-allyl cysteine levels, and toxicity. European Journal of Cancer Prevention2001;10(3):257-63. ZhangL , GailMH , WangYQ , BrownLM , PanKF , MaJL , et al. A randomized factorial study of the effects of long-term garlic and micronutrient supplementation and of 2-wk antibiotic treatment for Helicobacter pylori infection on serum cholesterol and lipoproteins. American Journal of Clinical Nutrition2006;86(4):912-9. ZhangL , MaJL , LiuWD , JiangJ , PanKF , PanYS , et al. A randomized multi-intervention trial to inhibit gastric cancer in Shandong (progress report). Chinese Journal of Clinical Oncology1998;25(5):338-40. ">You 2006 ‐ Li 2019</a>). Only one study was conducted in non‐Asians, among a population at high risk of gastric cancer in Colombia (<a href="./references#CD005583-bbs2-0002" title="CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacterpylori therapy. Journal of the National Cancer Institute2000;92(23):1881-8. CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Re: Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. Journal of the National Cancer Institute2001;93(7):559-60. MeraR , FonthamET , BravoLE , BravoJC , PiazueloMB , CamargoMC , et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut2005;54(11):1536-40. RuizB , GarayJ , CorreaP , FonthamET , BravoJC , BravoLE , et al. Morphometric evaluation of gastric antral atrophy: improvement after cure of Helicobacter pylori infection. American Journal of Gastroenterology2001;96(12):3281-7. ">Correa 2000‐Correa 2001</a>). The shortest duration of follow‐up was greater than or equal to 4 years (<a href="./references#CD005583-bbs2-0004" title="SaitoD , BokuN , FujiokaT , FukudaY , MatsushimaY , SakakiN , et al. Impact of H. pylori eradication on gastric cancer prevention: endoscopic results of the Japanese Intervention Trial (JITHP-Study). A randomized multi-center trial. In: Gastroenterology. Vol. 128 4 (Supp2). 2005:A4. Abstract 23. SaitoD . Present state of Japanese intervention trial of H. pylori . Nihon Rinsho2003;61(1):50-5. ">Saito 2005</a>), and the longest was 22 years (<a href="./references#CD005583-bbs2-0007" title="GailMH , YouWC , ChangYS , ZhangL , BlotWJ , BrownLM , et al. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. Controlled Clinical Trials1998;19(4):352-69. LiWQ , MaJL , ZhangL , BrownLM , LiJY , ShenL , et al. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. Journal of the National Cancer Institute2014;106(7). [DOI: DOI:10.1093/jnci/dju116] [PMID: 24925350]LiWQ , ZhangJY , MaJL , LiZX , ZhangL , ZhangY , et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. BMJ2019;366:l5016. [PMID: 31511230]LiWQ , ZhangL , MaJL , BrownL , LiJY , ShenL , et al. Fifteen-year effects of Helicobacter pylori treatment on gastric cancer incidence and mortality among participants with different baseline gastric lesions and ages. American Journal of Epidemiology2013;177 (Suppl 11):S61. MaJL , ZhangL , BrownLM , LiJY , ShenL , PanKF , et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. Journal of the National Cancer Institute2012;104(6):488-92. WangY , ZhangL , MoslehiR , MaJ , PanK , ZhouT , et al. Long-term garlic or micronutrient supplementation, but not anti-Helicobacter pylori therapy, increases serum folate or glutathione without affecting serum vitamin B-12 or homocysteine in a rural Chinese population. Journal of Nutrition2009;139(1):106-12. YouWC , BrownLM , ZhangL , LiJY , JinML , ChangYS , et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. Journal of the National Cancer Institute2006;98(14):974-83. YouWC , ChangYS , HeinrichJ , MaJL , LiuWD , ZhangL , et al. An intervention trial to inhibit the progression of precancerous gastric lesions: compliance, serum micronutrients and S-allyl cysteine levels, and toxicity. European Journal of Cancer Prevention2001;10(3):257-63. ZhangL , GailMH , WangYQ , BrownLM , PanKF , MaJL , et al. A randomized factorial study of the effects of long-term garlic and micronutrient supplementation and of 2-wk antibiotic treatment for Helicobacter pylori infection on serum cholesterol and lipoproteins. American Journal of Clinical Nutrition2006;86(4):912-9. ZhangL , MaJL , LiuWD , JiangJ , PanKF , PanYS , et al. A randomized multi-intervention trial to inhibit gastric cancer in Shandong (progress report). Chinese Journal of Clinical Oncology1998;25(5):338-40. ">You 2006 ‐ Li 2019</a>). The largest study contained 2258 participants (<a href="./references#CD005583-bbs2-0007" title="GailMH , YouWC , ChangYS , ZhangL , BlotWJ , BrownLM , et al. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. Controlled Clinical Trials1998;19(4):352-69. LiWQ , MaJL , ZhangL , BrownLM , LiJY , ShenL , et al. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. Journal of the National Cancer Institute2014;106(7). [DOI: DOI:10.1093/jnci/dju116] [PMID: 24925350]LiWQ , ZhangJY , MaJL , LiZX , ZhangL , ZhangY , et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. BMJ2019;366:l5016. [PMID: 31511230]LiWQ , ZhangL , MaJL , BrownL , LiJY , ShenL , et al. Fifteen-year effects of Helicobacter pylori treatment on gastric cancer incidence and mortality among participants with different baseline gastric lesions and ages. American Journal of Epidemiology2013;177 (Suppl 11):S61. MaJL , ZhangL , BrownLM , LiJY , ShenL , PanKF , et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. Journal of the National Cancer Institute2012;104(6):488-92. WangY , ZhangL , MoslehiR , MaJ , PanK , ZhouT , et al. Long-term garlic or micronutrient supplementation, but not anti-Helicobacter pylori therapy, increases serum folate or glutathione without affecting serum vitamin B-12 or homocysteine in a rural Chinese population. Journal of Nutrition2009;139(1):106-12. YouWC , BrownLM , ZhangL , LiJY , JinML , ChangYS , et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. Journal of the National Cancer Institute2006;98(14):974-83. YouWC , ChangYS , HeinrichJ , MaJL , LiuWD , ZhangL , et al. An intervention trial to inhibit the progression of precancerous gastric lesions: compliance, serum micronutrients and S-allyl cysteine levels, and toxicity. European Journal of Cancer Prevention2001;10(3):257-63. ZhangL , GailMH , WangYQ , BrownLM , PanKF , MaJL , et al. A randomized factorial study of the effects of long-term garlic and micronutrient supplementation and of 2-wk antibiotic treatment for Helicobacter pylori infection on serum cholesterol and lipoproteins. American Journal of Clinical Nutrition2006;86(4):912-9. ZhangL , MaJL , LiuWD , JiangJ , PanKF , PanYS , et al. A randomized multi-intervention trial to inhibit gastric cancer in Shandong (progress report). Chinese Journal of Clinical Oncology1998;25(5):338-40. ">You 2006 ‐ Li 2019</a>), and the smallest 513 participants (<a href="./references#CD005583-bbs2-0006" title="FengGS , MaJL , WongBC , ZhangL , LiuWD , PanKF , et al. Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention. World Journal of Gastroenterology2008;14(28):4535-9. WongBC , ZhangL , MaJL , PanKF , LiJY , ShenL , et al. Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut2012;61(6):812-8. WongBC . Eradication of Helicobacter pylori for prevention of gastric cancer. In: Journal of Gastroenterology and Hepatology. Vol. 27 (Suppl. 5). 2012:5-6. Abstract UA01-05. ">Wong 2012a</a>). </p> </section> <section id="CD005583-sec-0052"> <h4 class="title">Excluded studies</h4> <p>Please see <a href="./references#CD005583-sec-0098" title="">Characteristics of excluded studies</a> table. </p> </section> </section> <section id="CD005583-sec-0053"> <h3 class="title">Risk of bias in included studies</h3> <p>Four trials were at low risk of bias (<a href="./references#CD005583-bbs2-0001" title="ChoiIJ , KimCG , LeeJY , KimYI , KookMC , ParkB , JooJ . Family History of Gastric Cancer and Helicobacter pylori Treatment. New England Journal of Medicine2020;382(5):427-436. ">Choi 2020</a>; <a href="./references#CD005583-bbs2-0005" title="WongBC , LamSK , WongWM , ChenJS , ZhengTT , FengRE , et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA2004;291(2):187-94. WongBCY , LamS , WongWM , et al. Eradication of Helicobacter pylori infection significantly slows down the progression of precancerous lesions in high risk populations: a 5 year prospective randomized study. In: Gastroenterology. Vol. 122. 2002:A588. Abstract W1216. ">Wong 2004</a>; <a href="./references#CD005583-bbs2-0006" title="FengGS , MaJL , WongBC , ZhangL , LiuWD , PanKF , et al. Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention. World Journal of Gastroenterology2008;14(28):4535-9. WongBC , ZhangL , MaJL , PanKF , LiJY , ShenL , et al. Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut2012;61(6):812-8. WongBC . Eradication of Helicobacter pylori for prevention of gastric cancer. In: Journal of Gastroenterology and Hepatology. Vol. 27 (Suppl. 5). 2012:5-6. Abstract UA01-05. ">Wong 2012a</a>; <a href="./references#CD005583-bbs2-0007" title="GailMH , YouWC , ChangYS , ZhangL , BlotWJ , BrownLM , et al. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. Controlled Clinical Trials1998;19(4):352-69. LiWQ , MaJL , ZhangL , BrownLM , LiJY , ShenL , et al. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. Journal of the National Cancer Institute2014;106(7). [DOI: DOI:10.1093/jnci/dju116] [PMID: 24925350]LiWQ , ZhangJY , MaJL , LiZX , ZhangL , ZhangY , et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. BMJ2019;366:l5016. [PMID: 31511230]LiWQ , ZhangL , MaJL , BrownL , LiJY , ShenL , et al. Fifteen-year effects of Helicobacter pylori treatment on gastric cancer incidence and mortality among participants with different baseline gastric lesions and ages. American Journal of Epidemiology2013;177 (Suppl 11):S61. MaJL , ZhangL , BrownLM , LiJY , ShenL , PanKF , et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. Journal of the National Cancer Institute2012;104(6):488-92. WangY , ZhangL , MoslehiR , MaJ , PanK , ZhouT , et al. Long-term garlic or micronutrient supplementation, but not anti-Helicobacter pylori therapy, increases serum folate or glutathione without affecting serum vitamin B-12 or homocysteine in a rural Chinese population. Journal of Nutrition2009;139(1):106-12. YouWC , BrownLM , ZhangL , LiJY , JinML , ChangYS , et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. Journal of the National Cancer Institute2006;98(14):974-83. YouWC , ChangYS , HeinrichJ , MaJL , LiuWD , ZhangL , et al. An intervention trial to inhibit the progression of precancerous gastric lesions: compliance, serum micronutrients and S-allyl cysteine levels, and toxicity. European Journal of Cancer Prevention2001;10(3):257-63. ZhangL , GailMH , WangYQ , BrownLM , PanKF , MaJL , et al. A randomized factorial study of the effects of long-term garlic and micronutrient supplementation and of 2-wk antibiotic treatment for Helicobacter pylori infection on serum cholesterol and lipoproteins. American Journal of Clinical Nutrition2006;86(4):912-9. ZhangL , MaJL , LiuWD , JiangJ , PanKF , PanYS , et al. A randomized multi-intervention trial to inhibit gastric cancer in Shandong (progress report). Chinese Journal of Clinical Oncology1998;25(5):338-40. ">You 2006 ‐ Li 2019</a>), one trial was at unclear risk (<a href="./references#CD005583-bbs2-0004" title="SaitoD , BokuN , FujiokaT , FukudaY , MatsushimaY , SakakiN , et al. Impact of H. pylori eradication on gastric cancer prevention: endoscopic results of the Japanese Intervention Trial (JITHP-Study). A randomized multi-center trial. In: Gastroenterology. Vol. 128 4 (Supp2). 2005:A4. Abstract 23. SaitoD . Present state of Japanese intervention trial of H. pylori . Nihon Rinsho2003;61(1):50-5. ">Saito 2005</a>), and two trials were at high risk of bias (<a href="./references#CD005583-bbs2-0002" title="CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacterpylori therapy. Journal of the National Cancer Institute2000;92(23):1881-8. CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Re: Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. Journal of the National Cancer Institute2001;93(7):559-60. MeraR , FonthamET , BravoLE , BravoJC , PiazueloMB , CamargoMC , et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut2005;54(11):1536-40. RuizB , GarayJ , CorreaP , FonthamET , BravoJC , BravoLE , et al. Morphometric evaluation of gastric antral atrophy: improvement after cure of Helicobacter pylori infection. American Journal of Gastroenterology2001;96(12):3281-7. ">Correa 2000‐Correa 2001</a>; <a href="./references#CD005583-bbs2-0003" title="LeungWK , LinSR , ChingJY , ToKF , NgEK , ChanFK , et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut2004;53(9):1244-9. SungJJ , LinSR , ChingJY , ZhouLY , ToKF , WangRT , et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology2000;119(1):7-14. SungJJ , LinSR , LeungW , NgEK , ChingJY , ToKF , et al. Does eradication of H. pylori prevent deterioration of gastric atrophy and intestinal metaplasia? A 5-year follow-up. In: Gastroenterology. Vol. 122(Suppl 4). 2002:A170. Abstract S1142. ZhouL , LinS , DingS , HuangX , JinZ , CuiR , et al. Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study. Chinese medical journal2014;127(8):1454-8. [PMID: 24762588]ZhouL , SungJJ , LinS , JinZ , DingS , HuangX , et al. A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chinese Medical Journal2003;116(1):11-4. [PMID: 12667379]ZhouL . Ten-year follow-up study on the incidence of gastric cancer and the pathological changes of gastric mucosa after H. pylori eradication in China. In: Gastroenterology. Vol. 134 (4, suppl 1). 2008:A233. Abstract S1606. ZhouLY , LinSR , DingSG , HuangSB , GuoCJ , ZhangL , et al. Eight-year follow-up study on prevalence of gastric cancer and the histological changes of gastric mucosa after H.pylori eradication [除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究]. Chinese Journal of Digestion2005;25(6):324-7. ZhouLY , LinSR , DingSG , HuangSB , GuoCJ , ZhangL , et al. Eight-year follow-up study on the morbidity of gastric cancer and the pathological changes of gastric mucosa after H.pylori eradication [除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究]. www.paper.edu.cn/scholar/downpaper/zhouliya-3 (accessed 10 June 2015). ZhouLY , LinSR , DingSG , HuangXB , ZhangL , MengLM , et al. The changing trends of the incidence of gastric cancer after Helicobacter pylori eradication in Shandong area. Chinese Journal of Digestive Diseases2005;6(3):114-5. ZhouLY , LinSR , ShenZY , ZhongSZ , DingSG , HuangXB , et al. Five-year follow-up study after Helicobacter pylori eradication: Reinfection and peptic ulcer status. Chinese Journal of Digestive Diseases2003;4(1):45-8. ZhouLY , SungJJ , LinSR , JinZ , DingSG , HuangXB , et al. Changes of gastric mucosa histopathology after Helicobacterpylori eradication [根除幽门螺杆菌对胃黏膜炎症变化的人群随访研究]. Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]2003;42(3):162-4. ">Leung 2004‐Zhou 2014</a>) (<a href="#CD005583-fig-0002">Figure 2</a>; <a href="#CD005583-fig-0003">Figure 3</a>). One study was at high risk of bias because no placebo comparator was used for the active eradication therapy regimen, and therefore this part of the trial was unblinded (<a href="./references#CD005583-bbs2-0002" title="CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacterpylori therapy. Journal of the National Cancer Institute2000;92(23):1881-8. CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Re: Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. Journal of the National Cancer Institute2001;93(7):559-60. MeraR , FonthamET , BravoLE , BravoJC , PiazueloMB , CamargoMC , et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut2005;54(11):1536-40. RuizB , GarayJ , CorreaP , FonthamET , BravoJC , BravoLE , et al. Morphometric evaluation of gastric antral atrophy: improvement after cure of Helicobacter pylori infection. American Journal of Gastroenterology2001;96(12):3281-7. ">Correa 2000‐Correa 2001</a>); the other study was at high risk of bias due to inconsistencies in data reporting at the two points of follow‐up, with 10 gastric cancers reported at 5 years (<a href="./references#CD005583-bbs2-0003" title="LeungWK , LinSR , ChingJY , ToKF , NgEK , ChanFK , et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut2004;53(9):1244-9. SungJJ , LinSR , ChingJY , ZhouLY , ToKF , WangRT , et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology2000;119(1):7-14. SungJJ , LinSR , LeungW , NgEK , ChingJY , ToKF , et al. Does eradication of H. pylori prevent deterioration of gastric atrophy and intestinal metaplasia? A 5-year follow-up. In: Gastroenterology. Vol. 122(Suppl 4). 2002:A170. Abstract S1142. ZhouL , LinS , DingS , HuangX , JinZ , CuiR , et al. Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study. Chinese medical journal2014;127(8):1454-8. [PMID: 24762588]ZhouL , SungJJ , LinS , JinZ , DingS , HuangX , et al. A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chinese Medical Journal2003;116(1):11-4. [PMID: 12667379]ZhouL . Ten-year follow-up study on the incidence of gastric cancer and the pathological changes of gastric mucosa after H. pylori eradication in China. In: Gastroenterology. Vol. 134 (4, suppl 1). 2008:A233. Abstract S1606. ZhouLY , LinSR , DingSG , HuangSB , GuoCJ , ZhangL , et al. Eight-year follow-up study on prevalence of gastric cancer and the histological changes of gastric mucosa after H.pylori eradication [除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究]. Chinese Journal of Digestion2005;25(6):324-7. ZhouLY , LinSR , DingSG , HuangSB , GuoCJ , ZhangL , et al. Eight-year follow-up study on the morbidity of gastric cancer and the pathological changes of gastric mucosa after H.pylori eradication [除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究]. www.paper.edu.cn/scholar/downpaper/zhouliya-3 (accessed 10 June 2015). ZhouLY , LinSR , DingSG , HuangXB , ZhangL , MengLM , et al. The changing trends of the incidence of gastric cancer after Helicobacter pylori eradication in Shandong area. Chinese Journal of Digestive Diseases2005;6(3):114-5. ZhouLY , LinSR , ShenZY , ZhongSZ , DingSG , HuangXB , et al. Five-year follow-up study after Helicobacter pylori eradication: Reinfection and peptic ulcer status. Chinese Journal of Digestive Diseases2003;4(1):45-8. ZhouLY , SungJJ , LinSR , JinZ , DingSG , HuangXB , et al. Changes of gastric mucosa histopathology after Helicobacterpylori eradication [根除幽门螺杆菌对胃黏膜炎症变化的人群随访研究]. Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]2003;42(3):162-4. ">Leung 2004‐Zhou 2014</a>), compared with nine at 10 years (<a href="./references#CD005583-bbs2-0106" title="ZhouL , LinS , DingS , HuangX , JinZ , CuiR , et al. Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study. Chinese medical journal2014;127(8):1454-8. [PMID: 24762588]">Zhou 2014</a>). Despite contacting the original authors, we were unable to resolve this discrepancy satisfactorily. In the case of this trial, we used data from the 10‐year follow‐up in our primary analysis, but substituted the 5‐year data in a sensitivity analysis. </p> <div class="figure" id="CD005583-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies." data-id="CD005583-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_n/nCD005583-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD005583-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study." data-id="CD005583-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_n/nCD005583-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study. </p> </div> </div> </div> <section id="CD005583-sec-0054"> <h4 class="title">Allocation</h4> <section id="CD005583-sec-0055"> <h5 class="title">Random sequence generation</h5> <p>We considered six studies to be at low risk of bias for random sequence generation: four studies generated the allocation sequence by a computer (<a href="./references#CD005583-bbs2-0001" title="ChoiIJ , KimCG , LeeJY , KimYI , KookMC , ParkB , JooJ . Family History of Gastric Cancer and Helicobacter pylori Treatment. New England Journal of Medicine2020;382(5):427-436. ">Choi 2020</a>; <a href="./references#CD005583-bbs2-0002" title="CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacterpylori therapy. Journal of the National Cancer Institute2000;92(23):1881-8. CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Re: Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. Journal of the National Cancer Institute2001;93(7):559-60. MeraR , FonthamET , BravoLE , BravoJC , PiazueloMB , CamargoMC , et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut2005;54(11):1536-40. RuizB , GarayJ , CorreaP , FonthamET , BravoJC , BravoLE , et al. Morphometric evaluation of gastric antral atrophy: improvement after cure of Helicobacter pylori infection. American Journal of Gastroenterology2001;96(12):3281-7. ">Correa 2000‐Correa 2001</a>; <a href="./references#CD005583-bbs2-0003" title="LeungWK , LinSR , ChingJY , ToKF , NgEK , ChanFK , et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut2004;53(9):1244-9. SungJJ , LinSR , ChingJY , ZhouLY , ToKF , WangRT , et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology2000;119(1):7-14. SungJJ , LinSR , LeungW , NgEK , ChingJY , ToKF , et al. Does eradication of H. pylori prevent deterioration of gastric atrophy and intestinal metaplasia? A 5-year follow-up. In: Gastroenterology. Vol. 122(Suppl 4). 2002:A170. Abstract S1142. ZhouL , LinS , DingS , HuangX , JinZ , CuiR , et al. Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study. Chinese medical journal2014;127(8):1454-8. [PMID: 24762588]ZhouL , SungJJ , LinS , JinZ , DingS , HuangX , et al. A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chinese Medical Journal2003;116(1):11-4. [PMID: 12667379]ZhouL . Ten-year follow-up study on the incidence of gastric cancer and the pathological changes of gastric mucosa after H. pylori eradication in China. In: Gastroenterology. Vol. 134 (4, suppl 1). 2008:A233. Abstract S1606. ZhouLY , LinSR , DingSG , HuangSB , GuoCJ , ZhangL , et al. Eight-year follow-up study on prevalence of gastric cancer and the histological changes of gastric mucosa after H.pylori eradication [除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究]. Chinese Journal of Digestion2005;25(6):324-7. ZhouLY , LinSR , DingSG , HuangSB , GuoCJ , ZhangL , et al. Eight-year follow-up study on the morbidity of gastric cancer and the pathological changes of gastric mucosa after H.pylori eradication [除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究]. www.paper.edu.cn/scholar/downpaper/zhouliya-3 (accessed 10 June 2015). ZhouLY , LinSR , DingSG , HuangXB , ZhangL , MengLM , et al. The changing trends of the incidence of gastric cancer after Helicobacter pylori eradication in Shandong area. Chinese Journal of Digestive Diseases2005;6(3):114-5. ZhouLY , LinSR , ShenZY , ZhongSZ , DingSG , HuangXB , et al. Five-year follow-up study after Helicobacter pylori eradication: Reinfection and peptic ulcer status. Chinese Journal of Digestive Diseases2003;4(1):45-8. ZhouLY , SungJJ , LinSR , JinZ , DingSG , HuangXB , et al. Changes of gastric mucosa histopathology after Helicobacterpylori eradication [根除幽门螺杆菌对胃黏膜炎症变化的人群随访研究]. Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]2003;42(3):162-4. ">Leung 2004‐Zhou 2014</a>; <a href="./references#CD005583-bbs2-0005" title="WongBC , LamSK , WongWM , ChenJS , ZhengTT , FengRE , et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA2004;291(2):187-94. WongBCY , LamS , WongWM , et al. Eradication of Helicobacter pylori infection significantly slows down the progression of precancerous lesions in high risk populations: a 5 year prospective randomized study. In: Gastroenterology. Vol. 122. 2002:A588. Abstract W1216. ">Wong 2004</a>), and two studies generated the assignments by a company (<a href="./references#CD005583-bbs2-0091" title="WongBC , ZhangL , MaJL , PanKF , LiJY , ShenL , et al. Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut2012;61(6):812-8. ">Wong 2012</a>; <a href="./references#CD005583-bbs2-0007" title="GailMH , YouWC , ChangYS , ZhangL , BlotWJ , BrownLM , et al. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. Controlled Clinical Trials1998;19(4):352-69. LiWQ , MaJL , ZhangL , BrownLM , LiJY , ShenL , et al. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. Journal of the National Cancer Institute2014;106(7). [DOI: DOI:10.1093/jnci/dju116] [PMID: 24925350]LiWQ , ZhangJY , MaJL , LiZX , ZhangL , ZhangY , et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. BMJ2019;366:l5016. [PMID: 31511230]LiWQ , ZhangL , MaJL , BrownL , LiJY , ShenL , et al. Fifteen-year effects of Helicobacter pylori treatment on gastric cancer incidence and mortality among participants with different baseline gastric lesions and ages. American Journal of Epidemiology2013;177 (Suppl 11):S61. MaJL , ZhangL , BrownLM , LiJY , ShenL , PanKF , et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. Journal of the National Cancer Institute2012;104(6):488-92. WangY , ZhangL , MoslehiR , MaJ , PanK , ZhouT , et al. Long-term garlic or micronutrient supplementation, but not anti-Helicobacter pylori therapy, increases serum folate or glutathione without affecting serum vitamin B-12 or homocysteine in a rural Chinese population. Journal of Nutrition2009;139(1):106-12. YouWC , BrownLM , ZhangL , LiJY , JinML , ChangYS , et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. Journal of the National Cancer Institute2006;98(14):974-83. YouWC , ChangYS , HeinrichJ , MaJL , LiuWD , ZhangL , et al. An intervention trial to inhibit the progression of precancerous gastric lesions: compliance, serum micronutrients and S-allyl cysteine levels, and toxicity. European Journal of Cancer Prevention2001;10(3):257-63. ZhangL , GailMH , WangYQ , BrownLM , PanKF , MaJL , et al. A randomized factorial study of the effects of long-term garlic and micronutrient supplementation and of 2-wk antibiotic treatment for Helicobacter pylori infection on serum cholesterol and lipoproteins. American Journal of Clinical Nutrition2006;86(4):912-9. ZhangL , MaJL , LiuWD , JiangJ , PanKF , PanYS , et al. A randomized multi-intervention trial to inhibit gastric cancer in Shandong (progress report). Chinese Journal of Clinical Oncology1998;25(5):338-40. ">You 2006 ‐ Li 2019</a>). We considered one study, in abstract form, to be at unclear risk of bias for random sequence generation, as no information was provided regarding the randomisation process (<a href="./references#CD005583-bbs2-0004" title="SaitoD , BokuN , FujiokaT , FukudaY , MatsushimaY , SakakiN , et al. Impact of H. pylori eradication on gastric cancer prevention: endoscopic results of the Japanese Intervention Trial (JITHP-Study). A randomized multi-center trial. In: Gastroenterology. Vol. 128 4 (Supp2). 2005:A4. Abstract 23. SaitoD . Present state of Japanese intervention trial of H. pylori . Nihon Rinsho2003;61(1):50-5. ">Saito 2005</a>). </p> </section> <section id="CD005583-sec-0056"> <h5 class="title">Allocation concealment</h5> <p>We considered six studies to be at low risk of bias for allocation concealment: two studies allocated participants by sealed envelopes (<a href="./references#CD005583-bbs2-0003" title="LeungWK , LinSR , ChingJY , ToKF , NgEK , ChanFK , et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut2004;53(9):1244-9. SungJJ , LinSR , ChingJY , ZhouLY , ToKF , WangRT , et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology2000;119(1):7-14. SungJJ , LinSR , LeungW , NgEK , ChingJY , ToKF , et al. Does eradication of H. pylori prevent deterioration of gastric atrophy and intestinal metaplasia? A 5-year follow-up. In: Gastroenterology. Vol. 122(Suppl 4). 2002:A170. Abstract S1142. ZhouL , LinS , DingS , HuangX , JinZ , CuiR , et al. Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study. Chinese medical journal2014;127(8):1454-8. [PMID: 24762588]ZhouL , SungJJ , LinS , JinZ , DingS , HuangX , et al. A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chinese Medical Journal2003;116(1):11-4. [PMID: 12667379]ZhouL . Ten-year follow-up study on the incidence of gastric cancer and the pathological changes of gastric mucosa after H. pylori eradication in China. In: Gastroenterology. Vol. 134 (4, suppl 1). 2008:A233. Abstract S1606. ZhouLY , LinSR , DingSG , HuangSB , GuoCJ , ZhangL , et al. Eight-year follow-up study on prevalence of gastric cancer and the histological changes of gastric mucosa after H.pylori eradication [除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究]. Chinese Journal of Digestion2005;25(6):324-7. ZhouLY , LinSR , DingSG , HuangSB , GuoCJ , ZhangL , et al. Eight-year follow-up study on the morbidity of gastric cancer and the pathological changes of gastric mucosa after H.pylori eradication [除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究]. www.paper.edu.cn/scholar/downpaper/zhouliya-3 (accessed 10 June 2015). ZhouLY , LinSR , DingSG , HuangXB , ZhangL , MengLM , et al. The changing trends of the incidence of gastric cancer after Helicobacter pylori eradication in Shandong area. Chinese Journal of Digestive Diseases2005;6(3):114-5. ZhouLY , LinSR , ShenZY , ZhongSZ , DingSG , HuangXB , et al. Five-year follow-up study after Helicobacter pylori eradication: Reinfection and peptic ulcer status. Chinese Journal of Digestive Diseases2003;4(1):45-8. ZhouLY , SungJJ , LinSR , JinZ , DingSG , HuangXB , et al. Changes of gastric mucosa histopathology after Helicobacterpylori eradication [根除幽门螺杆菌对胃黏膜炎症变化的人群随访研究]. Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]2003;42(3):162-4. ">Leung 2004‐Zhou 2014</a>; <a href="./references#CD005583-bbs2-0005" title="WongBC , LamSK , WongWM , ChenJS , ZhengTT , FengRE , et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA2004;291(2):187-94. WongBCY , LamS , WongWM , et al. Eradication of Helicobacter pylori infection significantly slows down the progression of precancerous lesions in high risk populations: a 5 year prospective randomized study. In: Gastroenterology. Vol. 122. 2002:A588. Abstract W1216. ">Wong 2004</a> ), one study involved the trial pharmacy keeping the randomization sequence (<a href="./references#CD005583-bbs2-0001" title="ChoiIJ , KimCG , LeeJY , KimYI , KookMC , ParkB , JooJ . Family History of Gastric Cancer and Helicobacter pylori Treatment. New England Journal of Medicine2020;382(5):427-436. ">Choi 2020</a>) and three studies involved central allocation (<a href="./references#CD005583-bbs2-0002" title="CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacterpylori therapy. Journal of the National Cancer Institute2000;92(23):1881-8. CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Re: Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. Journal of the National Cancer Institute2001;93(7):559-60. MeraR , FonthamET , BravoLE , BravoJC , PiazueloMB , CamargoMC , et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut2005;54(11):1536-40. RuizB , GarayJ , CorreaP , FonthamET , BravoJC , BravoLE , et al. Morphometric evaluation of gastric antral atrophy: improvement after cure of Helicobacter pylori infection. American Journal of Gastroenterology2001;96(12):3281-7. ">Correa 2000‐Correa 2001</a>; <a href="./references#CD005583-bbs2-0006" title="FengGS , MaJL , WongBC , ZhangL , LiuWD , PanKF , et al. Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention. World Journal of Gastroenterology2008;14(28):4535-9. WongBC , ZhangL , MaJL , PanKF , LiJY , ShenL , et al. Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut2012;61(6):812-8. WongBC . Eradication of Helicobacter pylori for prevention of gastric cancer. In: Journal of Gastroenterology and Hepatology. Vol. 27 (Suppl. 5). 2012:5-6. Abstract UA01-05. ">Wong 2012a</a>; <a href="./references#CD005583-bbs2-0007" title="GailMH , YouWC , ChangYS , ZhangL , BlotWJ , BrownLM , et al. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. Controlled Clinical Trials1998;19(4):352-69. LiWQ , MaJL , ZhangL , BrownLM , LiJY , ShenL , et al. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. Journal of the National Cancer Institute2014;106(7). [DOI: DOI:10.1093/jnci/dju116] [PMID: 24925350]LiWQ , ZhangJY , MaJL , LiZX , ZhangL , ZhangY , et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. BMJ2019;366:l5016. [PMID: 31511230]LiWQ , ZhangL , MaJL , BrownL , LiJY , ShenL , et al. Fifteen-year effects of Helicobacter pylori treatment on gastric cancer incidence and mortality among participants with different baseline gastric lesions and ages. American Journal of Epidemiology2013;177 (Suppl 11):S61. MaJL , ZhangL , BrownLM , LiJY , ShenL , PanKF , et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. Journal of the National Cancer Institute2012;104(6):488-92. WangY , ZhangL , MoslehiR , MaJ , PanK , ZhouT , et al. Long-term garlic or micronutrient supplementation, but not anti-Helicobacter pylori therapy, increases serum folate or glutathione without affecting serum vitamin B-12 or homocysteine in a rural Chinese population. Journal of Nutrition2009;139(1):106-12. YouWC , BrownLM , ZhangL , LiJY , JinML , ChangYS , et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. Journal of the National Cancer Institute2006;98(14):974-83. YouWC , ChangYS , HeinrichJ , MaJL , LiuWD , ZhangL , et al. An intervention trial to inhibit the progression of precancerous gastric lesions: compliance, serum micronutrients and S-allyl cysteine levels, and toxicity. European Journal of Cancer Prevention2001;10(3):257-63. ZhangL , GailMH , WangYQ , BrownLM , PanKF , MaJL , et al. A randomized factorial study of the effects of long-term garlic and micronutrient supplementation and of 2-wk antibiotic treatment for Helicobacter pylori infection on serum cholesterol and lipoproteins. American Journal of Clinical Nutrition2006;86(4):912-9. ZhangL , MaJL , LiuWD , JiangJ , PanKF , PanYS , et al. A randomized multi-intervention trial to inhibit gastric cancer in Shandong (progress report). Chinese Journal of Clinical Oncology1998;25(5):338-40. ">You 2006 ‐ Li 2019</a>). One study, in abstract form, had uncertain concealment (<a href="./references#CD005583-bbs2-0004" title="SaitoD , BokuN , FujiokaT , FukudaY , MatsushimaY , SakakiN , et al. Impact of H. pylori eradication on gastric cancer prevention: endoscopic results of the Japanese Intervention Trial (JITHP-Study). A randomized multi-center trial. In: Gastroenterology. Vol. 128 4 (Supp2). 2005:A4. Abstract 23. SaitoD . Present state of Japanese intervention trial of H. pylori . Nihon Rinsho2003;61(1):50-5. ">Saito 2005</a>). </p> </section> </section> <section id="CD005583-sec-0057"> <h4 class="title">Blinding</h4> <p>Blinding of participants, health providers, data collectors, and outcome assessors should be possible for this type of eradication study. We considered five double‐blind, placebo‐controlled studies to be at low risk of bias for blinding of participants and personnel, as well as blinding of outcome assessors (<a href="./references#CD005583-bbs2-0001" title="ChoiIJ , KimCG , LeeJY , KimYI , KookMC , ParkB , JooJ . Family History of Gastric Cancer and Helicobacter pylori Treatment. New England Journal of Medicine2020;382(5):427-436. ">Choi 2020</a>; <a href="./references#CD005583-bbs2-0003" title="LeungWK , LinSR , ChingJY , ToKF , NgEK , ChanFK , et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut2004;53(9):1244-9. SungJJ , LinSR , ChingJY , ZhouLY , ToKF , WangRT , et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology2000;119(1):7-14. SungJJ , LinSR , LeungW , NgEK , ChingJY , ToKF , et al. Does eradication of H. pylori prevent deterioration of gastric atrophy and intestinal metaplasia? A 5-year follow-up. In: Gastroenterology. Vol. 122(Suppl 4). 2002:A170. Abstract S1142. ZhouL , LinS , DingS , HuangX , JinZ , CuiR , et al. Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study. Chinese medical journal2014;127(8):1454-8. [PMID: 24762588]ZhouL , SungJJ , LinS , JinZ , DingS , HuangX , et al. A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chinese Medical Journal2003;116(1):11-4. [PMID: 12667379]ZhouL . Ten-year follow-up study on the incidence of gastric cancer and the pathological changes of gastric mucosa after H. pylori eradication in China. In: Gastroenterology. Vol. 134 (4, suppl 1). 2008:A233. Abstract S1606. ZhouLY , LinSR , DingSG , HuangSB , GuoCJ , ZhangL , et al. Eight-year follow-up study on prevalence of gastric cancer and the histological changes of gastric mucosa after H.pylori eradication [除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究]. Chinese Journal of Digestion2005;25(6):324-7. ZhouLY , LinSR , DingSG , HuangSB , GuoCJ , ZhangL , et al. Eight-year follow-up study on the morbidity of gastric cancer and the pathological changes of gastric mucosa after H.pylori eradication [除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究]. www.paper.edu.cn/scholar/downpaper/zhouliya-3 (accessed 10 June 2015). ZhouLY , LinSR , DingSG , HuangXB , ZhangL , MengLM , et al. The changing trends of the incidence of gastric cancer after Helicobacter pylori eradication in Shandong area. Chinese Journal of Digestive Diseases2005;6(3):114-5. ZhouLY , LinSR , ShenZY , ZhongSZ , DingSG , HuangXB , et al. Five-year follow-up study after Helicobacter pylori eradication: Reinfection and peptic ulcer status. Chinese Journal of Digestive Diseases2003;4(1):45-8. ZhouLY , SungJJ , LinSR , JinZ , DingSG , HuangXB , et al. Changes of gastric mucosa histopathology after Helicobacterpylori eradication [根除幽门螺杆菌对胃黏膜炎症变化的人群随访研究]. Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]2003;42(3):162-4. ">Leung 2004‐Zhou 2014</a>; <a href="./references#CD005583-bbs2-0005" title="WongBC , LamSK , WongWM , ChenJS , ZhengTT , FengRE , et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA2004;291(2):187-94. WongBCY , LamS , WongWM , et al. Eradication of Helicobacter pylori infection significantly slows down the progression of precancerous lesions in high risk populations: a 5 year prospective randomized study. In: Gastroenterology. Vol. 122. 2002:A588. Abstract W1216. ">Wong 2004</a>; <a href="./references#CD005583-bbs2-0006" title="FengGS , MaJL , WongBC , ZhangL , LiuWD , PanKF , et al. Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention. World Journal of Gastroenterology2008;14(28):4535-9. WongBC , ZhangL , MaJL , PanKF , LiJY , ShenL , et al. Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut2012;61(6):812-8. WongBC . Eradication of Helicobacter pylori for prevention of gastric cancer. In: Journal of Gastroenterology and Hepatology. Vol. 27 (Suppl. 5). 2012:5-6. Abstract UA01-05. ">Wong 2012a</a>; <a href="./references#CD005583-bbs2-0007" title="GailMH , YouWC , ChangYS , ZhangL , BlotWJ , BrownLM , et al. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. Controlled Clinical Trials1998;19(4):352-69. LiWQ , MaJL , ZhangL , BrownLM , LiJY , ShenL , et al. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. Journal of the National Cancer Institute2014;106(7). [DOI: DOI:10.1093/jnci/dju116] [PMID: 24925350]LiWQ , ZhangJY , MaJL , LiZX , ZhangL , ZhangY , et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. BMJ2019;366:l5016. [PMID: 31511230]LiWQ , ZhangL , MaJL , BrownL , LiJY , ShenL , et al. Fifteen-year effects of Helicobacter pylori treatment on gastric cancer incidence and mortality among participants with different baseline gastric lesions and ages. American Journal of Epidemiology2013;177 (Suppl 11):S61. MaJL , ZhangL , BrownLM , LiJY , ShenL , PanKF , et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. Journal of the National Cancer Institute2012;104(6):488-92. WangY , ZhangL , MoslehiR , MaJ , PanK , ZhouT , et al. Long-term garlic or micronutrient supplementation, but not anti-Helicobacter pylori therapy, increases serum folate or glutathione without affecting serum vitamin B-12 or homocysteine in a rural Chinese population. Journal of Nutrition2009;139(1):106-12. YouWC , BrownLM , ZhangL , LiJY , JinML , ChangYS , et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. Journal of the National Cancer Institute2006;98(14):974-83. YouWC , ChangYS , HeinrichJ , MaJL , LiuWD , ZhangL , et al. An intervention trial to inhibit the progression of precancerous gastric lesions: compliance, serum micronutrients and S-allyl cysteine levels, and toxicity. European Journal of Cancer Prevention2001;10(3):257-63. ZhangL , GailMH , WangYQ , BrownLM , PanKF , MaJL , et al. A randomized factorial study of the effects of long-term garlic and micronutrient supplementation and of 2-wk antibiotic treatment for Helicobacter pylori infection on serum cholesterol and lipoproteins. American Journal of Clinical Nutrition2006;86(4):912-9. ZhangL , MaJL , LiuWD , JiangJ , PanKF , PanYS , et al. A randomized multi-intervention trial to inhibit gastric cancer in Shandong (progress report). Chinese Journal of Clinical Oncology1998;25(5):338-40. ">You 2006 ‐ Li 2019</a>). Pathologists were blinded in three studies (<a href="./references#CD005583-bbs2-0001" title="ChoiIJ , KimCG , LeeJY , KimYI , KookMC , ParkB , JooJ . Family History of Gastric Cancer and Helicobacter pylori Treatment. New England Journal of Medicine2020;382(5):427-436. ">Choi 2020</a>; <a href="./references#CD005583-bbs2-0002" title="CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacterpylori therapy. Journal of the National Cancer Institute2000;92(23):1881-8. CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Re: Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. Journal of the National Cancer Institute2001;93(7):559-60. MeraR , FonthamET , BravoLE , BravoJC , PiazueloMB , CamargoMC , et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut2005;54(11):1536-40. RuizB , GarayJ , CorreaP , FonthamET , BravoJC , BravoLE , et al. Morphometric evaluation of gastric antral atrophy: improvement after cure of Helicobacter pylori infection. American Journal of Gastroenterology2001;96(12):3281-7. ">Correa 2000‐Correa 2001</a>; <a href="./references#CD005583-bbs2-0003" title="LeungWK , LinSR , ChingJY , ToKF , NgEK , ChanFK , et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut2004;53(9):1244-9. SungJJ , LinSR , ChingJY , ZhouLY , ToKF , WangRT , et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology2000;119(1):7-14. SungJJ , LinSR , LeungW , NgEK , ChingJY , ToKF , et al. Does eradication of H. pylori prevent deterioration of gastric atrophy and intestinal metaplasia? A 5-year follow-up. In: Gastroenterology. Vol. 122(Suppl 4). 2002:A170. Abstract S1142. ZhouL , LinS , DingS , HuangX , JinZ , CuiR , et al. Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study. Chinese medical journal2014;127(8):1454-8. [PMID: 24762588]ZhouL , SungJJ , LinS , JinZ , DingS , HuangX , et al. A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chinese Medical Journal2003;116(1):11-4. [PMID: 12667379]ZhouL . Ten-year follow-up study on the incidence of gastric cancer and the pathological changes of gastric mucosa after H. pylori eradication in China. In: Gastroenterology. Vol. 134 (4, suppl 1). 2008:A233. Abstract S1606. ZhouLY , LinSR , DingSG , HuangSB , GuoCJ , ZhangL , et al. Eight-year follow-up study on prevalence of gastric cancer and the histological changes of gastric mucosa after H.pylori eradication [除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究]. Chinese Journal of Digestion2005;25(6):324-7. ZhouLY , LinSR , DingSG , HuangSB , GuoCJ , ZhangL , et al. Eight-year follow-up study on the morbidity of gastric cancer and the pathological changes of gastric mucosa after H.pylori eradication [除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究]. www.paper.edu.cn/scholar/downpaper/zhouliya-3 (accessed 10 June 2015). ZhouLY , LinSR , DingSG , HuangXB , ZhangL , MengLM , et al. The changing trends of the incidence of gastric cancer after Helicobacter pylori eradication in Shandong area. Chinese Journal of Digestive Diseases2005;6(3):114-5. ZhouLY , LinSR , ShenZY , ZhongSZ , DingSG , HuangXB , et al. Five-year follow-up study after Helicobacter pylori eradication: Reinfection and peptic ulcer status. Chinese Journal of Digestive Diseases2003;4(1):45-8. ZhouLY , SungJJ , LinSR , JinZ , DingSG , HuangXB , et al. Changes of gastric mucosa histopathology after Helicobacterpylori eradication [根除幽门螺杆菌对胃黏膜炎症变化的人群随访研究]. Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]2003;42(3):162-4. ">Leung 2004‐Zhou 2014</a>), two of which were considered a double‐blind study because a placebo was used (<a href="./references#CD005583-bbs2-0001" title="ChoiIJ , KimCG , LeeJY , KimYI , KookMC , ParkB , JooJ . Family History of Gastric Cancer and Helicobacter pylori Treatment. New England Journal of Medicine2020;382(5):427-436. ">Choi 2020</a>; <a href="./references#CD005583-bbs2-0003" title="LeungWK , LinSR , ChingJY , ToKF , NgEK , ChanFK , et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut2004;53(9):1244-9. SungJJ , LinSR , ChingJY , ZhouLY , ToKF , WangRT , et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology2000;119(1):7-14. SungJJ , LinSR , LeungW , NgEK , ChingJY , ToKF , et al. Does eradication of H. pylori prevent deterioration of gastric atrophy and intestinal metaplasia? A 5-year follow-up. In: Gastroenterology. Vol. 122(Suppl 4). 2002:A170. Abstract S1142. ZhouL , LinS , DingS , HuangX , JinZ , CuiR , et al. Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study. Chinese medical journal2014;127(8):1454-8. [PMID: 24762588]ZhouL , SungJJ , LinS , JinZ , DingS , HuangX , et al. A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chinese Medical Journal2003;116(1):11-4. [PMID: 12667379]ZhouL . Ten-year follow-up study on the incidence of gastric cancer and the pathological changes of gastric mucosa after H. pylori eradication in China. In: Gastroenterology. Vol. 134 (4, suppl 1). 2008:A233. Abstract S1606. ZhouLY , LinSR , DingSG , HuangSB , GuoCJ , ZhangL , et al. Eight-year follow-up study on prevalence of gastric cancer and the histological changes of gastric mucosa after H.pylori eradication [除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究]. Chinese Journal of Digestion2005;25(6):324-7. ZhouLY , LinSR , DingSG , HuangSB , GuoCJ , ZhangL , et al. Eight-year follow-up study on the morbidity of gastric cancer and the pathological changes of gastric mucosa after H.pylori eradication [除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究]. www.paper.edu.cn/scholar/downpaper/zhouliya-3 (accessed 10 June 2015). ZhouLY , LinSR , DingSG , HuangXB , ZhangL , MengLM , et al. The changing trends of the incidence of gastric cancer after Helicobacter pylori eradication in Shandong area. Chinese Journal of Digestive Diseases2005;6(3):114-5. ZhouLY , LinSR , ShenZY , ZhongSZ , DingSG , HuangXB , et al. Five-year follow-up study after Helicobacter pylori eradication: Reinfection and peptic ulcer status. Chinese Journal of Digestive Diseases2003;4(1):45-8. ZhouLY , SungJJ , LinSR , JinZ , DingSG , HuangXB , et al. Changes of gastric mucosa histopathology after Helicobacterpylori eradication [根除幽门螺杆菌对胃黏膜炎症变化的人群随访研究]. Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]2003;42(3):162-4. ">Leung 2004‐Zhou 2014</a>). We considered <a href="./references#CD005583-bbs2-0002" title="CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacterpylori therapy. Journal of the National Cancer Institute2000;92(23):1881-8. CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Re: Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. Journal of the National Cancer Institute2001;93(7):559-60. MeraR , FonthamET , BravoLE , BravoJC , PiazueloMB , CamargoMC , et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut2005;54(11):1536-40. RuizB , GarayJ , CorreaP , FonthamET , BravoJC , BravoLE , et al. Morphometric evaluation of gastric antral atrophy: improvement after cure of Helicobacter pylori infection. American Journal of Gastroenterology2001;96(12):3281-7. ">Correa 2000‐Correa 2001</a> to be at high risk of bias for blinding of participants and personnel because an appropriate placebo was not available for bismuth subsalicylate, and double blinding only applied to the dietary supplements versus placebo part of the trial. We considered this study to be at low risk of bias for blinding of outcome assessment because pathologists were blinded. One study, in abstract form, had uncertain risk of bias for blinding (<a href="./references#CD005583-bbs2-0004" title="SaitoD , BokuN , FujiokaT , FukudaY , MatsushimaY , SakakiN , et al. Impact of H. pylori eradication on gastric cancer prevention: endoscopic results of the Japanese Intervention Trial (JITHP-Study). A randomized multi-center trial. In: Gastroenterology. Vol. 128 4 (Supp2). 2005:A4. Abstract 23. SaitoD . Present state of Japanese intervention trial of H. pylori . Nihon Rinsho2003;61(1):50-5. ">Saito 2005</a>). </p> </section> <section id="CD005583-sec-0058"> <h4 class="title">Incomplete outcome data</h4> <p>We considered one study to be at high risk of bias for incomplete outcome data (<a href="./references#CD005583-bbs2-0003" title="LeungWK , LinSR , ChingJY , ToKF , NgEK , ChanFK , et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut2004;53(9):1244-9. SungJJ , LinSR , ChingJY , ZhouLY , ToKF , WangRT , et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology2000;119(1):7-14. SungJJ , LinSR , LeungW , NgEK , ChingJY , ToKF , et al. Does eradication of H. pylori prevent deterioration of gastric atrophy and intestinal metaplasia? A 5-year follow-up. In: Gastroenterology. Vol. 122(Suppl 4). 2002:A170. Abstract S1142. ZhouL , LinS , DingS , HuangX , JinZ , CuiR , et al. Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study. Chinese medical journal2014;127(8):1454-8. [PMID: 24762588]ZhouL , SungJJ , LinS , JinZ , DingS , HuangX , et al. A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chinese Medical Journal2003;116(1):11-4. [PMID: 12667379]ZhouL . Ten-year follow-up study on the incidence of gastric cancer and the pathological changes of gastric mucosa after H. pylori eradication in China. In: Gastroenterology. Vol. 134 (4, suppl 1). 2008:A233. Abstract S1606. ZhouLY , LinSR , DingSG , HuangSB , GuoCJ , ZhangL , et al. Eight-year follow-up study on prevalence of gastric cancer and the histological changes of gastric mucosa after H.pylori eradication [除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究]. Chinese Journal of Digestion2005;25(6):324-7. ZhouLY , LinSR , DingSG , HuangSB , GuoCJ , ZhangL , et al. Eight-year follow-up study on the morbidity of gastric cancer and the pathological changes of gastric mucosa after H.pylori eradication [除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究]. www.paper.edu.cn/scholar/downpaper/zhouliya-3 (accessed 10 June 2015). ZhouLY , LinSR , DingSG , HuangXB , ZhangL , MengLM , et al. The changing trends of the incidence of gastric cancer after Helicobacter pylori eradication in Shandong area. Chinese Journal of Digestive Diseases2005;6(3):114-5. ZhouLY , LinSR , ShenZY , ZhongSZ , DingSG , HuangXB , et al. Five-year follow-up study after Helicobacter pylori eradication: Reinfection and peptic ulcer status. Chinese Journal of Digestive Diseases2003;4(1):45-8. ZhouLY , SungJJ , LinSR , JinZ , DingSG , HuangXB , et al. Changes of gastric mucosa histopathology after Helicobacterpylori eradication [根除幽门螺杆菌对胃黏膜炎症变化的人群随访研究]. Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]2003;42(3):162-4. ">Leung 2004‐Zhou 2014</a>). Data from <a href="./references#CD005583-bbs2-0106" title="ZhouL , LinS , DingS , HuangX , JinZ , CuiR , et al. Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study. Chinese medical journal2014;127(8):1454-8. [PMID: 24762588]">Zhou 2014</a> were used for the main analysis due to the longer follow‐up period. However, the 10‐year follow‐up data reported in <a href="./references#CD005583-bbs2-0106" title="ZhouL , LinS , DingS , HuangX , JinZ , CuiR , et al. Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study. Chinese medical journal2014;127(8):1454-8. [PMID: 24762588]">Zhou 2014</a> had a smaller sample size, and fewer gastric cancer cases, than those in the earlier full publication (<a href="./references#CD005583-bbs2-0068" title="LeungWK , LinSR , ChingJY , ToKF , NgEK , ChanFK , et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut2004;53(9):1244-9.">Leung 2004</a>). According to <a href="./references#CD005583-bbs2-0068" title="LeungWK , LinSR , ChingJY , ToKF , NgEK , ChanFK , et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut2004;53(9):1244-9.">Leung 2004</a>, 152 (75 vs 77) were lost to follow‐up; these participants were considered as no gastric cancer in the ITT analysis. After 10 years, 378 subjects had completed the study (<a href="./references#CD005583-bbs2-0106" title="ZhouL , LinS , DingS , HuangX , JinZ , CuiR , et al. Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study. Chinese medical journal2014;127(8):1454-8. [PMID: 24762588]">Zhou 2014</a>). Therefore, in total there would be more than 31% participants lost to follow‐up. We considered three studies to be at unclear risk of bias (<a href="./references#CD005583-bbs2-0002" title="CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacterpylori therapy. Journal of the National Cancer Institute2000;92(23):1881-8. CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Re: Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. Journal of the National Cancer Institute2001;93(7):559-60. MeraR , FonthamET , BravoLE , BravoJC , PiazueloMB , CamargoMC , et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut2005;54(11):1536-40. RuizB , GarayJ , CorreaP , FonthamET , BravoJC , BravoLE , et al. Morphometric evaluation of gastric antral atrophy: improvement after cure of Helicobacter pylori infection. American Journal of Gastroenterology2001;96(12):3281-7. ">Correa 2000‐Correa 2001</a>; <a href="./references#CD005583-bbs2-0004" title="SaitoD , BokuN , FujiokaT , FukudaY , MatsushimaY , SakakiN , et al. Impact of H. pylori eradication on gastric cancer prevention: endoscopic results of the Japanese Intervention Trial (JITHP-Study). A randomized multi-center trial. In: Gastroenterology. Vol. 128 4 (Supp2). 2005:A4. Abstract 23. SaitoD . Present state of Japanese intervention trial of H. pylori . Nihon Rinsho2003;61(1):50-5. ">Saito 2005</a>; <a href="./references#CD005583-bbs2-0007" title="GailMH , YouWC , ChangYS , ZhangL , BlotWJ , BrownLM , et al. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. Controlled Clinical Trials1998;19(4):352-69. LiWQ , MaJL , ZhangL , BrownLM , LiJY , ShenL , et al. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. Journal of the National Cancer Institute2014;106(7). [DOI: DOI:10.1093/jnci/dju116] [PMID: 24925350]LiWQ , ZhangJY , MaJL , LiZX , ZhangL , ZhangY , et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. BMJ2019;366:l5016. [PMID: 31511230]LiWQ , ZhangL , MaJL , BrownL , LiJY , ShenL , et al. Fifteen-year effects of Helicobacter pylori treatment on gastric cancer incidence and mortality among participants with different baseline gastric lesions and ages. American Journal of Epidemiology2013;177 (Suppl 11):S61. MaJL , ZhangL , BrownLM , LiJY , ShenL , PanKF , et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. Journal of the National Cancer Institute2012;104(6):488-92. WangY , ZhangL , MoslehiR , MaJ , PanK , ZhouT , et al. Long-term garlic or micronutrient supplementation, but not anti-Helicobacter pylori therapy, increases serum folate or glutathione without affecting serum vitamin B-12 or homocysteine in a rural Chinese population. Journal of Nutrition2009;139(1):106-12. YouWC , BrownLM , ZhangL , LiJY , JinML , ChangYS , et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. Journal of the National Cancer Institute2006;98(14):974-83. YouWC , ChangYS , HeinrichJ , MaJL , LiuWD , ZhangL , et al. An intervention trial to inhibit the progression of precancerous gastric lesions: compliance, serum micronutrients and S-allyl cysteine levels, and toxicity. European Journal of Cancer Prevention2001;10(3):257-63. ZhangL , GailMH , WangYQ , BrownLM , PanKF , MaJL , et al. A randomized factorial study of the effects of long-term garlic and micronutrient supplementation and of 2-wk antibiotic treatment for Helicobacter pylori infection on serum cholesterol and lipoproteins. American Journal of Clinical Nutrition2006;86(4):912-9. ZhangL , MaJL , LiuWD , JiangJ , PanKF , PanYS , et al. A randomized multi-intervention trial to inhibit gastric cancer in Shandong (progress report). Chinese Journal of Clinical Oncology1998;25(5):338-40. ">You 2006 ‐ Li 2019</a>). In one study, the average rate of loss was 4.3% per year over the 6‐year trial; withdrawals in the 72 months of follow‐up were 117 (26.8%) versus 104 (25%) in all <i>H. pylori</i> eradication arms versus control arms (<a href="./references#CD005583-bbs2-0002" title="CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacterpylori therapy. Journal of the National Cancer Institute2000;92(23):1881-8. CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Re: Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. Journal of the National Cancer Institute2001;93(7):559-60. MeraR , FonthamET , BravoLE , BravoJC , PiazueloMB , CamargoMC , et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut2005;54(11):1536-40. RuizB , GarayJ , CorreaP , FonthamET , BravoJC , BravoLE , et al. Morphometric evaluation of gastric antral atrophy: improvement after cure of Helicobacter pylori infection. American Journal of Gastroenterology2001;96(12):3281-7. ">Correa 2000‐Correa 2001</a>). However, it is likely that participants who had cancer would have come back for treatment, although these individuals did not complete follow‐up. One conference proceeding did not provide detailed information (<a href="./references#CD005583-bbs2-0004" title="SaitoD , BokuN , FujiokaT , FukudaY , MatsushimaY , SakakiN , et al. Impact of H. pylori eradication on gastric cancer prevention: endoscopic results of the Japanese Intervention Trial (JITHP-Study). A randomized multi-center trial. In: Gastroenterology. Vol. 128 4 (Supp2). 2005:A4. Abstract 23. SaitoD . Present state of Japanese intervention trial of H. pylori . Nihon Rinsho2003;61(1):50-5. ">Saito 2005</a>). We considered four studies to be at low risk of bias, because the numbers of participants who were lost to follow‐up were balanced between treatment arms and were fewer than 20% (<a href="./references#CD005583-bbs2-0001" title="ChoiIJ , KimCG , LeeJY , KimYI , KookMC , ParkB , JooJ . Family History of Gastric Cancer and Helicobacter pylori Treatment. New England Journal of Medicine2020;382(5):427-436. ">Choi 2020</a>; <a href="./references#CD005583-bbs2-0005" title="WongBC , LamSK , WongWM , ChenJS , ZhengTT , FengRE , et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA2004;291(2):187-94. WongBCY , LamS , WongWM , et al. Eradication of Helicobacter pylori infection significantly slows down the progression of precancerous lesions in high risk populations: a 5 year prospective randomized study. In: Gastroenterology. Vol. 122. 2002:A588. Abstract W1216. ">Wong 2004</a>; <a href="./references#CD005583-bbs2-0006" title="FengGS , MaJL , WongBC , ZhangL , LiuWD , PanKF , et al. Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention. World Journal of Gastroenterology2008;14(28):4535-9. WongBC , ZhangL , MaJL , PanKF , LiJY , ShenL , et al. Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut2012;61(6):812-8. WongBC . Eradication of Helicobacter pylori for prevention of gastric cancer. In: Journal of Gastroenterology and Hepatology. Vol. 27 (Suppl. 5). 2012:5-6. Abstract UA01-05. ">Wong 2012a</a>; <a href="./references#CD005583-bbs2-0007" title="GailMH , YouWC , ChangYS , ZhangL , BlotWJ , BrownLM , et al. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. Controlled Clinical Trials1998;19(4):352-69. LiWQ , MaJL , ZhangL , BrownLM , LiJY , ShenL , et al. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. Journal of the National Cancer Institute2014;106(7). [DOI: DOI:10.1093/jnci/dju116] [PMID: 24925350]LiWQ , ZhangJY , MaJL , LiZX , ZhangL , ZhangY , et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. BMJ2019;366:l5016. [PMID: 31511230]LiWQ , ZhangL , MaJL , BrownL , LiJY , ShenL , et al. Fifteen-year effects of Helicobacter pylori treatment on gastric cancer incidence and mortality among participants with different baseline gastric lesions and ages. American Journal of Epidemiology2013;177 (Suppl 11):S61. MaJL , ZhangL , BrownLM , LiJY , ShenL , PanKF , et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. Journal of the National Cancer Institute2012;104(6):488-92. WangY , ZhangL , MoslehiR , MaJ , PanK , ZhouT , et al. Long-term garlic or micronutrient supplementation, but not anti-Helicobacter pylori therapy, increases serum folate or glutathione without affecting serum vitamin B-12 or homocysteine in a rural Chinese population. Journal of Nutrition2009;139(1):106-12. YouWC , BrownLM , ZhangL , LiJY , JinML , ChangYS , et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. Journal of the National Cancer Institute2006;98(14):974-83. YouWC , ChangYS , HeinrichJ , MaJL , LiuWD , ZhangL , et al. An intervention trial to inhibit the progression of precancerous gastric lesions: compliance, serum micronutrients and S-allyl cysteine levels, and toxicity. European Journal of Cancer Prevention2001;10(3):257-63. ZhangL , GailMH , WangYQ , BrownLM , PanKF , MaJL , et al. A randomized factorial study of the effects of long-term garlic and micronutrient supplementation and of 2-wk antibiotic treatment for Helicobacter pylori infection on serum cholesterol and lipoproteins. American Journal of Clinical Nutrition2006;86(4):912-9. ZhangL , MaJL , LiuWD , JiangJ , PanKF , PanYS , et al. A randomized multi-intervention trial to inhibit gastric cancer in Shandong (progress report). Chinese Journal of Clinical Oncology1998;25(5):338-40. ">You 2006 ‐ Li 2019</a>). </p> </section> <section id="CD005583-sec-0059"> <h4 class="title">Selective reporting</h4> <p>Four studies reported all important outcomes, and we therefore considered them to be at low risk of bias for selective reporting (<a href="./references#CD005583-bbs2-0001" title="ChoiIJ , KimCG , LeeJY , KimYI , KookMC , ParkB , JooJ . Family History of Gastric Cancer and Helicobacter pylori Treatment. New England Journal of Medicine2020;382(5):427-436. ">Choi 2020</a>; <a href="./references#CD005583-bbs2-0005" title="WongBC , LamSK , WongWM , ChenJS , ZhengTT , FengRE , et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA2004;291(2):187-94. WongBCY , LamS , WongWM , et al. Eradication of Helicobacter pylori infection significantly slows down the progression of precancerous lesions in high risk populations: a 5 year prospective randomized study. In: Gastroenterology. Vol. 122. 2002:A588. Abstract W1216. ">Wong 2004</a>; <a href="./references#CD005583-bbs2-0006" title="FengGS , MaJL , WongBC , ZhangL , LiuWD , PanKF , et al. Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention. World Journal of Gastroenterology2008;14(28):4535-9. WongBC , ZhangL , MaJL , PanKF , LiJY , ShenL , et al. Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut2012;61(6):812-8. WongBC . Eradication of Helicobacter pylori for prevention of gastric cancer. In: Journal of Gastroenterology and Hepatology. Vol. 27 (Suppl. 5). 2012:5-6. Abstract UA01-05. ">Wong 2012a</a>; <a href="./references#CD005583-bbs2-0007" title="GailMH , YouWC , ChangYS , ZhangL , BlotWJ , BrownLM , et al. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. Controlled Clinical Trials1998;19(4):352-69. LiWQ , MaJL , ZhangL , BrownLM , LiJY , ShenL , et al. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. Journal of the National Cancer Institute2014;106(7). [DOI: DOI:10.1093/jnci/dju116] [PMID: 24925350]LiWQ , ZhangJY , MaJL , LiZX , ZhangL , ZhangY , et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. BMJ2019;366:l5016. [PMID: 31511230]LiWQ , ZhangL , MaJL , BrownL , LiJY , ShenL , et al. Fifteen-year effects of Helicobacter pylori treatment on gastric cancer incidence and mortality among participants with different baseline gastric lesions and ages. American Journal of Epidemiology2013;177 (Suppl 11):S61. MaJL , ZhangL , BrownLM , LiJY , ShenL , PanKF , et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. Journal of the National Cancer Institute2012;104(6):488-92. WangY , ZhangL , MoslehiR , MaJ , PanK , ZhouT , et al. Long-term garlic or micronutrient supplementation, but not anti-Helicobacter pylori therapy, increases serum folate or glutathione without affecting serum vitamin B-12 or homocysteine in a rural Chinese population. Journal of Nutrition2009;139(1):106-12. YouWC , BrownLM , ZhangL , LiJY , JinML , ChangYS , et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. Journal of the National Cancer Institute2006;98(14):974-83. YouWC , ChangYS , HeinrichJ , MaJL , LiuWD , ZhangL , et al. An intervention trial to inhibit the progression of precancerous gastric lesions: compliance, serum micronutrients and S-allyl cysteine levels, and toxicity. European Journal of Cancer Prevention2001;10(3):257-63. ZhangL , GailMH , WangYQ , BrownLM , PanKF , MaJL , et al. A randomized factorial study of the effects of long-term garlic and micronutrient supplementation and of 2-wk antibiotic treatment for Helicobacter pylori infection on serum cholesterol and lipoproteins. American Journal of Clinical Nutrition2006;86(4):912-9. ZhangL , MaJL , LiuWD , JiangJ , PanKF , PanYS , et al. A randomized multi-intervention trial to inhibit gastric cancer in Shandong (progress report). Chinese Journal of Clinical Oncology1998;25(5):338-40. ">You 2006 ‐ Li 2019</a>). We considered three studies to be at unclear risk of bias. In one of these studies, death from gastric cancer was not reported (<a href="./references#CD005583-bbs2-0002" title="CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacterpylori therapy. Journal of the National Cancer Institute2000;92(23):1881-8. CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Re: Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. Journal of the National Cancer Institute2001;93(7):559-60. MeraR , FonthamET , BravoLE , BravoJC , PiazueloMB , CamargoMC , et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut2005;54(11):1536-40. RuizB , GarayJ , CorreaP , FonthamET , BravoJC , BravoLE , et al. Morphometric evaluation of gastric antral atrophy: improvement after cure of Helicobacter pylori infection. American Journal of Gastroenterology2001;96(12):3281-7. ">Correa 2000‐Correa 2001</a>). In another study, mortality data were reported in the 2004 full publication (<a href="./references#CD005583-bbs2-0068" title="LeungWK , LinSR , ChingJY , ToKF , NgEK , ChanFK , et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut2004;53(9):1244-9.">Leung 2004</a>), but not in the 2014 article (<a href="./references#CD005583-bbs2-0106" title="ZhouL , LinS , DingS , HuangX , JinZ , CuiR , et al. Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study. Chinese medical journal2014;127(8):1454-8. [PMID: 24762588]">Zhou 2014</a>), which led to an inconsistent sample size between the incidence of gastric cancer and mortality analyses (<a href="./references#CD005583-bbs2-0003" title="LeungWK , LinSR , ChingJY , ToKF , NgEK , ChanFK , et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut2004;53(9):1244-9. SungJJ , LinSR , ChingJY , ZhouLY , ToKF , WangRT , et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology2000;119(1):7-14. SungJJ , LinSR , LeungW , NgEK , ChingJY , ToKF , et al. Does eradication of H. pylori prevent deterioration of gastric atrophy and intestinal metaplasia? A 5-year follow-up. In: Gastroenterology. Vol. 122(Suppl 4). 2002:A170. Abstract S1142. ZhouL , LinS , DingS , HuangX , JinZ , CuiR , et al. Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study. Chinese medical journal2014;127(8):1454-8. [PMID: 24762588]ZhouL , SungJJ , LinS , JinZ , DingS , HuangX , et al. A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chinese Medical Journal2003;116(1):11-4. [PMID: 12667379]ZhouL . Ten-year follow-up study on the incidence of gastric cancer and the pathological changes of gastric mucosa after H. pylori eradication in China. In: Gastroenterology. Vol. 134 (4, suppl 1). 2008:A233. Abstract S1606. ZhouLY , LinSR , DingSG , HuangSB , GuoCJ , ZhangL , et al. Eight-year follow-up study on prevalence of gastric cancer and the histological changes of gastric mucosa after H.pylori eradication [除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究]. Chinese Journal of Digestion2005;25(6):324-7. ZhouLY , LinSR , DingSG , HuangSB , GuoCJ , ZhangL , et al. Eight-year follow-up study on the morbidity of gastric cancer and the pathological changes of gastric mucosa after H.pylori eradication [除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究]. www.paper.edu.cn/scholar/downpaper/zhouliya-3 (accessed 10 June 2015). ZhouLY , LinSR , DingSG , HuangXB , ZhangL , MengLM , et al. The changing trends of the incidence of gastric cancer after Helicobacter pylori eradication in Shandong area. Chinese Journal of Digestive Diseases2005;6(3):114-5. ZhouLY , LinSR , ShenZY , ZhongSZ , DingSG , HuangXB , et al. Five-year follow-up study after Helicobacter pylori eradication: Reinfection and peptic ulcer status. Chinese Journal of Digestive Diseases2003;4(1):45-8. ZhouLY , SungJJ , LinSR , JinZ , DingSG , HuangXB , et al. Changes of gastric mucosa histopathology after Helicobacterpylori eradication [根除幽门螺杆菌对胃黏膜炎症变化的人群随访研究]. Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]2003;42(3):162-4. ">Leung 2004‐Zhou 2014</a>). One study, reported in abstract form, did not provide any mortality data (<a href="./references#CD005583-bbs2-0004" title="SaitoD , BokuN , FujiokaT , FukudaY , MatsushimaY , SakakiN , et al. Impact of H. pylori eradication on gastric cancer prevention: endoscopic results of the Japanese Intervention Trial (JITHP-Study). A randomized multi-center trial. In: Gastroenterology. Vol. 128 4 (Supp2). 2005:A4. Abstract 23. SaitoD . Present state of Japanese intervention trial of H. pylori . Nihon Rinsho2003;61(1):50-5. ">Saito 2005</a>). </p> </section> <section id="CD005583-sec-0060"> <h4 class="title">Other potential sources of bias</h4> <p>We considered one study to be at high risk of bias for other potential sources of bias, due to inconsistent data noted between serial publications (<a href="./references#CD005583-bbs2-0003" title="LeungWK , LinSR , ChingJY , ToKF , NgEK , ChanFK , et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut2004;53(9):1244-9. SungJJ , LinSR , ChingJY , ZhouLY , ToKF , WangRT , et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology2000;119(1):7-14. SungJJ , LinSR , LeungW , NgEK , ChingJY , ToKF , et al. Does eradication of H. pylori prevent deterioration of gastric atrophy and intestinal metaplasia? A 5-year follow-up. In: Gastroenterology. Vol. 122(Suppl 4). 2002:A170. Abstract S1142. ZhouL , LinS , DingS , HuangX , JinZ , CuiR , et al. Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study. Chinese medical journal2014;127(8):1454-8. [PMID: 24762588]ZhouL , SungJJ , LinS , JinZ , DingS , HuangX , et al. A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chinese Medical Journal2003;116(1):11-4. [PMID: 12667379]ZhouL . Ten-year follow-up study on the incidence of gastric cancer and the pathological changes of gastric mucosa after H. pylori eradication in China. In: Gastroenterology. Vol. 134 (4, suppl 1). 2008:A233. Abstract S1606. ZhouLY , LinSR , DingSG , HuangSB , GuoCJ , ZhangL , et al. Eight-year follow-up study on prevalence of gastric cancer and the histological changes of gastric mucosa after H.pylori eradication [除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究]. Chinese Journal of Digestion2005;25(6):324-7. ZhouLY , LinSR , DingSG , HuangSB , GuoCJ , ZhangL , et al. Eight-year follow-up study on the morbidity of gastric cancer and the pathological changes of gastric mucosa after H.pylori eradication [除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究]. www.paper.edu.cn/scholar/downpaper/zhouliya-3 (accessed 10 June 2015). ZhouLY , LinSR , DingSG , HuangXB , ZhangL , MengLM , et al. The changing trends of the incidence of gastric cancer after Helicobacter pylori eradication in Shandong area. Chinese Journal of Digestive Diseases2005;6(3):114-5. ZhouLY , LinSR , ShenZY , ZhongSZ , DingSG , HuangXB , et al. Five-year follow-up study after Helicobacter pylori eradication: Reinfection and peptic ulcer status. Chinese Journal of Digestive Diseases2003;4(1):45-8. ZhouLY , SungJJ , LinSR , JinZ , DingSG , HuangXB , et al. Changes of gastric mucosa histopathology after Helicobacterpylori eradication [根除幽门螺杆菌对胃黏膜炎症变化的人群随访研究]. Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]2003;42(3):162-4. ">Leung 2004‐Zhou 2014</a>). We identified a total of 11 publications from this study (<a href="./references#CD005583-bbs2-0068" title="LeungWK , LinSR , ChingJY , ToKF , NgEK , ChanFK , et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut2004;53(9):1244-9.">Leung 2004</a>; <a href="./references#CD005583-bbs2-0084" title="SungJJ , LinSR , ChingJY , ZhouLY , ToKF , WangRT , et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology2000;119(1):7-14.">Sung 2000</a>; <a href="./references#CD005583-bbs2-0085" title="SungJJ , LinSR , LeungW , NgEK , ChingJY , ToKF , et al. Does eradication of H. pylori prevent deterioration of gastric atrophy and intestinal metaplasia? A 5-year follow-up. In: Gastroenterology. Vol. 122(Suppl 4). 2002:A170. Abstract S1142.">Sung 2002</a>; <a href="./references#CD005583-bbs2-0099" title="ZhouL , SungJJ , LinS , JinZ , DingS , HuangX , et al. A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chinese Medical Journal2003;116(1):11-4.">Zhou 2003a</a>; <a href="./references#CD005583-bbs2-0100" title="ZhouLY , LinSR , ShenZY , ZhongSZ , DingSG , HuangXB , et al. Five-year follow-up study after Helicobacter pylori eradication: Reinfection and peptic ulcer status. Chinese Journal of Digestive Diseases2003;4(1):45-8.">Zhou 2003b</a>; <a href="./references#CD005583-bbs2-0101" title="ZhouLY , SungJJ , LinSR , JinZ , DingSG , HuangXB , et al. Changes of gastric mucosa histopathology after Helicobacterpylori eradication [根除幽门螺杆菌对胃黏膜炎症变化的人群随访研究]. Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]2003;42(3):162-4.">Zhou 2003c</a>; <a href="./references#CD005583-bbs2-0102" title="ZhouLY , LinSR , DingSG , HuangSB , GuoCJ , ZhangL , et al. Eight-year follow-up study on prevalence of gastric cancer and the histological changes of gastric mucosa after H.pylori eradication [除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究]. Chinese Journal of Digestion2005;25(6):324-7.">Zhou 2005a</a>; <a href="./references#CD005583-bbs2-0103" title="ZhouLY , LinSR , DingSG , HuangSB , GuoCJ , ZhangL , et al. Eight-year follow-up study on the morbidity of gastric cancer and the pathological changes of gastric mucosa after H.pylori eradication [除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究]. www.paper.edu.cn/scholar/downpaper/zhouliya-3 (accessed 10 June 2015).">Zhou 2005b</a>; <a href="./references#CD005583-bbs2-0104" title="ZhouLY , LinSR , DingSG , HuangXB , ZhangL , MengLM , et al. The changing trends of the incidence of gastric cancer after Helicobacter pylori eradication in Shandong area. Chinese Journal of Digestive Diseases2005;6(3):114-5.">Zhou 2005c</a>; <a href="./references#CD005583-bbs2-0105" title="ZhouL . Ten-year follow-up study on the incidence of gastric cancer and the pathological changes of gastric mucosa after H. pylori eradication in China. In: Gastroenterology. Vol. 134 (4, suppl 1). 2008:A233. Abstract S1606.">Zhou 2008</a>; <a href="./references#CD005583-bbs2-0106" title="ZhouL , LinS , DingS , HuangX , JinZ , CuiR , et al. Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study. Chinese medical journal2014;127(8):1454-8. [PMID: 24762588]">Zhou 2014</a>), with the latest publications reporting data out to 10 years of follow‐up, <a href="./references#CD005583-bbs2-0105" title="ZhouL . Ten-year follow-up study on the incidence of gastric cancer and the pathological changes of gastric mucosa after H. pylori eradication in China. In: Gastroenterology. Vol. 134 (4, suppl 1). 2008:A233. Abstract S1606.">Zhou 2008</a> and <a href="./references#CD005583-bbs2-0106" title="ZhouL , LinS , DingS , HuangX , JinZ , CuiR , et al. Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study. Chinese medical journal2014;127(8):1454-8. [PMID: 24762588]">Zhou 2014</a>, having a smaller sample size and fewer gastric cancer cases than the 2004 full publication. Specifically, 10 gastric cancer cases were reported at 5 years, compared with only nine at 10 years. We considered two studies to be at unclear risk for other potential sources of bias. One was in abstract format (<a href="./references#CD005583-bbs2-0004" title="SaitoD , BokuN , FujiokaT , FukudaY , MatsushimaY , SakakiN , et al. Impact of H. pylori eradication on gastric cancer prevention: endoscopic results of the Japanese Intervention Trial (JITHP-Study). A randomized multi-center trial. In: Gastroenterology. Vol. 128 4 (Supp2). 2005:A4. Abstract 23. SaitoD . Present state of Japanese intervention trial of H. pylori . Nihon Rinsho2003;61(1):50-5. ">Saito 2005</a>), and the other demonstrated an inconsistent sample size between the full publication, which reported data at 7.5 years (817 versus 813) (<a href="./references#CD005583-bbs2-0005" title="WongBC , LamSK , WongWM , ChenJS , ZhengTT , FengRE , et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA2004;291(2):187-94. WongBCY , LamS , WongWM , et al. Eradication of Helicobacter pylori infection significantly slows down the progression of precancerous lesions in high risk populations: a 5 year prospective randomized study. In: Gastroenterology. Vol. 122. 2002:A588. Abstract W1216. ">Wong 2004</a>), and the conference abstract, which reported data at 7 years (819 versus 809) (<a href="./references#CD005583-bbs2-0090" title="WongBCY , LamS , WongWM , et al. Eradication of Helicobacter pylori infection significantly slows down the progression of precancerous lesions in high risk populations: a 5 year prospective randomized study. In: Gastroenterology. Vol. 122. 2002:A588. Abstract W1216.">Wong 2002</a>). We considered the other four studies to be at low risk of bias. </p> </section> </section> <section id="CD005583-sec-0061"> <h3 class="title" id="CD005583-sec-0061">Effects of interventions</h3> <p>See: <a href="./full#CD005583-tbl-0001"><b>Summary of findings 1</b> H. pylori eradication therapy compared to control for the prevention of gastric neoplasia in healthy asymptomatic infected individuals</a> </p> <section id="CD005583-sec-0062"> <h4 class="title">Effect of H. pylori eradication therapy, compared with placebo or no therapy, on development of subsequent gastric cancer </h4> <p>All seven trials reported a dichotomous outcome for subsequent incidence of gastric cancer. In our primary, modified intention‐to‐treat (ITT) analysis, we included all arms in the two trials of factorial design that also randomised participants to receive antioxidants or vitamins, as well as the 10‐year follow‐up data from <a href="./references#CD005583-bbs2-0106" title="ZhouL , LinS , DingS , HuangX , JinZ , CuiR , et al. Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study. Chinese medical journal2014;127(8):1454-8. [PMID: 24762588]">Zhou 2014</a>. Overall, 68 (1.6%) of 4206 participants assigned to eradication therapy subsequently developed gastric cancer, compared with 125 (3.0%) of 4117 participants allocated to placebo or no treatment. There was no statistically significant heterogeneity between individual trial results (heterogeneity test, I<sup>2</sup> = 0%, P = 0.61). <i>H. pylori e</i>radication therapy reduced the risk of gastric cancer in healthy asymptomatic infected individuals (risk ratio (RR) 0.54; 95% confidence interval (CI) 0.40 to 0.72) (NNTB = 72; 95% CI 55 to 118) (<a href="./references#CD005583-fig-0004" title="">Analysis 1.1</a>). The certainty of the evidence was moderate (<a href="./full#CD005583-tbl-0001">summary of findings Table 1</a>) with the evidence being downgraded because one trial was at unclear risk, and two trials were at high risk of bias. In addition, because of the factorial design of some of the trials, it is difficult to determine whether the reduction in relative risk of subsequent gastric cancer was due to <i>H. pylori</i> eradication therapy alone. </p> <p>We performed several sensitivity analyses when pooling data from these seven trials. In our complete case analysis, where all participants for whom data were missing or unavailable were excluded from the analysis altogether, the RR of developing subsequent gastric cancer was 0.53 (95% CI 0.40 to 0.71) (<a href="./references#CD005583-fig-0005" title="">Analysis 1.2</a>). When we performed a modified ITT analysis, substituting the 10‐year follow‐up data from <a href="./references#CD005583-bbs2-0106" title="ZhouL , LinS , DingS , HuangX , JinZ , CuiR , et al. Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study. Chinese medical journal2014;127(8):1454-8. [PMID: 24762588]">Zhou 2014</a> with the 5‐year follow‐up data from <a href="./references#CD005583-bbs2-0068" title="LeungWK , LinSR , ChingJY , ToKF , NgEK , ChanFK , et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut2004;53(9):1244-9.">Leung 2004</a>., the RR of developing gastric cancer was 0.56 (95% CI 0.42 to 0.74) (<a href="./references#CD005583-fig-0011" title="">Analysis 4.1</a>). When we performed a complete case analysis, but substituted the 10‐year follow‐up data from <a href="./references#CD005583-bbs2-0106" title="ZhouL , LinS , DingS , HuangX , JinZ , CuiR , et al. Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study. Chinese medical journal2014;127(8):1454-8. [PMID: 24762588]">Zhou 2014</a> with the 5‐year follow‐up data from <a href="./references#CD005583-bbs2-0068" title="LeungWK , LinSR , ChingJY , ToKF , NgEK , ChanFK , et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut2004;53(9):1244-9.">Leung 2004</a>, the RR was 0.55 (95% CI 0.41 to 0.74) (<a href="./references#CD005583-fig-0012" title="">Analysis 4.2</a>). When we performed a modified ITT analysis, but also included the celecoxib arms from the trial by <a href="./references#CD005583-bbs2-0091" title="WongBC , ZhangL , MaJL , PanKF , LiJY , ShenL , et al. Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut2012;61(6):812-8. ">Wong 2012</a>, the RR was 0.55 (95% CI 0.41 to 0.74) (<a href="./references#CD005583-fig-0013" title="">Analysis 4.3</a>). When we included all randomised participants from <a href="./references#CD005583-bbs2-0002" title="CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacterpylori therapy. Journal of the National Cancer Institute2000;92(23):1881-8. CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Re: Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. Journal of the National Cancer Institute2001;93(7):559-60. MeraR , FonthamET , BravoLE , BravoJC , PiazueloMB , CamargoMC , et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut2005;54(11):1536-40. RuizB , GarayJ , CorreaP , FonthamET , BravoJC , BravoLE , et al. Morphometric evaluation of gastric antral atrophy: improvement after cure of Helicobacter pylori infection. American Journal of Gastroenterology2001;96(12):3281-7. ">Correa 2000‐Correa 2001</a> and <a href="./references#CD005583-bbs2-0007" title="GailMH , YouWC , ChangYS , ZhangL , BlotWJ , BrownLM , et al. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. Controlled Clinical Trials1998;19(4):352-69. LiWQ , MaJL , ZhangL , BrownLM , LiJY , ShenL , et al. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. Journal of the National Cancer Institute2014;106(7). [DOI: DOI:10.1093/jnci/dju116] [PMID: 24925350]LiWQ , ZhangJY , MaJL , LiZX , ZhangL , ZhangY , et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. BMJ2019;366:l5016. [PMID: 31511230]LiWQ , ZhangL , MaJL , BrownL , LiJY , ShenL , et al. Fifteen-year effects of Helicobacter pylori treatment on gastric cancer incidence and mortality among participants with different baseline gastric lesions and ages. American Journal of Epidemiology2013;177 (Suppl 11):S61. MaJL , ZhangL , BrownLM , LiJY , ShenL , PanKF , et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. Journal of the National Cancer Institute2012;104(6):488-92. WangY , ZhangL , MoslehiR , MaJ , PanK , ZhouT , et al. Long-term garlic or micronutrient supplementation, but not anti-Helicobacter pylori therapy, increases serum folate or glutathione without affecting serum vitamin B-12 or homocysteine in a rural Chinese population. Journal of Nutrition2009;139(1):106-12. YouWC , BrownLM , ZhangL , LiJY , JinML , ChangYS , et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. Journal of the National Cancer Institute2006;98(14):974-83. YouWC , ChangYS , HeinrichJ , MaJL , LiuWD , ZhangL , et al. An intervention trial to inhibit the progression of precancerous gastric lesions: compliance, serum micronutrients and S-allyl cysteine levels, and toxicity. European Journal of Cancer Prevention2001;10(3):257-63. ZhangL , GailMH , WangYQ , BrownLM , PanKF , MaJL , et al. A randomized factorial study of the effects of long-term garlic and micronutrient supplementation and of 2-wk antibiotic treatment for Helicobacter pylori infection on serum cholesterol and lipoproteins. American Journal of Clinical Nutrition2006;86(4):912-9. ZhangL , MaJL , LiuWD , JiangJ , PanKF , PanYS , et al. A randomized multi-intervention trial to inhibit gastric cancer in Shandong (progress report). Chinese Journal of Clinical Oncology1998;25(5):338-40. ">You 2006 ‐ Li 2019</a> in the analysis, that is we also included participants who were found to be ineligible after randomisation or those who did not take any medication (the most strict ITT definition), the RR was 0.54 (95% CI 0.40 to 0.72) (<a href="./references#CD005583-fig-0014" title="">Analysis 4.4</a>). Finally, we performed two data imputation analyses. If we assumed the incidence of gastric cancer for missing participants in both arms was the same as that observed in the trial control arm, the RR was 0.55 (95% CI 0.41 to 0.73). If we assumed the incidence of gastric cancer for missing participants in the treatment arm was the same as that observed in the trial control arm, but there were no new gastric cancer cases in the control arm among those with missing data, the RR was 0.56 (95% CI 0.42 to 0.74) (<a href="./references#CD005583-fig-0015" title="">Analysis 4.5</a>). We can therefore be reasonably confident that our conclusions are robust, regardless of the assumptions made about missing data. </p> </section> <section id="CD005583-sec-0063"> <h4 class="title">Effect of H. pylori eradication therapy, compared with placebo or no therapy, on development of subsequent gastric cancer according to presence or absence of preneoplastic lesions at baseline </h4> <p>We found no evidence of any benefit of <i>H. pylori</i> eradication therapy in preventing the subsequent occurrence of gastric cancer when we considered only those with preneoplastic lesions at baseline in the analysis. Overall, 42 (2.4%) of 1734 participants assigned to eradication therapy subsequently developed gastric cancer, compared with 57 (3.4%) of 1691 participants allocated to placebo or no treatment (RR 0.86; 95% CI 0.47 to 1.59) (<a href="./references#CD005583-fig-0009" title="">Analysis 2.1</a>). There was no statistically significant heterogeneity between individual trial results (heterogeneity test, I<sup>2</sup> = 23%, P = 0.27). Nor was there evidence of any benefit of <i>H. pylori</i> eradication therapy in preventing subsequent occurrence of gastric cancer when only those participants without preneoplastic lesions at baseline were considered in the analysis. Four (0.4%) of 894 participants randomised to receive eradication therapy subsequently developed gastric cancer, compared with nine (1.0%) of 918 participants who were assigned to placebo (RR 0.42; 95% CI 0.02 to 7.69) (<a href="./references#CD005583-fig-0009" title="">Analysis 2.1</a>). There was statistically significant heterogeneity between individual trial results (heterogeneity test, I<sup>2</sup> = 70%, P = 0.07). Three studies were included in the subgroup of "mixed" patients with and without precancerous lesions. Of them, <a href="./references#CD005583-bbs2-0001" title="ChoiIJ , KimCG , LeeJY , KimYI , KookMC , ParkB , JooJ . Family History of Gastric Cancer and Helicobacter pylori Treatment. New England Journal of Medicine2020;382(5):427-436. ">Choi 2020</a> reported that they excluded patients with gastric dysplasia, but stated in the protocol that patients both with or without precancerous lesions (atrophy and intestinal metaplasia) would be included and compared. However, no such data were provided in the final report, so we considered this study to include "mixed" patients, both with and without precancerous lesions. In this subgroup analysis the pooled RR was 0.42 (95% CI 0.22 to 0.78; test for heterogeneity, I<sup>2</sup> = 0%, P = 0.85) (<a href="./references#CD005583-fig-0009" title="">Analysis 2.1</a>). There was no significant difference between the subgroups (I<sup>2</sup> = 0%, P = 0.85). It should be noted that there would be reduced power to detect significant differences in these subgroup analyses. </p> </section> <section id="CD005583-sec-0064"> <h4 class="title">Effect of H. pylori eradication therapy, compared with placebo or no therapy, on development of subsequent gastric cancer according to whether participants were co‐administered vitamins or antioxidants </h4> <p>We found no evidence of any benefit of <i>H. pylori</i> eradication therapy in preventing subsequent occurrence of gastric cancer when we considered only those participants who received eradication therapy alone in the analysis. Overall, 40 (1.3%) of 3082 participants assigned to eradication therapy alone subsequently developed gastric cancer, compared with 58 (2.0%) of 2958 participants allocated to placebo or no treatment alone (RR 0.69; 95% CI 0.41 to 1.14). There was no statistically significant heterogeneity between individual trial results (heterogeneity test, I<sup>2</sup> = 22%, P = 0.26) (<a href="./references#CD005583-fig-0010" title="">Analysis 3.1</a>). However, when we considered those participants receiving eradication therapy in combination with antioxidants or vitamins in the analysis, 21 (1.8%) of 1178 participants randomised to receive eradication therapy and antioxidants or vitamins subsequently developed gastric cancer, compared with 41 (3.5%) of 1159 participants who were assigned to placebo or no treatment plus antioxidants or vitamins (RR 0.52; 95% CI 0.31 to 0.87). There was no statistically significant heterogeneity between individual trial results (heterogeneity test, I<sup>2</sup> = 0%, P = 0.51) (<a href="./references#CD005583-fig-0010" title="">Analysis 3.1</a>). There was no significant difference between the subgroups (I<sup>2</sup> = 0%, P = 0.46). Again, it should be noted that there would be reduced power to detect significant differences in these subgroup analyses, . </p> </section> <section id="CD005583-sec-0065"> <h4 class="title">Effect of H. pylori eradication therapy, compared with placebo or no therapy, on development of subsequent oesophageal cancer </h4> <p>Only two trials reported these data (<a href="./references#CD005583-bbs2-0005" title="WongBC , LamSK , WongWM , ChenJS , ZhengTT , FengRE , et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA2004;291(2):187-94. WongBCY , LamS , WongWM , et al. Eradication of Helicobacter pylori infection significantly slows down the progression of precancerous lesions in high risk populations: a 5 year prospective randomized study. In: Gastroenterology. Vol. 122. 2002:A588. Abstract W1216. ">Wong 2004</a>;<a href="./references#CD005583-bbs2-0007" title="GailMH , YouWC , ChangYS , ZhangL , BlotWJ , BrownLM , et al. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. Controlled Clinical Trials1998;19(4):352-69. LiWQ , MaJL , ZhangL , BrownLM , LiJY , ShenL , et al. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. Journal of the National Cancer Institute2014;106(7). [DOI: DOI:10.1093/jnci/dju116] [PMID: 24925350]LiWQ , ZhangJY , MaJL , LiZX , ZhangL , ZhangY , et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. BMJ2019;366:l5016. [PMID: 31511230]LiWQ , ZhangL , MaJL , BrownL , LiJY , ShenL , et al. Fifteen-year effects of Helicobacter pylori treatment on gastric cancer incidence and mortality among participants with different baseline gastric lesions and ages. American Journal of Epidemiology2013;177 (Suppl 11):S61. MaJL , ZhangL , BrownLM , LiJY , ShenL , PanKF , et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. Journal of the National Cancer Institute2012;104(6):488-92. WangY , ZhangL , MoslehiR , MaJ , PanK , ZhouT , et al. Long-term garlic or micronutrient supplementation, but not anti-Helicobacter pylori therapy, increases serum folate or glutathione without affecting serum vitamin B-12 or homocysteine in a rural Chinese population. Journal of Nutrition2009;139(1):106-12. YouWC , BrownLM , ZhangL , LiJY , JinML , ChangYS , et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. Journal of the National Cancer Institute2006;98(14):974-83. YouWC , ChangYS , HeinrichJ , MaJL , LiuWD , ZhangL , et al. An intervention trial to inhibit the progression of precancerous gastric lesions: compliance, serum micronutrients and S-allyl cysteine levels, and toxicity. European Journal of Cancer Prevention2001;10(3):257-63. ZhangL , GailMH , WangYQ , BrownLM , PanKF , MaJL , et al. A randomized factorial study of the effects of long-term garlic and micronutrient supplementation and of 2-wk antibiotic treatment for Helicobacter pylori infection on serum cholesterol and lipoproteins. American Journal of Clinical Nutrition2006;86(4):912-9. ZhangL , MaJL , LiuWD , JiangJ , PanKF , PanYS , et al. A randomized multi-intervention trial to inhibit gastric cancer in Shandong (progress report). Chinese Journal of Clinical Oncology1998;25(5):338-40. ">You 2006 ‐ Li 2019</a>). 16 (0.8%) of 1947 participants assigned to eradication therapy developed oesophageal cancer, compared with 13 (0.7%) of 1941 participants allocated to placebo (RR 1.22; 95% CI 0.59 to 2.54, P = 0.68). All three cases were squamous cell cancers in <a href="./references#CD005583-bbs2-0005" title="WongBC , LamSK , WongWM , ChenJS , ZhengTT , FengRE , et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA2004;291(2):187-94. WongBCY , LamS , WongWM , et al. Eradication of Helicobacter pylori infection significantly slows down the progression of precancerous lesions in high risk populations: a 5 year prospective randomized study. In: Gastroenterology. Vol. 122. 2002:A588. Abstract W1216. ">Wong 2004</a> but histological subtype was not clear in <a href="./references#CD005583-bbs2-0007" title="GailMH , YouWC , ChangYS , ZhangL , BlotWJ , BrownLM , et al. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. Controlled Clinical Trials1998;19(4):352-69. LiWQ , MaJL , ZhangL , BrownLM , LiJY , ShenL , et al. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. Journal of the National Cancer Institute2014;106(7). [DOI: DOI:10.1093/jnci/dju116] [PMID: 24925350]LiWQ , ZhangJY , MaJL , LiZX , ZhangL , ZhangY , et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. BMJ2019;366:l5016. [PMID: 31511230]LiWQ , ZhangL , MaJL , BrownL , LiJY , ShenL , et al. Fifteen-year effects of Helicobacter pylori treatment on gastric cancer incidence and mortality among participants with different baseline gastric lesions and ages. American Journal of Epidemiology2013;177 (Suppl 11):S61. MaJL , ZhangL , BrownLM , LiJY , ShenL , PanKF , et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. Journal of the National Cancer Institute2012;104(6):488-92. WangY , ZhangL , MoslehiR , MaJ , PanK , ZhouT , et al. Long-term garlic or micronutrient supplementation, but not anti-Helicobacter pylori therapy, increases serum folate or glutathione without affecting serum vitamin B-12 or homocysteine in a rural Chinese population. Journal of Nutrition2009;139(1):106-12. YouWC , BrownLM , ZhangL , LiJY , JinML , ChangYS , et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. Journal of the National Cancer Institute2006;98(14):974-83. YouWC , ChangYS , HeinrichJ , MaJL , LiuWD , ZhangL , et al. An intervention trial to inhibit the progression of precancerous gastric lesions: compliance, serum micronutrients and S-allyl cysteine levels, and toxicity. European Journal of Cancer Prevention2001;10(3):257-63. ZhangL , GailMH , WangYQ , BrownLM , PanKF , MaJL , et al. A randomized factorial study of the effects of long-term garlic and micronutrient supplementation and of 2-wk antibiotic treatment for Helicobacter pylori infection on serum cholesterol and lipoproteins. American Journal of Clinical Nutrition2006;86(4):912-9. ZhangL , MaJL , LiuWD , JiangJ , PanKF , PanYS , et al. A randomized multi-intervention trial to inhibit gastric cancer in Shandong (progress report). Chinese Journal of Clinical Oncology1998;25(5):338-40. ">You 2006 ‐ Li 2019</a> (<a href="./references#CD005583-fig-0008" title="">Analysis 1.5</a>). The certainty of the evidence is moderate (<a href="./full#CD005583-tbl-0001">summary of findings Table 1</a>) with the evidence being downgraded because of imprecision. </p> </section> <section id="CD005583-sec-0066"> <h4 class="title">Effect of H. pylori eradication therapy, compared with placebo or no therapy, on death from gastric cancer </h4> <p>Four studies, containing 6301 participants, provided data on mortality from gastric cancer (<a href="./references#CD005583-bbs2-0001" title="ChoiIJ , KimCG , LeeJY , KimYI , KookMC , ParkB , JooJ . Family History of Gastric Cancer and Helicobacter pylori Treatment. New England Journal of Medicine2020;382(5):427-436. ">Choi 2020</a>; <a href="./references#CD005583-bbs2-0003" title="LeungWK , LinSR , ChingJY , ToKF , NgEK , ChanFK , et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut2004;53(9):1244-9. SungJJ , LinSR , ChingJY , ZhouLY , ToKF , WangRT , et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology2000;119(1):7-14. SungJJ , LinSR , LeungW , NgEK , ChingJY , ToKF , et al. Does eradication of H. pylori prevent deterioration of gastric atrophy and intestinal metaplasia? A 5-year follow-up. In: Gastroenterology. Vol. 122(Suppl 4). 2002:A170. Abstract S1142. ZhouL , LinS , DingS , HuangX , JinZ , CuiR , et al. Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study. Chinese medical journal2014;127(8):1454-8. [PMID: 24762588]ZhouL , SungJJ , LinS , JinZ , DingS , HuangX , et al. A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chinese Medical Journal2003;116(1):11-4. [PMID: 12667379]ZhouL . Ten-year follow-up study on the incidence of gastric cancer and the pathological changes of gastric mucosa after H. pylori eradication in China. In: Gastroenterology. Vol. 134 (4, suppl 1). 2008:A233. Abstract S1606. ZhouLY , LinSR , DingSG , HuangSB , GuoCJ , ZhangL , et al. Eight-year follow-up study on prevalence of gastric cancer and the histological changes of gastric mucosa after H.pylori eradication [除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究]. Chinese Journal of Digestion2005;25(6):324-7. ZhouLY , LinSR , DingSG , HuangSB , GuoCJ , ZhangL , et al. Eight-year follow-up study on the morbidity of gastric cancer and the pathological changes of gastric mucosa after H.pylori eradication [除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究]. www.paper.edu.cn/scholar/downpaper/zhouliya-3 (accessed 10 June 2015). ZhouLY , LinSR , DingSG , HuangXB , ZhangL , MengLM , et al. The changing trends of the incidence of gastric cancer after Helicobacter pylori eradication in Shandong area. Chinese Journal of Digestive Diseases2005;6(3):114-5. ZhouLY , LinSR , ShenZY , ZhongSZ , DingSG , HuangXB , et al. Five-year follow-up study after Helicobacter pylori eradication: Reinfection and peptic ulcer status. Chinese Journal of Digestive Diseases2003;4(1):45-8. ZhouLY , SungJJ , LinSR , JinZ , DingSG , HuangXB , et al. Changes of gastric mucosa histopathology after Helicobacterpylori eradication [根除幽门螺杆菌对胃黏膜炎症变化的人群随访研究]. Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]2003;42(3):162-4. ">Leung 2004‐Zhou 2014</a>; <a href="./references#CD005583-bbs2-0005" title="WongBC , LamSK , WongWM , ChenJS , ZhengTT , FengRE , et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA2004;291(2):187-94. WongBCY , LamS , WongWM , et al. Eradication of Helicobacter pylori infection significantly slows down the progression of precancerous lesions in high risk populations: a 5 year prospective randomized study. In: Gastroenterology. Vol. 122. 2002:A588. Abstract W1216. ">Wong 2004</a>; <a href="./references#CD005583-bbs2-0007" title="GailMH , YouWC , ChangYS , ZhangL , BlotWJ , BrownLM , et al. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. Controlled Clinical Trials1998;19(4):352-69. LiWQ , MaJL , ZhangL , BrownLM , LiJY , ShenL , et al. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. Journal of the National Cancer Institute2014;106(7). [DOI: DOI:10.1093/jnci/dju116] [PMID: 24925350]LiWQ , ZhangJY , MaJL , LiZX , ZhangL , ZhangY , et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. BMJ2019;366:l5016. [PMID: 31511230]LiWQ , ZhangL , MaJL , BrownL , LiJY , ShenL , et al. Fifteen-year effects of Helicobacter pylori treatment on gastric cancer incidence and mortality among participants with different baseline gastric lesions and ages. American Journal of Epidemiology2013;177 (Suppl 11):S61. MaJL , ZhangL , BrownLM , LiJY , ShenL , PanKF , et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. Journal of the National Cancer Institute2012;104(6):488-92. WangY , ZhangL , MoslehiR , MaJ , PanK , ZhouT , et al. Long-term garlic or micronutrient supplementation, but not anti-Helicobacter pylori therapy, increases serum folate or glutathione without affecting serum vitamin B-12 or homocysteine in a rural Chinese population. Journal of Nutrition2009;139(1):106-12. YouWC , BrownLM , ZhangL , LiJY , JinML , ChangYS , et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. Journal of the National Cancer Institute2006;98(14):974-83. YouWC , ChangYS , HeinrichJ , MaJL , LiuWD , ZhangL , et al. An intervention trial to inhibit the progression of precancerous gastric lesions: compliance, serum micronutrients and S-allyl cysteine levels, and toxicity. European Journal of Cancer Prevention2001;10(3):257-63. ZhangL , GailMH , WangYQ , BrownLM , PanKF , MaJL , et al. A randomized factorial study of the effects of long-term garlic and micronutrient supplementation and of 2-wk antibiotic treatment for Helicobacter pylori infection on serum cholesterol and lipoproteins. American Journal of Clinical Nutrition2006;86(4):912-9. ZhangL , MaJL , LiuWD , JiangJ , PanKF , PanYS , et al. A randomized multi-intervention trial to inhibit gastric cancer in Shandong (progress report). Chinese Journal of Clinical Oncology1998;25(5):338-40. ">You 2006 ‐ Li 2019</a>). Follow‐up ranged from 5 years to 22 years. Overall, there were 36 deaths (1.1%) from gastric cancer among 3154 participants randomised to eradication therapy, compared with 59 (1.2%) deaths in 3147 participants receiving placebo. There was no statistically significant heterogeneity between individual trial results (heterogeneity test, I<sup>2</sup> = 0%, P = 0.95). There was evidence of benefit of <i>H. pylori</i> eradication therapy in preventing death from gastric cancer in healthy asymptomatic infected individuals (RR 0.61; 95% CI 0.40 to 0.92) (<a href="./references#CD005583-fig-0006" title="">Analysis 1.3</a>). The NNTB was 137 (95% CI 89 to 667).Certainty of the evidence is moderate (<a href="./full#CD005583-tbl-0001">summary of findings Table 1</a>) and this was downgraded . </p> </section> <section id="CD005583-sec-0067"> <h4 class="title">Effect of H. pylori eradication therapy, compared with placebo or no therapy, on all‐cause mortality </h4> <p>Five studies, containing 7079 participants, provided data on all‐cause mortality (<a href="./references#CD005583-bbs2-0001" title="ChoiIJ , KimCG , LeeJY , KimYI , KookMC , ParkB , JooJ . Family History of Gastric Cancer and Helicobacter pylori Treatment. New England Journal of Medicine2020;382(5):427-436. ">Choi 2020</a>; <a href="./references#CD005583-bbs2-0002" title="CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacterpylori therapy. Journal of the National Cancer Institute2000;92(23):1881-8. CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Re: Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. Journal of the National Cancer Institute2001;93(7):559-60. MeraR , FonthamET , BravoLE , BravoJC , PiazueloMB , CamargoMC , et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut2005;54(11):1536-40. RuizB , GarayJ , CorreaP , FonthamET , BravoJC , BravoLE , et al. Morphometric evaluation of gastric antral atrophy: improvement after cure of Helicobacter pylori infection. American Journal of Gastroenterology2001;96(12):3281-7. ">Correa 2000‐Correa 2001</a>; <a href="./references#CD005583-bbs2-0005" title="WongBC , LamSK , WongWM , ChenJS , ZhengTT , FengRE , et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA2004;291(2):187-94. WongBCY , LamS , WongWM , et al. Eradication of Helicobacter pylori infection significantly slows down the progression of precancerous lesions in high risk populations: a 5 year prospective randomized study. In: Gastroenterology. Vol. 122. 2002:A588. Abstract W1216. ">Wong 2004</a>; <a href="./references#CD005583-bbs2-0006" title="FengGS , MaJL , WongBC , ZhangL , LiuWD , PanKF , et al. Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention. World Journal of Gastroenterology2008;14(28):4535-9. WongBC , ZhangL , MaJL , PanKF , LiJY , ShenL , et al. Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut2012;61(6):812-8. WongBC . Eradication of Helicobacter pylori for prevention of gastric cancer. In: Journal of Gastroenterology and Hepatology. Vol. 27 (Suppl. 5). 2012:5-6. Abstract UA01-05. ">Wong 2012a</a>; <a href="./references#CD005583-bbs2-0007" title="GailMH , YouWC , ChangYS , ZhangL , BlotWJ , BrownLM , et al. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. Controlled Clinical Trials1998;19(4):352-69. LiWQ , MaJL , ZhangL , BrownLM , LiJY , ShenL , et al. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. Journal of the National Cancer Institute2014;106(7). [DOI: DOI:10.1093/jnci/dju116] [PMID: 24925350]LiWQ , ZhangJY , MaJL , LiZX , ZhangL , ZhangY , et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. BMJ2019;366:l5016. [PMID: 31511230]LiWQ , ZhangL , MaJL , BrownL , LiJY , ShenL , et al. Fifteen-year effects of Helicobacter pylori treatment on gastric cancer incidence and mortality among participants with different baseline gastric lesions and ages. American Journal of Epidemiology2013;177 (Suppl 11):S61. MaJL , ZhangL , BrownLM , LiJY , ShenL , PanKF , et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. Journal of the National Cancer Institute2012;104(6):488-92. WangY , ZhangL , MoslehiR , MaJ , PanK , ZhouT , et al. Long-term garlic or micronutrient supplementation, but not anti-Helicobacter pylori therapy, increases serum folate or glutathione without affecting serum vitamin B-12 or homocysteine in a rural Chinese population. Journal of Nutrition2009;139(1):106-12. YouWC , BrownLM , ZhangL , LiJY , JinML , ChangYS , et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. Journal of the National Cancer Institute2006;98(14):974-83. YouWC , ChangYS , HeinrichJ , MaJL , LiuWD , ZhangL , et al. An intervention trial to inhibit the progression of precancerous gastric lesions: compliance, serum micronutrients and S-allyl cysteine levels, and toxicity. European Journal of Cancer Prevention2001;10(3):257-63. ZhangL , GailMH , WangYQ , BrownLM , PanKF , MaJL , et al. A randomized factorial study of the effects of long-term garlic and micronutrient supplementation and of 2-wk antibiotic treatment for Helicobacter pylori infection on serum cholesterol and lipoproteins. American Journal of Clinical Nutrition2006;86(4):912-9. ZhangL , MaJL , LiuWD , JiangJ , PanKF , PanYS , et al. A randomized multi-intervention trial to inhibit gastric cancer in Shandong (progress report). Chinese Journal of Clinical Oncology1998;25(5):338-40. ">You 2006 ‐ Li 2019</a>). Follow‐up ranged from 6 to 22 years. Overall, 315 (8.9%) of 3551 participants receiving eradication therapy were dead at last point of follow‐up, compared with 323 (9.2%) of 3528 participants receiving placebo or no treatment. There was no statistically significant heterogeneity between individual trial results (heterogeneity test, I<sup>2</sup> = 0%, P = 0.50). There was no evidence of any benefit of <i>H. pylori</i> eradication therapy in preventing death from any cause in healthy asymptomatic infected individuals (RR 0.97; 95% CI 0.85 to 1.12) (<a href="./references#CD005583-fig-0007" title="">Analysis 1.4</a>). Certainty of the evidence is moderate (<a href="./full#CD005583-tbl-0001">summary of findings Table 1</a>) and downgraded because three of the studies were either unclear or high risk of bias. </p> </section> <section id="CD005583-sec-0068"> <h4 class="title">Adverse events with H. pylori eradication therapy, compared with placebo or no therapy</h4> <p>Only two of the studies we identified reported individual adverse events data with eradication therapy compared with placebo or no treatment (<a href="./references#CD005583-bbs2-0001" title="ChoiIJ , KimCG , LeeJY , KimYI , KookMC , ParkB , JooJ . Family History of Gastric Cancer and Helicobacter pylori Treatment. New England Journal of Medicine2020;382(5):427-436. ">Choi 2020</a>; <a href="./references#CD005583-bbs2-0059" title="GailMH , YouWC , ChangYS , ZhangL , BlotWJ , BrownLM , et al. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. Controlled Clinical Trials1998;19(4):352-69.">Gail 1998</a>). <a href="./references#CD005583-bbs2-0059" title="GailMH , YouWC , ChangYS , ZhangL , BlotWJ , BrownLM , et al. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. Controlled Clinical Trials1998;19(4):352-69.">Gail 1998</a> reported that there was no difference in the incidence of adverse events with eradication therapy, with the exception of skin rash, which occurred in 3.1% of those receiving eradication therapy compared with 0.1% of those allocated placebo. <a href="./references#CD005583-bbs2-0001" title="ChoiIJ , KimCG , LeeJY , KimYI , KookMC , ParkB , JooJ . Family History of Gastric Cancer and Helicobacter pylori Treatment. New England Journal of Medicine2020;382(5):427-436. ">Choi 2020</a> reported that any adverse event was higher in the eradication group (53.0% vs 19.1% P &lt;0.001), and that any adverse event ≥ grade 3 occurred in 0.8% vs 0.1% (P = 0.04). Another study reported that side effects were monitored closely, and none of any clinical importance were detected, although no dichotomous data were reported to support this statement (<a href="./references#CD005583-bbs2-0002" title="CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacterpylori therapy. Journal of the National Cancer Institute2000;92(23):1881-8. CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Re: Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. Journal of the National Cancer Institute2001;93(7):559-60. MeraR , FonthamET , BravoLE , BravoJC , PiazueloMB , CamargoMC , et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut2005;54(11):1536-40. RuizB , GarayJ , CorreaP , FonthamET , BravoJC , BravoLE , et al. Morphometric evaluation of gastric antral atrophy: improvement after cure of Helicobacter pylori infection. American Journal of Gastroenterology2001;96(12):3281-7. ">Correa 2000‐Correa 2001</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD005583-sec-0069" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD005583-sec-0069"></div> <section id="CD005583-sec-0070"> <h3 class="title" id="CD005583-sec-0070">Summary of main results</h3> <p>This systematic review and meta‐analysis suggests that searching for and eradicating <i>H. pylori</i> infection in otherwise healthy and asymptomatic infected individuals reduces the subsequent incidence of gastric cancer. The risk of a subsequent gastric cancer with eradication therapy was reduced by 46%, and the NNTB to prevent one case of gastric cancer was 72. The effect size we observed remained robust through the majority of sensitivity analyses we performed. We were unable to confirm or refute whether any benefit of <i>H. pylori</i> eradication therapy depended on the presence or absence of preneoplastic lesions at baseline. However, it is important to highlight that there would be reduced power to detect significant differences in most of the subgroup analyses we conducted, and the original trials were not powered for secondary endpoints, such as mortality from gastric cancer or effect on oesophageal cancer. Finally, there were few cases of subsequent oesophageal cancer, and adverse events data were poorly reported in the studies we identified. The data now suggest an effect of <i>H. pylori</i> eradication in reducing gastric cancer‐related mortality, with a NNTB of 137, but trials still show no impact of <i>H. pylori</i> eradication on all cause mortality. This would be the most robust end‐point to evaluate but as gastric cancer accounts for only a small proportion of the overall death rate the sample size for trials would need to be extremely large. </p> </section> <section id="CD005583-sec-0071"> <h3 class="title" id="CD005583-sec-0071">Overall completeness and applicability of evidence</h3> <p>As all but one of the eligible trials we identified were conducted in Asian populations, and the other trial in a South American population, it is not possible to assess the effect of screening and treatment of <i>H. pylori</i> in healthy and asymptomatic individuals in Western populations. In addition, none of the RCTs we identified reported individual adverse events data, which means that we were unable to assess the balance of benefits and harms if population screening and treatment for <i>H. pylori</i> infection were to be adopted as a public health measure. Most trials recruited participants with a mean age of approximately 50 years of age with and age range of 20‐65 years. It would be helpful to know the optimum age when <i>H. pylori</i> should be eradicated as preneoplastic changes will be minimized if treatment is offered in younger age groups but in these groups it will take longer before any benefit of the intervention is realized so this may be less cost‐effective. Elucidating this issue would be helpful for policy makers. Currently most guidelines do not suggests population H. pylori eradication and treatment <a href="./references#CD005583-bbs2-0044" title="CheyWD , LeontiadisGI , HowdenDW , Moss S. ACG guideline: treatment of Helicobacter pylori infection. American Journal of Gastroenterology2017;112(2):212-39.">Chey 2017</a> although this changing and now some are recommending this approach in high gastric cancer risk countries (<a href="./references#CD005583-bbs2-0064" title="IARC Helicobacter pylori Working Group. Helicobacter pylori eradication as a strategy for preventing gastric cancer. IARC Working Group Reports 8.">IARC 2014</a>; <a href="./references#CD005583-bbs2-0053" title="FockKM , KatelarisP , SuganoK , AngTL , Hunt RH et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori eradication. Journal of Gastroenterology and Hepatology2009;24:1587-600.">Fock 2009</a>; <a href="./references#CD005583-bbs2-0073" title="MalfertheinerP , MegraudF , OMorainCA , GisbertJP , Kuipers EJ et al. Management of Helicobacter pylori infection- the Maastricht V Florence Consensus report. Gut2017;66:6-30.">Malfertheiner 2017</a>). </p> </section> <section id="CD005583-sec-0072"> <h3 class="title" id="CD005583-sec-0072">Quality of the evidence</h3> <p>Only four of the RCTs we identified were at low risk of bias (<a href="./references#CD005583-bbs2-0001" title="ChoiIJ , KimCG , LeeJY , KimYI , KookMC , ParkB , JooJ . Family History of Gastric Cancer and Helicobacter pylori Treatment. New England Journal of Medicine2020;382(5):427-436. ">Choi 2020</a>; <a href="./references#CD005583-bbs2-0005" title="WongBC , LamSK , WongWM , ChenJS , ZhengTT , FengRE , et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA2004;291(2):187-94. WongBCY , LamS , WongWM , et al. Eradication of Helicobacter pylori infection significantly slows down the progression of precancerous lesions in high risk populations: a 5 year prospective randomized study. In: Gastroenterology. Vol. 122. 2002:A588. Abstract W1216. ">Wong 2004</a>; <a href="./references#CD005583-bbs2-0006" title="FengGS , MaJL , WongBC , ZhangL , LiuWD , PanKF , et al. Celecoxib-related gastroduodenal ulcer and cardiovascular events in a randomized trial for gastric cancer prevention. World Journal of Gastroenterology2008;14(28):4535-9. WongBC , ZhangL , MaJL , PanKF , LiJY , ShenL , et al. Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut2012;61(6):812-8. WongBC . Eradication of Helicobacter pylori for prevention of gastric cancer. In: Journal of Gastroenterology and Hepatology. Vol. 27 (Suppl. 5). 2012:5-6. Abstract UA01-05. ">Wong 2012a</a>; <a href="./references#CD005583-bbs2-0007" title="GailMH , YouWC , ChangYS , ZhangL , BlotWJ , BrownLM , et al. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. Controlled Clinical Trials1998;19(4):352-69. LiWQ , MaJL , ZhangL , BrownLM , LiJY , ShenL , et al. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. Journal of the National Cancer Institute2014;106(7). [DOI: DOI:10.1093/jnci/dju116] [PMID: 24925350]LiWQ , ZhangJY , MaJL , LiZX , ZhangL , ZhangY , et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. BMJ2019;366:l5016. [PMID: 31511230]LiWQ , ZhangL , MaJL , BrownL , LiJY , ShenL , et al. Fifteen-year effects of Helicobacter pylori treatment on gastric cancer incidence and mortality among participants with different baseline gastric lesions and ages. American Journal of Epidemiology2013;177 (Suppl 11):S61. MaJL , ZhangL , BrownLM , LiJY , ShenL , PanKF , et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. Journal of the National Cancer Institute2012;104(6):488-92. WangY , ZhangL , MoslehiR , MaJ , PanK , ZhouT , et al. Long-term garlic or micronutrient supplementation, but not anti-Helicobacter pylori therapy, increases serum folate or glutathione without affecting serum vitamin B-12 or homocysteine in a rural Chinese population. Journal of Nutrition2009;139(1):106-12. YouWC , BrownLM , ZhangL , LiJY , JinML , ChangYS , et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. Journal of the National Cancer Institute2006;98(14):974-83. YouWC , ChangYS , HeinrichJ , MaJL , LiuWD , ZhangL , et al. An intervention trial to inhibit the progression of precancerous gastric lesions: compliance, serum micronutrients and S-allyl cysteine levels, and toxicity. European Journal of Cancer Prevention2001;10(3):257-63. ZhangL , GailMH , WangYQ , BrownLM , PanKF , MaJL , et al. A randomized factorial study of the effects of long-term garlic and micronutrient supplementation and of 2-wk antibiotic treatment for Helicobacter pylori infection on serum cholesterol and lipoproteins. American Journal of Clinical Nutrition2006;86(4):912-9. ZhangL , MaJL , LiuWD , JiangJ , PanKF , PanYS , et al. A randomized multi-intervention trial to inhibit gastric cancer in Shandong (progress report). Chinese Journal of Clinical Oncology1998;25(5):338-40. ">You 2006 ‐ Li 2019</a>), one trial was at unclear risk because it was reported in abstract form (<a href="./references#CD005583-bbs2-0004" title="SaitoD , BokuN , FujiokaT , FukudaY , MatsushimaY , SakakiN , et al. Impact of H. pylori eradication on gastric cancer prevention: endoscopic results of the Japanese Intervention Trial (JITHP-Study). A randomized multi-center trial. In: Gastroenterology. Vol. 128 4 (Supp2). 2005:A4. Abstract 23. SaitoD . Present state of Japanese intervention trial of H. pylori . Nihon Rinsho2003;61(1):50-5. ">Saito 2005</a>), and two trials were at high risk of bias (<a href="./references#CD005583-bbs2-0002" title="CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacterpylori therapy. Journal of the National Cancer Institute2000;92(23):1881-8. CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Re: Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. Journal of the National Cancer Institute2001;93(7):559-60. MeraR , FonthamET , BravoLE , BravoJC , PiazueloMB , CamargoMC , et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut2005;54(11):1536-40. RuizB , GarayJ , CorreaP , FonthamET , BravoJC , BravoLE , et al. Morphometric evaluation of gastric antral atrophy: improvement after cure of Helicobacter pylori infection. American Journal of Gastroenterology2001;96(12):3281-7. ">Correa 2000‐Correa 2001</a>; <a href="./references#CD005583-bbs2-0003" title="LeungWK , LinSR , ChingJY , ToKF , NgEK , ChanFK , et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut2004;53(9):1244-9. SungJJ , LinSR , ChingJY , ZhouLY , ToKF , WangRT , et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology2000;119(1):7-14. SungJJ , LinSR , LeungW , NgEK , ChingJY , ToKF , et al. Does eradication of H. pylori prevent deterioration of gastric atrophy and intestinal metaplasia? A 5-year follow-up. In: Gastroenterology. Vol. 122(Suppl 4). 2002:A170. Abstract S1142. ZhouL , LinS , DingS , HuangX , JinZ , CuiR , et al. Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study. Chinese medical journal2014;127(8):1454-8. [PMID: 24762588]ZhouL , SungJJ , LinS , JinZ , DingS , HuangX , et al. A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chinese Medical Journal2003;116(1):11-4. [PMID: 12667379]ZhouL . Ten-year follow-up study on the incidence of gastric cancer and the pathological changes of gastric mucosa after H. pylori eradication in China. In: Gastroenterology. Vol. 134 (4, suppl 1). 2008:A233. Abstract S1606. ZhouLY , LinSR , DingSG , HuangSB , GuoCJ , ZhangL , et al. Eight-year follow-up study on prevalence of gastric cancer and the histological changes of gastric mucosa after H.pylori eradication [除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究]. Chinese Journal of Digestion2005;25(6):324-7. ZhouLY , LinSR , DingSG , HuangSB , GuoCJ , ZhangL , et al. Eight-year follow-up study on the morbidity of gastric cancer and the pathological changes of gastric mucosa after H.pylori eradication [除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究]. www.paper.edu.cn/scholar/downpaper/zhouliya-3 (accessed 10 June 2015). ZhouLY , LinSR , DingSG , HuangXB , ZhangL , MengLM , et al. The changing trends of the incidence of gastric cancer after Helicobacter pylori eradication in Shandong area. Chinese Journal of Digestive Diseases2005;6(3):114-5. ZhouLY , LinSR , ShenZY , ZhongSZ , DingSG , HuangXB , et al. Five-year follow-up study after Helicobacter pylori eradication: Reinfection and peptic ulcer status. Chinese Journal of Digestive Diseases2003;4(1):45-8. ZhouLY , SungJJ , LinSR , JinZ , DingSG , HuangXB , et al. Changes of gastric mucosa histopathology after Helicobacterpylori eradication [根除幽门螺杆菌对胃黏膜炎症变化的人群随访研究]. Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]2003;42(3):162-4. ">Leung 2004‐Zhou 2014</a>). In <a href="./references#CD005583-bbs2-0002" title="CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacterpylori therapy. Journal of the National Cancer Institute2000;92(23):1881-8. CorreaP , FonthamET , BravoJC , BravoLE , RuizB , ZaramaG , et al. Re: Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. Journal of the National Cancer Institute2001;93(7):559-60. MeraR , FonthamET , BravoLE , BravoJC , PiazueloMB , CamargoMC , et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut2005;54(11):1536-40. RuizB , GarayJ , CorreaP , FonthamET , BravoJC , BravoLE , et al. Morphometric evaluation of gastric antral atrophy: improvement after cure of Helicobacter pylori infection. American Journal of Gastroenterology2001;96(12):3281-7. ">Correa 2000‐Correa 2001</a>, this was because no placebo comparator was used for the active eradication therapy regimen, and therefore this part of the trial was unblinded, and in <a href="./references#CD005583-bbs2-0003" title="LeungWK , LinSR , ChingJY , ToKF , NgEK , ChanFK , et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut2004;53(9):1244-9. SungJJ , LinSR , ChingJY , ZhouLY , ToKF , WangRT , et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology2000;119(1):7-14. SungJJ , LinSR , LeungW , NgEK , ChingJY , ToKF , et al. Does eradication of H. pylori prevent deterioration of gastric atrophy and intestinal metaplasia? A 5-year follow-up. In: Gastroenterology. Vol. 122(Suppl 4). 2002:A170. Abstract S1142. ZhouL , LinS , DingS , HuangX , JinZ , CuiR , et al. Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study. Chinese medical journal2014;127(8):1454-8. [PMID: 24762588]ZhouL , SungJJ , LinS , JinZ , DingS , HuangX , et al. A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chinese Medical Journal2003;116(1):11-4. [PMID: 12667379]ZhouL . Ten-year follow-up study on the incidence of gastric cancer and the pathological changes of gastric mucosa after H. pylori eradication in China. In: Gastroenterology. Vol. 134 (4, suppl 1). 2008:A233. Abstract S1606. ZhouLY , LinSR , DingSG , HuangSB , GuoCJ , ZhangL , et al. Eight-year follow-up study on prevalence of gastric cancer and the histological changes of gastric mucosa after H.pylori eradication [除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究]. Chinese Journal of Digestion2005;25(6):324-7. ZhouLY , LinSR , DingSG , HuangSB , GuoCJ , ZhangL , et al. Eight-year follow-up study on the morbidity of gastric cancer and the pathological changes of gastric mucosa after H.pylori eradication [除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究]. www.paper.edu.cn/scholar/downpaper/zhouliya-3 (accessed 10 June 2015). ZhouLY , LinSR , DingSG , HuangXB , ZhangL , MengLM , et al. The changing trends of the incidence of gastric cancer after Helicobacter pylori eradication in Shandong area. Chinese Journal of Digestive Diseases2005;6(3):114-5. ZhouLY , LinSR , ShenZY , ZhongSZ , DingSG , HuangXB , et al. Five-year follow-up study after Helicobacter pylori eradication: Reinfection and peptic ulcer status. Chinese Journal of Digestive Diseases2003;4(1):45-8. ZhouLY , SungJJ , LinSR , JinZ , DingSG , HuangXB , et al. Changes of gastric mucosa histopathology after Helicobacterpylori eradication [根除幽门螺杆菌对胃黏膜炎症变化的人群随访研究]. Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]2003;42(3):162-4. ">Leung 2004‐Zhou 2014</a> it was due to inconsistencies in data reporting at the two follow‐up points, with 10 gastric cancers reported at 5 years, compared with nine at 10 years (<a href="./references#CD005583-bbs2-0105" title="ZhouL . Ten-year follow-up study on the incidence of gastric cancer and the pathological changes of gastric mucosa after H. pylori eradication in China. In: Gastroenterology. Vol. 134 (4, suppl 1). 2008:A233. Abstract S1606.">Zhou 2008</a>). Despite contacting the original authors, we were unable to resolve this discrepancy satisfactorily. Certainty of the evidence is downgraded from high to moderate (<a href="./full#CD005583-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD005583-sec-0073"> <h3 class="title" id="CD005583-sec-0073">Potential biases in the review process</h3> <p>There were limitations of this review due to the quality and characteristics of the published literature identified, which we have highlighted above. Because of the factorial design of some of the trials, it was also difficult to ascertain whether the significant reduction in the risk of subsequent gastric cancer was due to <i>H. pylori</i> eradication therapy alone, or to the antioxidants or vitamins that were co‐administered in some of the trials. Certainly, the beneficial effect of eradication therapy appeared to be more pronounced in the two studies that co‐administered antioxidants and vitamins to participants, suggesting that there may have been some additive benefit derived from these supplements, although power to demonstrate effect modification due to these different treatments is again limited. However, it should be noted that one of these trials contained the majority of gastric cancers, and had the longest duration of follow‐up of almost 22 years. </p> </section> <section id="CD005583-sec-0074"> <h3 class="title" id="CD005583-sec-0074">Agreements and disagreements with other studies or reviews</h3> <p>A previous systematic review and meta‐analysis that examined this issue 11 years ago reported that there was a benefit of eradicating <i>H. pylori</i> to prevent future development of gastric cancer (<a href="./references#CD005583-bbs2-0058" title="FuccioL , ZagariRM , EusebiLH , LaterzaL , CennamoV , CeroniL , et al. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer?Annals of Internal Medicine2009;151(2):121-8.">Fuccio 2009</a>). The magnitude of this effect was less than that we observed, with a RR of subsequent gastric cancer of 0.65 (95% CI 0.43 to 0.98),due to longer follow‐up in one of the trials (<a href="./references#CD005583-bbs2-0007" title="GailMH , YouWC , ChangYS , ZhangL , BlotWJ , BrownLM , et al. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. Controlled Clinical Trials1998;19(4):352-69. LiWQ , MaJL , ZhangL , BrownLM , LiJY , ShenL , et al. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. Journal of the National Cancer Institute2014;106(7). [DOI: DOI:10.1093/jnci/dju116] [PMID: 24925350]LiWQ , ZhangJY , MaJL , LiZX , ZhangL , ZhangY , et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. BMJ2019;366:l5016. [PMID: 31511230]LiWQ , ZhangL , MaJL , BrownL , LiJY , ShenL , et al. Fifteen-year effects of Helicobacter pylori treatment on gastric cancer incidence and mortality among participants with different baseline gastric lesions and ages. American Journal of Epidemiology2013;177 (Suppl 11):S61. MaJL , ZhangL , BrownLM , LiJY , ShenL , PanKF , et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. Journal of the National Cancer Institute2012;104(6):488-92. WangY , ZhangL , MoslehiR , MaJ , PanK , ZhouT , et al. Long-term garlic or micronutrient supplementation, but not anti-Helicobacter pylori therapy, increases serum folate or glutathione without affecting serum vitamin B-12 or homocysteine in a rural Chinese population. Journal of Nutrition2009;139(1):106-12. YouWC , BrownLM , ZhangL , LiJY , JinML , ChangYS , et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. Journal of the National Cancer Institute2006;98(14):974-83. YouWC , ChangYS , HeinrichJ , MaJL , LiuWD , ZhangL , et al. An intervention trial to inhibit the progression of precancerous gastric lesions: compliance, serum micronutrients and S-allyl cysteine levels, and toxicity. European Journal of Cancer Prevention2001;10(3):257-63. ZhangL , GailMH , WangYQ , BrownLM , PanKF , MaJL , et al. A randomized factorial study of the effects of long-term garlic and micronutrient supplementation and of 2-wk antibiotic treatment for Helicobacter pylori infection on serum cholesterol and lipoproteins. American Journal of Clinical Nutrition2006;86(4):912-9. ZhangL , MaJL , LiuWD , JiangJ , PanKF , PanYS , et al. A randomized multi-intervention trial to inhibit gastric cancer in Shandong (progress report). Chinese Journal of Clinical Oncology1998;25(5):338-40. ">You 2006 ‐ Li 2019</a>), plus the inclusion of the newly identified trial (<a href="./references#CD005583-bbs2-0001" title="ChoiIJ , KimCG , LeeJY , KimYI , KookMC , ParkB , JooJ . Family History of Gastric Cancer and Helicobacter pylori Treatment. New England Journal of Medicine2020;382(5):427-436. ">Choi 2020</a>) . </p> <p>Although these data suggest that population <i>H. pylori</i> screening and treatment may reduce the incidence of gastric cancer, the 95% CIs are relatively wide, and the result is somewhat dependent on one study (<a href="./references#CD005583-bbs2-0007" title="GailMH , YouWC , ChangYS , ZhangL , BlotWJ , BrownLM , et al. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. Controlled Clinical Trials1998;19(4):352-69. LiWQ , MaJL , ZhangL , BrownLM , LiJY , ShenL , et al. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. Journal of the National Cancer Institute2014;106(7). [DOI: DOI:10.1093/jnci/dju116] [PMID: 24925350]LiWQ , ZhangJY , MaJL , LiZX , ZhangL , ZhangY , et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. BMJ2019;366:l5016. [PMID: 31511230]LiWQ , ZhangL , MaJL , BrownL , LiJY , ShenL , et al. Fifteen-year effects of Helicobacter pylori treatment on gastric cancer incidence and mortality among participants with different baseline gastric lesions and ages. American Journal of Epidemiology2013;177 (Suppl 11):S61. MaJL , ZhangL , BrownLM , LiJY , ShenL , PanKF , et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. Journal of the National Cancer Institute2012;104(6):488-92. WangY , ZhangL , MoslehiR , MaJ , PanK , ZhouT , et al. Long-term garlic or micronutrient supplementation, but not anti-Helicobacter pylori therapy, increases serum folate or glutathione without affecting serum vitamin B-12 or homocysteine in a rural Chinese population. Journal of Nutrition2009;139(1):106-12. YouWC , BrownLM , ZhangL , LiJY , JinML , ChangYS , et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. Journal of the National Cancer Institute2006;98(14):974-83. YouWC , ChangYS , HeinrichJ , MaJL , LiuWD , ZhangL , et al. An intervention trial to inhibit the progression of precancerous gastric lesions: compliance, serum micronutrients and S-allyl cysteine levels, and toxicity. European Journal of Cancer Prevention2001;10(3):257-63. ZhangL , GailMH , WangYQ , BrownLM , PanKF , MaJL , et al. A randomized factorial study of the effects of long-term garlic and micronutrient supplementation and of 2-wk antibiotic treatment for Helicobacter pylori infection on serum cholesterol and lipoproteins. American Journal of Clinical Nutrition2006;86(4):912-9. ZhangL , MaJL , LiuWD , JiangJ , PanKF , PanYS , et al. A randomized multi-intervention trial to inhibit gastric cancer in Shandong (progress report). Chinese Journal of Clinical Oncology1998;25(5):338-40. ">You 2006 ‐ Li 2019</a>). However, there was still a significant effect of eradication therapy, compared with placebo or no treatment, in preventing subsequent occurrence of gastric cancer when this trial was excluded from the analysis (RR = 0.56; 95% CI 0.35 to 0.92), with no heterogeneity between studies (I2 = 0%, P = 0.49), and a NNTB of 144. In addition, there are data from other sources that support our findings. Three RCTs have suggested that <i>H. pylori</i> eradication can reduce the future incidence of a metachronous cancer among people who have had an endoscopic mucosal resection of gastric cancer (<a href="./references#CD005583-bbs2-0014" title="FukaseK , KatoM , KikuchiS , InoueK , UemuraN , OkamotoS , et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. The Lancet2008;372(9636):392-7. ">Fukase 2008</a>; <a href="./references#CD005583-bbs2-0009" title="ChoiJM , KimSG , ChoiJ , ParkJY , OhS , YangHJ , LimJH , ImJP , KimJS , JungHC . Effects of Helicobacter pylori eradication for metachronous gastric cancer prevention: a randomized controlled trial. Gastrointest Endosc2018;88(3):475-485.e2. [DOI: 10.1016/j.gie.2018.05.009] [Clinical trial registration number: NCT01510730]">Choi 2018a</a>; <a href="./references#CD005583-bbs2-0010" title="ChoiIJ , KookMC , KimYI , ChoSJ , LeeJY , KimCG , ParkB , NamBH . Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer. N Engl J Med2018;378(12):1085-1095. [DOI: 10.1056/NEJMoa1708423] [ClinicalTrials.gov number, NCT02407119]">Choi 2018b</a>). On Matsu Island in Taiwan, where population screening and treatment was adopted in 2004, <i>H. pylori</i> prevalence fell from 63% at baseline to less than 14% during the subsequent 4 years, and prevalence of gastric atrophy fell from almost 60% to less than 14% (<a href="./references#CD005583-bbs2-0066" title="LeeYC , ChenTH , ChiuHM , ShunCT , ChiangH , LiuTY , et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut2013;62(5):676-82.">Lee 2013</a>). At the same time, the 5‐year average incidence of gastric cancer declined from 40.3 per 100,000 person‐years to 30.4, yielding a rate ratio of 0.75 (95% CI 0.37 to 1.52), at a time when the incidence of gastric cancer elsewhere in Taiwan remained unchanged. However, the intervention did not affect the incidence of intestinal metaplasia, adding support to the theory that there is a 'point of no return' in the histological changes induced by <i>H. pylori</i> beyond which cancer prevention by eradication of the infection is no longer possible. There was no significant effect on mortality from gastric cancer observed during the period of this study, although follow‐up was limited to four years, which is shorter than all but one of the studies included in our meta‐analysis. Finally, the prevalence of erosive oesophagitis at upper gastrointestinal endoscopy increased from 14% at baseline to 27% by 2008, suggesting possible deleterious effects of population screening and treatment for <i>H. pylori</i> infection, due to a potential for an increased risk of oesophageal adenocarcinoma in the long term. This was something we aimed to assess in our meta‐analysis, but incomplete reporting of oesophageal cancers among our included studies prevented us from achieving this. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD005583-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/urn:x-wiley:14651858:media:CD005583:CD005583-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram: review update" data-id="CD005583-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_n/nCD005583-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_t/tCD005583-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram: review update</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/full#CD005583-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_n/nCD005583-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005583-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/urn:x-wiley:14651858:media:CD005583:CD005583-FIG-02" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies." data-id="CD005583-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_n/nCD005583-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_t/tCD005583-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/full#CD005583-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_n/nCD005583-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005583-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/urn:x-wiley:14651858:media:CD005583:CD005583-FIG-03" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study." data-id="CD005583-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_n/nCD005583-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_t/tCD005583-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/full#CD005583-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_n/nCD005583-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005583-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/urn:x-wiley:14651858:media:CD005583:CD005583-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: H. pylori eradication vs control ‐ main analyses, Outcome 1: Incidence of gastric cancer ‐ modified ITT analysis" data-id="CD005583-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_n/nCD005583-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_t/tCD005583-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: <i>H. pylori</i> eradication vs control ‐ main analyses, Outcome 1: Incidence of gastric cancer ‐ modified ITT analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/references#CD005583-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_n/nCD005583-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005583-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/urn:x-wiley:14651858:media:CD005583:CD005583-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: H. pylori eradication vs control ‐ main analyses, Outcome 2: Incidence of gastric cancer ‐ complete case analysis" data-id="CD005583-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_n/nCD005583-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_t/tCD005583-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: <i>H. pylori</i> eradication vs control ‐ main analyses, Outcome 2: Incidence of gastric cancer ‐ complete case analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/references#CD005583-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_n/nCD005583-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005583-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/urn:x-wiley:14651858:media:CD005583:CD005583-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: H. pylori eradication vs control ‐ main analyses, Outcome 3: Death from gastric cancer ‐ modified ITT analysis" data-id="CD005583-fig-0006" src="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_n/nCD005583-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_t/tCD005583-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: <i>H. pylori</i> eradication vs control ‐ main analyses, Outcome 3: Death from gastric cancer ‐ modified ITT analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/references#CD005583-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_n/nCD005583-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005583-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/urn:x-wiley:14651858:media:CD005583:CD005583-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: H. pylori eradication vs control ‐ main analyses, Outcome 4: Death from all causes ‐ modified ITT analysis" data-id="CD005583-fig-0007" src="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_n/nCD005583-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_t/tCD005583-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: <i>H. pylori</i> eradication vs control ‐ main analyses, Outcome 4: Death from all causes ‐ modified ITT analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/references#CD005583-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_n/nCD005583-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005583-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/urn:x-wiley:14651858:media:CD005583:CD005583-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: H. pylori eradication vs control ‐ main analyses, Outcome 5: Incidence of oesophageal squamous cell carcinoma ‐ modified ITT analysis" data-id="CD005583-fig-0008" src="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_n/nCD005583-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_t/tCD005583-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: <i>H. pylori</i> eradication vs control ‐ main analyses, Outcome 5: Incidence of oesophageal squamous cell carcinoma ‐ modified ITT analysis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/references#CD005583-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_n/nCD005583-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005583-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/urn:x-wiley:14651858:media:CD005583:CD005583-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: H. pylori eradication vs control ‐ subgroup analysis according to presence or absence of pre‐neoplastic lesions at baseline, Outcome 1: Incidence of gastric cancer according to presence or absence of pre‐neoplastic lesions at baseline" data-id="CD005583-fig-0009" src="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_n/nCD005583-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_t/tCD005583-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: <i>H. pylori</i> eradication vs control ‐ subgroup analysis according to presence or absence of pre‐neoplastic lesions at baseline, Outcome 1: Incidence of gastric cancer according to presence or absence of pre‐neoplastic lesions at baseline </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/references#CD005583-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_n/nCD005583-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005583-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/urn:x-wiley:14651858:media:CD005583:CD005583-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: H. pylori eradication vs control ‐ subgroup analysis according to use of vitamins or antioxidants, Outcome 1: Incidence of gastric cancer according to use of vitamins or anti‐oxidants" data-id="CD005583-fig-0010" src="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_n/nCD005583-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_t/tCD005583-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: <i>H. pylori</i> eradication vs control ‐ subgroup analysis according to use of vitamins or antioxidants, Outcome 1: Incidence of gastric cancer according to use of vitamins or anti‐oxidants </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/references#CD005583-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_n/nCD005583-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005583-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/urn:x-wiley:14651858:media:CD005583:CD005583-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: H. pylori eradication vs control ‐ sensitivity analyses, Outcome 1: Incidence of gastric cancer ‐ modified ITT analysis substituting the 10‐year follow‐up data from Zhou 2014 with the 5‐year follow‐up data from Leung 2004" data-id="CD005583-fig-0011" src="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_n/nCD005583-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_t/tCD005583-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: <i>H. pylori</i> eradication vs control ‐ sensitivity analyses, Outcome 1: Incidence of gastric cancer ‐ modified ITT analysis substituting the 10‐year follow‐up data from Zhou 2014 with the 5‐year follow‐up data from Leung 2004 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/references#CD005583-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_n/nCD005583-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005583-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/urn:x-wiley:14651858:media:CD005583:CD005583-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: H. pylori eradication vs control ‐ sensitivity analyses, Outcome 2: Incidence of gastric cancer ‐ complete case analysis substituting the 10‐year follow‐up data from Zhou 2014 with the 5‐year follow‐up data from Leung 2004" data-id="CD005583-fig-0012" src="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_n/nCD005583-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_t/tCD005583-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: <i>H. pylori</i> eradication vs control ‐ sensitivity analyses, Outcome 2: Incidence of gastric cancer ‐ complete case analysis substituting the 10‐year follow‐up data from Zhou 2014 with the 5‐year follow‐up data from Leung 2004 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/references#CD005583-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_n/nCD005583-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005583-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/urn:x-wiley:14651858:media:CD005583:CD005583-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: H. pylori eradication vs control ‐ sensitivity analyses, Outcome 3: Incidence of gastric cancer‐ modified ITT analysis including the two arms of celecoxib from Wong 2012" data-id="CD005583-fig-0013" src="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_n/nCD005583-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_t/tCD005583-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: <i>H. pylori</i> eradication vs control ‐ sensitivity analyses, Outcome 3: Incidence of gastric cancer‐ modified ITT analysis including the two arms of celecoxib from Wong 2012 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/references#CD005583-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_n/nCD005583-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005583-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/urn:x-wiley:14651858:media:CD005583:CD005583-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: H. pylori eradication vs control ‐ sensitivity analyses, Outcome 4: Incidence of gastric cancer ‐ modified ITT analysis including all randomised patients from Correa 2000 and You 2006 who were found subsequently to be ineligible or did not receive treatment" data-id="CD005583-fig-0014" src="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_n/nCD005583-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_t/tCD005583-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: <i>H. pylori</i> eradication vs control ‐ sensitivity analyses, Outcome 4: Incidence of gastric cancer ‐ modified ITT analysis including all randomised patients from Correa 2000 and You 2006 who were found subsequently to be ineligible or did not receive treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/references#CD005583-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_n/nCD005583-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005583-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/urn:x-wiley:14651858:media:CD005583:CD005583-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: H. pylori eradication vs control ‐ sensitivity analyses, Outcome 5: Incidence of gastric cancer ‐ missing data imputation based on various assumptions" data-id="CD005583-fig-0015" src="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_n/nCD005583-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_t/tCD005583-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: <i>H. pylori</i> eradication vs control ‐ sensitivity analyses, Outcome 5: Incidence of gastric cancer ‐ missing data imputation based on various assumptions </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/references#CD005583-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/media/CDSR/CD005583/image_n/nCD005583-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD005583-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">H. pylori eradication therapy compared to control for the prevention of gastric neoplasia in healthy asymptomatic infected individuals</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><i><b>H. pylori</b> </i><b>eradication therapy compared to control for the prevention of gastric neoplasia in healthy asymptomatic infected individuals</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> healthy asymptomatic <i>H. pylori‐</i>infected individuals<br/><b>Settings:</b> general population<sup>1</sup><br/><b>Intervention:</b><i>H. pylori</i> eradication therapy to prevent subsequent gastric cancer <sup>2</sup><br/><b>Comparison:</b> control </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Control</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><i><b>H. pylori</b> </i><b>eradication therapy to prevent subsequent gastric cancer</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of gastric cancer ‐ modified ITT analysis</b><br/>Histological examination<br/>Follow‐up: 4 to 22 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>30 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>16 per 1000</b><br/>(12 to 22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.54</b> <br/>(0.40 to 0.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8323<br/>(7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>3,4,5,6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number need to treat to benefit was 72 (95% CI 55 to 118)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death from gastric cancer ‐ modified ITT analysis</b> </p> <p>Follow up: 7‐22 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>11 per 1000</b><br/>(7 to 17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.61</b> <br/>(0.40 to 0.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6301<br/>(4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>4,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number need to treat to benefit was 137 (95% CI 89 to 667)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death from all causes ‐ modified ITT analysis</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>92 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>89 per 1000</b><br/>(78 to 103) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.97</b> <br/>(0.85 to 1.12) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7079<br/>(5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>4,6,7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of oesophageal squamous cell carcinoma ‐ modified ITT analysis</b> </p> <p>Follow up: 7‐22 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>7 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b><br/>(4 to 17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.22</b> <br/>(0.59 to 2.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3888<br/>(2 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/><b>moderate</b><sup>8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/>(0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events were poorly reported across the studies and could not be summarised.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; ITT: intention‐to‐treat; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> As all but one study was conducted in East Asia, it is not possible to assess the effect of searching for and eradicating <i>H. pylori</i> in Western populations.<br/><sup>2</sup> Modified ITT analysis.<br/><sup>3</sup> The quality of evidence was downgraded from high to moderate due to serious risk of bias: Fourtrials were at low risk of bias, one trial was at unclear risk, and two trials were at high risk of bias. In addition, because of the factorial design of some of the trials, it is difficult to determine whether the reduction in relative risk of subsequent gastric cancer was due to <i>H. pylori</i> eradication therapy alone. The eradication regimens used varied considerably between the individual trials, although this reflects the fact that several of these studies were designed before the widespread adoption of proton pump inhibitor triple therapy, which was first described in 1994, as the gold standard for H. pylori eradication.<br/><sup>4</sup> No significant heterogeneity was seen between studies.<br/><sup>5</sup> The beneficial effect seemed to be more pronounced in the two studies that co‐administered antioxidants and vitamins to participants, but it should be noted that one of these contained the majority of gastric cancers and had the longest duration of follow‐up. There was no significant benefit of <i>H. pylori</i> eradication therapy in preventing subsequent occurrence of gastric cancer when only those participants either with or without preneoplastic lesions at baseline were considered in the analysis. There were no significant subgroup differences.<br/><sup>6</sup> Funnel plots were not produced, as there were less than 10 studies included in the analyses.<br/><sup>7</sup> The quality of evidence was downgraded from high to moderate due to serious risk of bias: one trial was at high risk of bias.<br/><sup>8</sup> Only two studies were available for this outcome, with wide 95% CI. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">H. pylori eradication therapy compared to control for the prevention of gastric neoplasia in healthy asymptomatic infected individuals</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/full#CD005583-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005583-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">H. pylori eradication vs control ‐ main analyses</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Incidence of gastric cancer ‐ modified ITT analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.40, 0.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Incidence of gastric cancer ‐ complete case analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7698</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.40, 0.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Death from gastric cancer ‐ modified ITT analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6301</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.40, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Death from all causes ‐ modified ITT analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7079</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.85, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Incidence of oesophageal squamous cell carcinoma ‐ modified ITT analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3888</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.59, 2.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">H. pylori eradication vs control ‐ main analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/references#CD005583-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005583-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">H. pylori eradication vs control ‐ subgroup analysis according to presence or absence of pre‐neoplastic lesions at baseline</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Incidence of gastric cancer according to presence or absence of pre‐neoplastic lesions at baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8307</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.43, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Patients with precancerous lesions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.47, 1.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Patients without precancerous lesions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1812</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.02, 7.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 Mixed patients with and without precancerous lesions or ulcer (can't separate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3070</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.22, 0.78]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">H. pylori eradication vs control ‐ subgroup analysis according to presence or absence of pre‐neoplastic lesions at baseline</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/references#CD005583-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005583-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">H. pylori eradication vs control ‐ subgroup analysis according to use of vitamins or antioxidants</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Incidence of gastric cancer according to use of vitamins or anti‐oxidants <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.43, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Without antioxidants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.41, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 With antioxidants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2337</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.31, 0.87]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">H. pylori eradication vs control ‐ subgroup analysis according to use of vitamins or antioxidants</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/references#CD005583-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005583-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">H. pylori eradication vs control ‐ sensitivity analyses</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Incidence of gastric cancer ‐ modified ITT analysis substituting the 10‐year follow‐up data from Zhou 2014 with the 5‐year follow‐up data from Leung 2004 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.42, 0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Incidence of gastric cancer ‐ complete case analysis substituting the 10‐year follow‐up data from Zhou 2014 with the 5‐year follow‐up data from Leung 2004 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7747</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.41, 0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Incidence of gastric cancer‐ modified ITT analysis including the two arms of celecoxib from Wong 2012 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8834</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.41, 0.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Incidence of gastric cancer ‐ modified ITT analysis including all randomised patients from Correa 2000 and You 2006 who were found subsequently to be ineligible or did not receive treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.40, 0.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 Incidence of gastric cancer ‐ missing data imputation based on various assumptions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.1 Assuming incidence of gastric cancer for missing participants in both arms same as observed in the trial control arm </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.41, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.2 Assuming incidence of gastric cancer for missing participants in treatment arm same as observed in the trial control arm, but no new gastric cancer cases in the control arm among those with missing data </p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.42, 0.74]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">H. pylori eradication vs control ‐ sensitivity analyses</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005583.pub3/references#CD005583-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD005583.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD005583-note-0013">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD005583-note-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD005583-note-0012">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD005583-note-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD005583-note-0009">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD005583-note-0007">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD005583-note-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="th#CD005583-note-0006">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD005583-note-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD005583-note-0005">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005583\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005583\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005583\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005583\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005583\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005583\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005583\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005583\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005583\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005583\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005583\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005583\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005583\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005583\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005583\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005583\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005583\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005583\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=QzbxnhyM&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005583.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005583.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD005583.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD005583.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005583.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717899529"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005583.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717899533"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005583.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dc3310d109377',t:'MTc0MDcxNzg5OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 